<SEC-DOCUMENT>0001193125-25-051072.txt : 20250310
<SEC-HEADER>0001193125-25-051072.hdr.sgml : 20250310
<ACCEPTANCE-DATETIME>20250310170252
ACCESSION NUMBER:		0001193125-25-051072
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		19
CONFORMED PERIOD OF REPORT:	20250310
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250310
DATE AS OF CHANGE:		20250310

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Beam Therapeutics Inc.
		CENTRAL INDEX KEY:			0001745999
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39208
		FILM NUMBER:		25724654

	BUSINESS ADDRESS:	
		STREET 1:		26 LANDSDOWNE STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
		BUSINESS PHONE:		857-327-8775

	MAIL ADDRESS:	
		STREET 1:		26 LANDSDOWNE STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d930164d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:beam="http://beamtx.com/20250310" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2025-03-10_to_2025-03-10" id="ixv-346">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2025-03-10_to_2025-03-10">0001745999</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="beam-20250310.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase"/> </ix:references> <ix:resources> <xbrli:context id="duration_2025-03-10_to_2025-03-10"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-03-10</xbrli:startDate> <xbrli:endDate>2025-03-10</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">WASHINGTON, D.C. 20549</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2025-03-10_to_2025-03-10" id="ixv-357">8-K</ix:nonNumeric></span></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section 13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2025-03-10_to_2025-03-10" format="ixt:datemonthdayyearen" id="ixv-358">March 10, 2025</ix:nonNumeric></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2025-03-10_to_2025-03-10" id="ixv-359">Beam Therapeutics Inc.</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of Registrant as Specified in Its Charter)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2025-03-10_to_2025-03-10" format="ixt-sec:stateprovnameen" id="ixv-360">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2025-03-10_to_2025-03-10" id="ixv-361">001-39208</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2025-03-10_to_2025-03-10" id="ixv-362">81-5238376</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(State or Other Jurisdiction<br/>of Incorporation)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(IRS Employer<br/>Identification No.)</span></td></tr></table> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:50%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:48%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2025-03-10_to_2025-03-10" id="ixv-363">238 Main Street</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2025-03-10_to_2025-03-10" id="ixv-364">Cambridge</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2025-03-10_to_2025-03-10" format="ixt-sec:stateprovnameen" id="ixv-365">Massachusetts</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2025-03-10_to_2025-03-10" id="ixv-366">02142</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(Address of Principal Executive Offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s Telephone Number, Including Area Code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2025-03-10_to_2025-03-10" id="ixv-367">857</ix:nonNumeric> <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2025-03-10_to_2025-03-10" id="ixv-368">327-8775</ix:nonNumeric></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former Name or Former Address, if Changed Since Last Report)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2025-03-10_to_2025-03-10" format="ixt-sec:boolballotbox" id="ixv-369">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2025-03-10_to_2025-03-10" format="ixt-sec:boolballotbox" id="ixv-370">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2025-03-10_to_2025-03-10" format="ixt-sec:boolballotbox" id="ixv-371">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2025-03-10_to_2025-03-10" format="ixt-sec:boolballotbox" id="ixv-372">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Securities registered pursuant to Section 12(b) of the Act:</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br/>Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2025-03-10_to_2025-03-10" id="ixv-373">Common Stock, par value $0.01 per share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2025-03-10_to_2025-03-10" id="ixv-374">BEAM</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2025-03-10_to_2025-03-10" format="ixt-sec:exchnameen" id="ixv-375">Nasdaq Global Select Market</ix:nonNumeric></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 (&#167; <span style="white-space:nowrap">240.12b-2</span> of this chapter).</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&#8194;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2025-03-10_to_2025-03-10" format="ixt-sec:boolballotbox" id="ixv-376">&#9744;</ix:nonNumeric></p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#8194;&#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;1.01.</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Entry into a Material Definitive Agreement. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">On March&#160;10, 2025, Beam Therapeutics Inc. (the &#8220;Company&#8221;) entered into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with J.P. Morgan Securities LLC, Jefferies LLC, Cantor Fitzgerald&#160;&amp; Co., Citigroup Global Markets Inc. and Wells Fargo Securities, LLC, acting as representatives of the several underwriters named therein (collectively, the &#8220;Underwriters&#8221;), relating to an underwritten offering of 16,151,686 shares (the &#8220;Shares&#8221;) of the Company&#8217;s common stock, par value $0.01 per share (the &#8220;Common Stock&#8221;) and, in lieu of Common Stock to certain investors, <span style="white-space:nowrap">pre-funded</span> warrants (the <span style="white-space:nowrap">&#8220;Pre-funded</span> Warrants&#8221;) to purchase 1,404,988 shares of Common Stock. All of the Shares and the Pre-funded Warrants are being sold by the Company. The offering price of the Shares is $28.48 per share and the offering price of the Pre-funded Warrants is $28.47 per share of Common Stock underlying each <span style="white-space:nowrap">Pre-funded</span> Warrant, and the Underwriters have agreed to purchase the Shares from the Company pursuant to the Underwriting Agreement at a price of $26.7712 per share and the <span style="white-space:nowrap">Pre-funded</span> Warrants from the Company pursuant to the Underwriting Agreement at a price of $26.7612 per share of Common Stock underlying each <span style="white-space:nowrap">Pre-funded</span> Warrant. After underwriting discounts and commissions and estimated offering expenses, the Company expects to receive net proceeds from the offering of approximately $469.7&#160;million. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Shares and the Pre-funded Warrants will be issued pursuant to an automatically effective shelf registration statement on Form <span style="white-space:nowrap">S-3</span> that the Company filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on February&#160;28, 2024 (File <span style="white-space:nowrap">No.&#160;333-277427).</span> A prospectus supplement relating to the offering has been filed with the SEC. The closing of the offering is expected to take place on or about March&#160;11, 2025, subject to the satisfaction of customary closing conditions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Company intends to use the net proceeds from the offering for continued advancement of its platform technology, for continued research, development and <span style="white-space:nowrap">pre-commercialization</span> activities for its current portfolio of base editing programs and for other potential programs, including biologics license application submission and <span style="white-space:nowrap">pre-commercial</span> activities for <span style="white-space:nowrap">BEAM-101,</span> for clinical trials, including advancement of a potential pivotal trial for <span style="white-space:nowrap">BEAM-302</span> for treatment of <span style="white-space:nowrap">alpha-1</span> antitrypsin deficiency and of a potential Phase 1/2 clinical trial of the ESCAPE conditioning platform in patients with sickle cell disease, and for general corporate purposes. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Each Pre-funded Warrant has an exercise price per share of Common Stock equal to $0.01 per share. Each Pre-funded Warrant will be exercisable at any time after the date of issuance. The Pre-funded Warrants will be exercisable solely by means of a cashless exercise. The exercise price and the number of shares of Common Stock issuable upon exercise of each Pre-funded Warrant is subject to appropriate adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the Common Stock, as well as upon any distributions of assets, including cash or stock, to the Company&#8217;s stockholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Under the terms of the Pre-funded Warrants, the Company may not effect the exercise of any <span style="white-space:nowrap">Pre-funded</span> Warrant, and a holder will not be entitled to exercise any portion of any <span style="white-space:nowrap">Pre-funded</span> Warrant that, upon giving effect to or immediately prior to such exercise, would cause: (1)&#160;the aggregate number of shares of the Common Stock beneficially owned by such holder (together with its affiliates) to exceed 4.99%, 9.99%, or 19.99%, as elected by the </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
holder, of the number of shares of Common Stock outstanding following such exercise; or (2)&#160;the combined voting power of the Company&#8217;s securities beneficially owned by such holder (together with its affiliates) to exceed 4.99%, 9.99%, or 19.99%, as elected by the holder, of the combined voting power of all of the Company&#8217;s securities outstanding following such exercises. Under the terms of the Pre-funded Warrants, a holder of a <span style="white-space:nowrap">Pre-funded</span> Warrant may increase or decrease such percentage to any other percentage not in excess of 19.99% provided that any such increase will not be effective until the 61st day after notice from the holder is delivered to the Company.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">In addition, in certain circumstances, upon a fundamental transaction, a holder of Pre-funded Warrants will be entitled to receive, upon exercise of the <span style="white-space:nowrap">Pre-funded</span> Warrants, the same amount and kind of securities, cash or property that such holder would have received had they exercised the <span style="white-space:nowrap">Pre-funded</span> Warrants immediately prior to the fundamental transaction, without regard to any limitations on exercise contained in the <span style="white-space:nowrap">Pre-funded</span> Warrants. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Underwriting Agreement contains customary representations, warranties, covenants and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and the Underwriters, including for liabilities under the Securities Act of 1933, as amended, other obligations of the parties and termination provisions. The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such agreement, and may be subject to limitations agreed upon by the contracting parties. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">A copy of the Underwriting Agreement and the form of Pre-funded Warrant are attached as Exhibit 1.1 and Exhibit 4.1 hereto, respectively, and are incorporated herein by reference. The foregoing descriptions of the Underwriting Agreement and the Pre-funded Warrants do not purport to be complete and are qualified in their entirety by reference to such exhibits. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">A copy of the legal opinion and consent of Wilmer Cutler Pickering Hale and Dorr LLP relating to the Shares, the Pre-funded Warrants and the shares of Common Stock underlying the <span style="white-space:nowrap">Pre-funded</span> Warrants is attached as Exhibit 5.1 hereto. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;8.01.</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Other Events. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The full text of the press release announcing the pricing of the offering on March&#160;10, 2025 is attached as Exhibit 99.1 hereto and is incorporated herein by reference. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Cautionary Note Regarding Forward-Looking Statements </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Statements in this Current Report on Form <span style="white-space:nowrap">8-K</span> about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute &#8220;forward-looking statements&#8221; within the meaning of The Private Securities Litigation Reform Act of 1995. The words &#8220;anticipate,&#8221; &#8220;expect,&#8221; &#8220;suggest,&#8221; &#8220;plan,&#8221; &#8220;vision,&#8221; &#8220;strategy,&#8221; &#8220;possibility,&#8221; &#8220;promise,&#8221; &#8220;believe,&#8221; &#8220;intend,&#8221; &#8220;project,&#8221; &#8220;estimates,&#8221; &#8220;targets,&#8221; &#8220;projections,&#8221; &#8220;potential,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; the negative thereof and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Investors are cautioned not to place undue reliance on these forward looking statements, including but not limited to, statements relating to the size, structure and closing of the offering; anticipated use of proceeds of the offering; the therapeutic applications and potential of our technology; and our ability to develop life long curative, precision genetic medicine for patients through base editing. Each forward-looking statement is subject to important risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement, including, without limitation, risks and uncertainties related to: market conditions and the completion of the offering on the anticipated terms or at all; our ability to develop, obtain regulatory approval for, and commercialize our product candidates, which may take longer or cost more than planned; our ability to raise additional funding, which may not be available; our ability to obtain, maintain and enforce patent and other intellectual property protection for our product candidates; the uncertainty that our product candidates will receive regulatory approval necessary to initiate human clinical trials; that preclinical testing of our product candidates and preliminary or interim data from preclinical studies and clinical trials may not be predictive of the results or success of ongoing or later clinical trials; that initiation and enrollment of, and anticipated timing to advance, our clinical trials may take longer than expected; that our product candidates or the delivery modalities we rely on to administer them may cause serious adverse events; that our product candidates may experience manufacturing or supply </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
interruptions or failures; risks related to competitive products; and the other risks and uncertainties identified under the headings &#8220;Risk Factors Summary&#8221; and &#8220;Risk Factors&#8221; in the Company&#8217;s Annual Report on Form <span style="white-space:nowrap">10-K</span> for the fiscal year ended December&#160;31, 2024, filed with the SEC on February&#160;25, 2025, the prospectus supplement related to the offering filed on March&#160;10, 2025, and in any subsequent filings with the SEC. Any forward-looking statements contained in this Current Report on Form <span style="white-space:nowrap">8-K</span> speak only as of the date hereof, and the Company specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise, except as may be required by applicable law. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;9.01.</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Exhibits </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:4%"/>
<td style="width:93%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap;text-align:center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit<br/>No.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8194;1.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d930164dex11.htm">Underwriting Agreement, dated March&#160;10, 2025, by and among Beam Therapeutics Inc., J.P. Morgan Securities LLC, Jefferies LLC, Cantor Fitzgerald&#160;&amp; Co., Citigroup Global Markets Inc. and Wells Fargo Securities, LLC </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8194;4.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d930164dex41.htm">Form of Pre-funded Warrant </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8194;5.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d930164dex51.htm">Opinion of Wilmer Cutler Pickering Hale and Dorr LLP </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">23.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d930164dex51.htm">Consent of Wilmer Cutler Pickering Hale and Dorr LLP (included in Exhibit 5.1) </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d930164dex991.htm">Press Release dated March 10, 2025 </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document)</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:45%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:4%"/>

<td style="vertical-align:bottom"/>
<td style="width:3%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:45%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3"><span style="font-weight:bold">BEAM THERAPEUTICS INC.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Date: March 10, 2025</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ John Evans</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">John Evans</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Chief Executive Officer</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>d930164dex11.htm
<DESCRIPTION>EX-1.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-1.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 1.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Beam Therapeutics Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16,151,686 Shares of Common Stock </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants to Purchase 1,404,988 Shares of Common Stock </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Underwriting Agreement </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">March&nbsp;10, 2025 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">J.P. Morgan Securities LLC
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jefferies LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cantor Fitzgerald&nbsp;&amp; Co. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Citigroup Global Markets Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Wells Fargo Securities, LLC </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As Representatives of the </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">several Underwriters listed </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">in <U>Schedule 1</U> hereto </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o J.P. Morgan Securities LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">383 Madison Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10179 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Jefferies LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">520 Madison Avenue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, NY 10022 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Cantor Fitzgerald&nbsp;&amp; Co. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">110 East 59th Street, 6th Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10022 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Citigroup Global Markets Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">388 Greenwich Street </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10013 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Wells Fargo Securities, LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">500 West 33rd Street, 14th Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10001 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beam Therapeutics Inc., a
Delaware corporation (the &#147;Company&#148;), proposes to issue and sell to the several underwriters listed in <U>Schedule 1</U> hereto (the &#147;Underwriters&#148;), for whom you </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
are acting as representatives (the &#147;Representatives&#148;), an aggregate of 16,151,686 shares of common stock, par value $0.01 per share (&#147;Common Stock&#148;), of the Company (the
&#147;Shares&#148;) and <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to purchase an aggregate of 1,404,988 shares of Common Stock of the Company, at an exercise price equal to $0.01 per share, in the form attached hereto as <U>Exhibit
B</U> (the &#147;Warrants&#148;). The Shares and Warrants are herein referred to as the &#147;Securities.&#148; The shares of common stock of the Company issuable upon exercise of the Warrants are herein referred to as the &#147;Warrant
Shares.&#148; The shares of Common Stock of the Company to be outstanding after giving effect to the sale of the Shares and the exercise of the Warrants are referred to herein as the &#147;Stock.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby confirms its agreement with the several Underwriters concerning the purchase and sale of the Securities, as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.&#8195;<U>Registration Statement</U>. The Company has prepared and filed with the Securities and Exchange Commission (the
&#147;Commission&#148;) under the Securities Act of 1933, as amended, and the rules and regulations of the Commission thereunder (collectively, the &#147;Securities Act&#148;), a registration statement on Form
<FONT STYLE="white-space:nowrap">S-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-277427),</FONT> including a prospectus, relating to the Securities and Warrant Shares. Such registration statement, as amended, at the time it became
effective, including the information, if any, deemed pursuant to Rule 430A, 430B or 430C under the Securities Act to be part of the registration statement at the time of its effectiveness (&#147;Rule 430 Information&#148;), is referred to herein as
the &#147;Registration Statement&#148;; and as used herein, the term &#147;Preliminary Prospectus&#148; means each prospectus included in such registration statement (and any amendments thereto) before effectiveness, any prospectus filed with the
Commission pursuant to Rule 424(a) under the Securities Act and the prospectus included in the Registration Statement at the time of its effectiveness that omits Rule 430 Information, and the term &#147;Prospectus&#148; means the prospectus relating
to the Securities in the form first used (or made available upon request of purchasers pursuant to Rule 173 under the Securities Act) in connection with confirmation of sales of the Securities. Any reference in this underwriting agreement (this
&#147;Agreement&#148;) to the Registration Statement, any Preliminary Prospectus or the Prospectus shall be deemed to refer to and include the documents incorporated by reference therein pursuant to Item 12 of Form
<FONT STYLE="white-space:nowrap">S-3</FONT> under the Securities Act, as of the effective date of the Registration Statement or the date of such Preliminary Prospectus or the Prospectus, as the case may be, and any reference to &#147;amend&#148;,
&#147;amendment&#148; or &#147;supplement&#148; with respect to the Registration Statement, any Preliminary Prospectus or the Prospectus shall be deemed to refer to and include any documents filed after such date under the Securities Exchange Act of
1934, as amended, and the rules and regulations of the Commission thereunder (collectively, the &#147;Exchange Act&#148;) that are deemed to be incorporated by reference therein. Capitalized terms used but not defined herein shall have the meanings
given to such terms in the Registration Statement and the Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At or prior to the Applicable Time (as defined below), the Company
had prepared the following information (collectively with the pricing information set forth on <U>Annex A</U>, the &#147;Pricing Disclosure Package&#148;): a Preliminary Prospectus dated March&nbsp;9, 2025 and each &#147;free-writing
prospectus&#148; (as defined pursuant to Rule 405 under the Securities Act) listed on <U>Annex A</U> hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Applicable Time&#148;
means 5:30 A.M., New York City time, on March&nbsp;10, 2025. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.&#8195;<U>Purchase of the Securities</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&#8195;The Company agrees to issue and sell the Shares and the Warrants to the several Underwriters as provided in this Agreement, and each
Underwriter, on the basis of the representations, warranties and agreements set forth herein and subject to the conditions set forth herein, agrees, severally and not jointly, to purchase at a price per share of $26.7712 (the &#147;Share Purchase
Price&#148;) from the Company the respective number of Shares set forth opposite such Underwriter&#146;s name in <U>Schedule 1</U> hereto, and to purchase at a price of $26.7612 per Warrant (the &#147;Warrant Purchase Price&#148;) from the Company
the respective number of Warrants set forth opposite such Underwriter&#146;s name in <U>Schedule 1</U> hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&#8195;The Company
understands that the Underwriters intend to make an offering of the Securities, and initially to offer the Securities on the terms set forth in the Pricing Disclosure Package. The Company acknowledges and agrees that the Underwriters may offer and
sell Securities to or through any affiliate of an Underwriter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&#8195;Payment for the Securities shall be made by wire transfer in
immediately available funds to the account specified by the Company to the Representatives at the offices of Davis Polk&nbsp;&amp; Wardwell LLP, 450 Lexington Avenue, New York, New York 10017 at 10:00 A.M. New York City time on March&nbsp;11, 2025,
or at such other time or place on the same or such other date, not later than the fifth business day thereafter, as the Representatives and the Company may agree upon in writing. The time and date of such payment for the Shares and Warrants is
referred to herein as the &#147;Closing Date.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payment for the Securities to be purchased on the Closing Date shall be made against
delivery to the Representatives for the respective accounts of the several Underwriters of the Securities to be purchased on such date, with any transfer taxes payable in connection with the sale of such Securities duly paid by the Company, as
applicable. Delivery of the Shares shall be made through the facilities of The Depository Trust Company (&#147;DTC&#148;) unless the Representatives shall otherwise instruct. The Warrants shall be delivered to the purchasers of the Warrants (or to
the Representatives as directed by the Representatives), in definitive form, registered in such names and in such denominations as the Representatives shall request in writing no later than one business day prior to the Closing Date. The Warrants
will be made available for inspection by the Representatives on the business day prior to the Closing Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the
foregoing, the Company and the Representatives shall instruct the purchasers of the Warrants in the offering to make payment for the Warrants on the Closing Date to the Company by wire transfer in immediately available funds to the account specified
by the Company at a purchase price of $28.47 per Warrant in lieu of payment by the Underwriters for such Warrants, and the Company shall deliver such Warrants to such purchasers on the Closing Date in definitive form against such payment in lieu of
the Company&#146;s obligation to deliver such Warrants to the Underwriters. The Company shall promptly (but in no event later than the Closing Date) pay $1.7088 per warrant (the &#147;Warrant Underwriting Discount&#148;) to the Representatives by
wire transfer in immediately available funds to the account specified by the Representatives, <I>provided</I>, <I>however</I>, that the Company agrees that the Representatives will be entitled at their discretion to set off the payment for the
Shares against the aggregate Warrant Underwriting Discount payable to the Representatives, and any excess amount will remain due </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and payable to the Company on the Closing Date. In the event the purchasers of the Warrants in the offering fail to make payment to the Company for all or part of the Warrants on the Closing
Date, the Underwriters agree to make payment to the Company for such Warrants at a price per Warrant equal to the Warrant Purchase Price; <I>provided</I>, <I>however</I>, that the Representatives may elect, by written notice to the Company, to
receive shares of common stock of the Company in lieu of all or a portion of such Warrants to be delivered to the Underwriters under this Agreement at a price per share equal to the Share Purchase Price (the &#147;Substitute Shares&#148;). The
aggregate amount of Substitute Shares and Warrants to be delivered to the Representatives hereunder may be reallocated at the discretion of the Representatives no later than the business day prior to the Closing Date, to increase or decrease the
number of Substitute Shares or Warrants, <I>provided </I>that the aggregate number of Substitute Shares and Warrants issued does not exceed 17,556,674. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&#8195;The Company acknowledges and agrees that the Representatives and the other Underwriters are acting solely in the capacity of an
arm&#146;s length contractual counterparty to the Company with respect to the offering of Securities contemplated hereby (including in connection with determining the terms of the offering) and not as a financial advisor or a fiduciary to, or an
agent of, the Company or any other person. Additionally, neither the Representatives nor any other Underwriter is advising the Company or any other person as to any legal, tax, investment, accounting or regulatory matters in any jurisdiction. The
Company shall consult with its own advisors concerning such matters and shall be responsible for making its own independent investigation and appraisal of the transactions contemplated hereby, and neither the Representatives nor the other
Underwriters shall have any responsibility or liability to the Company with respect thereto. Any review by the Representatives and the other Underwriters of the Company, the transactions contemplated hereby or other matters relating to such
transactions will be performed solely for the benefit of the Underwriters and shall not be on behalf of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.&#8195;<U>Representations and Warranties of the Company</U>. The Company represents and warrants to each Underwriter that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&#8195;<I>Preliminary Prospectus.</I> No order preventing or suspending the use of any Preliminary Prospectus has been issued by the
Commission, and each Preliminary Prospectus, at the time of filing thereof, complied in all material respects with the applicable requirements of the Securities Act, and no Preliminary Prospectus, at the time of filing thereof, contained any untrue
statement of a material fact or omitted to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; <U>provided</U> that the Company makes no
representation or warranty with respect to any statements or omissions made in reliance upon and in conformity with information relating to any Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly
for use in any Preliminary Prospectus, it being understood and agreed that the only such information furnished by any Underwriter consists of the information described as such in Section&nbsp;7(b) hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&#8195;<I>Pricing Disclosure Package</I>. The Pricing Disclosure Package as of the Applicable Time did not, and as of the Closing Date,
will not, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; <U>provided</U> that the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company makes no representation or warranty with respect to any statements or omissions made in reliance upon and in conformity with information relating to any Underwriter furnished to the
Company in writing by such Underwriter through the Representatives expressly for use in such Pricing Disclosure Package, it being understood and agreed that the only such information furnished by any Underwriter consists of the information described
as such in Section&nbsp;7(b) hereof. No statement of material fact included in the Prospectus has been omitted from the Pricing Disclosure Package and no statement of material fact included in the Pricing Disclosure Package that is required to be
included in the Prospectus has been omitted therefrom. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&#8195;<I>Issuer Free Writing Prospectus. </I>Other than the Registration
Statement, any Preliminary Prospectus and the Prospectus, the Company (including its agents and representatives, other than the Underwriters in their capacity as such) has not prepared, made, used, authorized, approved or referred to and will not
prepare, make, use, authorize, approve or refer to any &#147;written communication&#148; (as defined in Rule 405 under the Securities Act) that constitutes an offer to sell or solicitation of an offer to buy the Securities (each such communication
by the Company or its agents and representatives (other than a communication referred to in clause (i)&nbsp;below) an &#147;Issuer Free Writing Prospectus&#148;) other than (i)&nbsp;any document not constituting a prospectus pursuant to
Section&nbsp;2(a)(10)(a) of the Securities Act or Rule 134 under the Securities Act or (ii)&nbsp;the free writing prospectus dated as of March&nbsp;10, 2025, each electronic road show and any other written communications approved in writing in
advance by the Representatives. Each such Issuer Free Writing Prospectus complies in all material respects with the Securities Act, has been or will be (within the time period specified in Rule 433) filed in accordance with the Securities Act (to
the extent required thereby) and (except as expressly set forth in such Issuer Free Writing Prospectus) does not conflict with the information contained in the Registration Statement or the Pricing Disclosure Package, and, when taken together with
any Preliminary Prospectus accompanying, or delivered prior to delivery of, such Issuer Free Writing Prospectus, did not, and as of the Closing Date, will not, contain any untrue statement of a material fact or omit to state a material fact
necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; <U>provided</U> that the Company makes no representation or warranty with respect to any statements or omissions made in
each such Issuer Free Writing Prospectus or Preliminary Prospectus in reliance upon and in conformity with information relating to any Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for use
in such Issuer Free Writing Prospectus or Preliminary Prospectus, it being understood and agreed that the only such information furnished by any Underwriter consists of the information described as such in Section&nbsp;7(b) hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&#8195;<I>Registration Statement and Prospectus.</I> The Registration Statement is an &#147;automatic shelf registration statement&#148; as
defined under Rule 405 of the Securities Act that has been filed with the Commission not earlier than three years prior to the date hereof; and no notice of objection of the Commission to the use of such registration statement or any post-effective
amendment thereto pursuant to Rule 401(g)(2) under the Securities Act has been received by the Company. No order suspending the effectiveness of the Registration Statement has been issued by the Commission, and no proceeding for that purpose or
pursuant to Section&nbsp;8A of the Securities Act against the Company or related to the offering of the Securities has been initiated or, to the knowledge of the Company, threatened by the Commission; as of the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
applicable effective date of the Registration Statement and any post-effective amendment thereto, the Registration Statement and any such post-effective amendment complied and will comply in all
material respects with the applicable requirements of the Securities Act, and did not and will not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the
statements therein not misleading; and as of the date of the Prospectus and any amendment or supplement thereto and as of the Closing Date, the Prospectus will comply in all material respects with the applicable requirements of the Securities Act
and will not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; <U>provided</U> that the
Company makes no representation or warranty with respect to any statements or omissions made in reliance upon and in conformity with information relating to any Underwriter furnished to the Company in writing by such Underwriter through the
Representatives expressly for use in the Registration Statement and the Prospectus and any amendment or supplement thereto, it being understood and agreed that the only such information furnished by any Underwriter consists of the information
described as such in Section&nbsp;7(b) hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&#8195;<I>Incorporated Documents</I>. The documents incorporated by reference in the
Registration Statement, the Prospectus and the Pricing Disclosure Package, when they were filed with the Commission conformed in all material respects to the requirements of the Securities Exchange Act of 1934, as amended, and the rules and
regulations of the Commission thereunder (collectively, the &#147;Exchange Act&#148;), and none of such documents contained any untrue statement of a material fact or omitted to state a material fact necessary to make the statements therein, in the
light of the circumstances under which they were made, not misleading; and any further documents so filed and incorporated by reference in the Registration Statement, the Prospectus or the Pricing Disclosure Package, when such documents are filed
with the Commission, will conform in all material respects to the requirements of the Exchange Act and will not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light
of the circumstances under which they were made, not misleading. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)&#8195;<I>Financial Statements.</I> The financial statements
(including the related notes thereto) of the Company and its subsidiaries included or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus comply in all material respects with the applicable
requirements of the Securities Act and the Exchange Act, as applicable, and present fairly in all material respects the financial position of the Company and its subsidiaries as of the dates indicated and the results of their operations and the
changes in their cash flows for the periods specified; such financial statements have been prepared in conformity with generally accepted accounting principles (&#147;GAAP&#148;) in the United States applied on a consistent basis throughout the
periods covered thereby, except in the case of unaudited financial statements, which are subject to normal <FONT STYLE="white-space:nowrap">year-end</FONT> adjustments and do not contain certain footnotes as permitted by the applicable rules of the
Commission; and any supporting schedules included or incorporated by reference in the Registration Statement present fairly in all material respects the information required to be stated therein; and the other financial information included or
incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus has been derived from the accounting records of the Company and its subsidiaries and presents fairly in all material respects the information
shown thereby. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g)&#8195;<I>No Material Adverse Change.</I> Since the date of the most recent financial
statements of the Company included or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus, (i)&nbsp;there has not been any change in the capital stock (other than the issuance of shares of
Common Stock upon exercise of stock options and warrants described as outstanding in, and the grant of options and awards under existing equity incentive plans described in, the Registration Statement, the Pricing Disclosure Package and the
Prospectus), short-term debt or long-term debt of the Company or its subsidiaries, or any dividend or distribution of any kind declared, set aside for payment, paid or made by the Company on any class of capital stock, or any material adverse
change, or any development that would reasonably be expected to result in a material adverse change, in or affecting the business, properties, management, financial position, stockholders&#146; equity, results of operations or prospects of the
Company and its subsidiaries taken as a whole; (ii)&nbsp;neither the Company nor its subsidiaries have entered into any transaction or agreement (whether or not in the ordinary course of business) that is material to the Company and its subsidiaries
taken as a whole or incurred any liability or obligation, direct or contingent, that is material to the Company and its subsidiaries taken as a whole; and (iii)&nbsp;neither the Company nor its subsidiaries have sustained any loss or interference
with its business that is material to the Company and its subsidiaries taken as a whole and that is either from fire, explosion, flood or other calamity, whether or not covered by insurance, or from any labor disturbance or dispute or any action,
order or decree of any court or arbitrator or governmental or regulatory authority, except in each case as otherwise disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h)&#8195;<I>Organization and Good Standing.</I> The Company and its subsidiaries have been duly organized and are validly existing and in
good standing under the laws of their respective jurisdictions of organization, are duly qualified to do business and are in good standing in each jurisdiction in which their respective ownership or lease of property or the conduct of their
respective businesses requires such qualification, and have all power and authority necessary to own or hold their respective properties and to conduct the businesses in which they are engaged, except where the failure to be so qualified or in good
standing or have such power or authority would not, individually or in the aggregate, reasonably be expected to have a material adverse effect on the business, properties, management, financial position, stockholders&#146; equity, results of
operations or prospects of the Company and its subsidiaries taken as a whole or on the performance by the Company of its obligations under this Agreement (a &#147;Material Adverse Effect&#148;). Each corporation, association or other entity
controlled, directly or indirectly, by the Company that would constitute a &#147;significant subsidiary&#148; as defined in Rule <FONT STYLE="white-space:nowrap">1-02(w)</FONT> of Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> is listed in
Exhibit 21.1 to the Company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2024. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&#8195;<I>Capitalization.</I> The Company has an authorized capitalization as set forth in the Registration Statement, the Pricing
Disclosure Package and the Prospectus under the heading &#147;Description of Capital Stock&#148;; all the outstanding shares of capital stock of the Company have been duly and validly authorized and issued and are fully paid and <FONT
STYLE="white-space:nowrap">non-assessable</FONT> and are not subject to any <FONT STYLE="white-space:nowrap">pre-emptive</FONT> or similar rights that have not been duly waived or satisfied; except as described in or expressly contemplated by the
Registration Statement, the Pricing Disclosure </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Package and the Prospectus, there are no outstanding rights (including, without limitation, <FONT STYLE="white-space:nowrap">pre-emptive</FONT> rights), warrants or options to acquire, or
instruments convertible into or exchangeable for, any shares of capital stock or other equity interest in the Company or its subsidiaries, or any contract, commitment, agreement, understanding or arrangement of any kind relating to the issuance of
any capital stock of the Company or any such subsidiaries, any such convertible or exchangeable securities or any such rights, warrants or options; the capital stock of the Company conforms in all material respects to the description thereof
contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus; and all the outstanding shares of capital stock or other equity interests of each subsidiary owned, directly or indirectly, by the Company have been duly and
validly authorized and issued, are fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> (except, in the case of any foreign subsidiary, for directors&#146; qualifying shares and except as otherwise described in the Registration
Statement, the Pricing Disclosure Package and the Prospectus,) and are owned directly or indirectly by the Company, free and clear of any lien, charge, encumbrance, security interest, restriction on voting or transfer or any other claim of any third
party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j)&#8195;<I>Stock Options. </I>With respect to the stock options (the &#147;Stock Options&#148;) granted pursuant to the
stock-based compensation plans of the Company and its subsidiaries (the &#147;Company Stock Plans&#148;), (i) each Stock Option intended to qualify as an &#147;incentive stock option&#148; under Section&nbsp;422 of the Internal Revenue Code of 1986,
as amended (the &#147;Code&#148;), so qualifies, (ii)&nbsp;each grant of a Stock Option was duly authorized no later than the date on which the grant of such Stock Option was by its terms to be effective by all necessary corporate action, including,
as applicable, approval by the board of directors of the Company (or a duly constituted and authorized committee thereof) and any required stockholder approval by the necessary number of votes or written consents, and the award agreement governing
such grant (if any) was duly executed and delivered by each party thereto, (iii)&nbsp;each such grant was made in accordance with the terms of the Company Stock Plans and all other applicable laws and regulatory rules or requirements, including the
rules of the Nasdaq Global Market (&#147;Nasdaq Market&#148;) and any other exchange on which Company securities are traded, and (iv)&nbsp;each such grant was properly accounted for in accordance with GAAP in the financial statements (including the
related notes) of the Company and disclosed in the Company&#146;s filings with the Commission in accordance with the Exchange Act and all other applicable laws. Each Company Stock Plan is accurately described in all material respects in the
Registration Statement, the Pricing Disclosure Package and the Prospectus. The Company has not knowingly granted, and there is no and has been no policy or practice of the Company of granting, Stock Options prior to, or otherwise coordinating the
grant of Stock Options with, the release or other public announcement of material information regarding the Company or its subsidiaries or their results of operations or prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k)&#8195;<I>Due Authorization.</I> The Company has full right, power and authority to execute and deliver this Agreement and to perform its
obligations hereunder; and all action required to be taken for the due and proper authorization, execution and delivery by it of this Agreement and the consummation by it of the transactions contemplated hereby has been duly and validly taken. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l)&#8195;<I>Underwriting Agreement. </I>This Agreement has been duly authorized, executed and delivered by the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m)&#8195;<I>The Securities and the Warrant Shares. </I>(i)&nbsp;The Shares to be issued and
sold by the Company hereunder have been duly authorized by the Company and, when issued and delivered and paid for as provided herein, will be duly and validly issued, will be fully paid and nonassessable and will conform in all material respects to
the descriptions thereof in the Registration Statement, the Pricing Disclosure Package and the Prospectus; (ii)&nbsp;the Warrants have been duly authorized by the Company and, when executed and delivered by the Company in accordance with this
Agreement, will constitute valid and legally binding agreements of the Company, enforceable against the Company in accordance with their terms, except as enforceability may be limited by applicable bankruptcy, insolvency or similar laws affecting
creditors&#146; rights generally or by equitable principles relating to enforceability; (iii)&nbsp;the Warrant Shares to be issued by the Company upon exercise of the Warrants, as provided therein, have been duly and validly authorized and, when
issued and delivered upon exercise as provided under the Warrants, will be duly and validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> and will conform in all material respects to the descriptions thereof in the
Registration Statement, the Pricing Disclosure Package and the Prospectus; and (iv)&nbsp;the issuance of the Securities and the Warrant Shares is not subject to any preemptive or similar rights that have not been duly waived or satisfied. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n)&#8195;<I>Description of the Underwriting Agreement.</I> This Agreement conforms in all material respects to the description thereof
contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o)&#8195;<I>No Violation or Default.</I>
Neither the Company nor its subsidiaries are (i)&nbsp;in violation of its charter or <FONT STYLE="white-space:nowrap">by-laws</FONT> or similar organizational documents; (ii)&nbsp;in default, and no event has occurred that, with notice or lapse of
time or both, would constitute such a default, in the due performance or observance of any term, covenant or condition contained in any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company or its
subsidiaries are a party or by which the Company or its subsidiaries are bound or to which any property or asset of the Company or its subsidiaries are subject; or (iii)&nbsp;in violation of any law or statute or any judgment, order, rule or
regulation of any court or arbitrator or governmental or regulatory authority, except, in the case of clauses (ii)&nbsp;and (iii) above, for any such default or violation that would not, individually or in the aggregate, reasonably be expected to
have a Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p)&#8195;<I>No Conflicts. </I>The execution, delivery and performance by the Company of this Agreement
and the Warrants, the issuance and sale of the Securities and the Warrant Shares and the consummation of the transactions contemplated by this Agreement and the Warrants or the Pricing Disclosure Package and the Prospectus will not (i)&nbsp;conflict
with or result in a breach or violation of any of the terms or provisions of, or constitute a default under, result in the termination, modification or acceleration of, or result in the creation or imposition of any lien, charge or encumbrance upon
any property, right or asset of the Company or its subsidiaries pursuant to, any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company or its subsidiaries are a party or by which the Company or its
subsidiaries are bound or to which any property, right or asset of the Company or its subsidiaries are subject, (ii)&nbsp;result in any violation of the provisions of the charter or <FONT STYLE="white-space:nowrap">by-laws</FONT> or similar
organizational documents of the Company or its subsidiaries or (iii)&nbsp;result in the violation of any law or statute or any judgment, order, rule or regulation of any court or arbitrator or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
governmental or regulatory authority, except, in the case of clauses (i)&nbsp;and (iii) above, for any such conflict, breach, violation, default, lien, charge or encumbrance that would not,
individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q)&#8195;<I>No Consents Required.</I> No
consent, approval, authorization, order, registration or qualification of or with any court or arbitrator or governmental or regulatory authority is required for the execution, delivery and performance by the Company of this Agreement, the issuance
and sale of the Securities and the consummation of the transactions contemplated by this Agreement, except for the registration of the Securities under the Securities Act and such consents, approvals, authorizations, orders and registrations or
qualifications as may be required by the Financial Industry Regulatory Authority, Inc. (&#147;FINRA&#148;) and under applicable state securities laws in connection with the purchase and distribution of the Securities by the Underwriters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(r)&#8195;<I>Legal Proceedings.</I> Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus,
there are no legal, governmental or regulatory investigations, actions, demands, claims, suits, arbitrations, inquiries or proceedings (&#147;Actions&#148;) pending to which the Company or its subsidiaries are or may reasonably be expected to become
a party or to which any property of the Company or its subsidiaries are or may reasonably be expected to become the subject that, individually or in the aggregate, if determined adversely to the Company or its subsidiaries, would reasonably be
expected to have a Material Adverse Effect; to the knowledge of the Company, no such Actions are threatened or contemplated by any governmental or regulatory authority or threatened by others; and (i)&nbsp;there are no current or pending Actions
that are required under the Securities Act to be described in the Registration Statement, the Pricing Disclosure Package or the Prospectus that are not so described in the Registration Statement, the Pricing Disclosure Package and the Prospectus and
(ii)&nbsp;there are no statutes, regulations or contracts or other documents that are required under the Securities Act to be filed as exhibits to the Registration Statement or described in the Registration Statement, the Pricing Disclosure Package
or the Prospectus that are not so filed as exhibits to the Registration Statement or described in the Registration Statement, the Pricing Disclosure Package and the Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(s)&#8195;<I>Independent Accountants</I>. Deloitte&nbsp;&amp; Touche LLP, who have certified certain financial statements of the Company and
its subsidiaries, is an independent registered public accounting firm with respect to the Company and its subsidiaries within the applicable rules and regulations adopted by the Commission and the Public Company Accounting Oversight Board (United
States) and as required by the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(t)&#8195;<I>Title to Real and Personal Property</I>. The Company and its subsidiaries
have good and marketable title in fee simple to, or have valid rights to lease or otherwise use, all items of real and personal property that are material to the respective businesses of the Company and its subsidiaries, in each case free and clear
of all liens, encumbrances, claims and defects and imperfections of title except those that (i)&nbsp;do not materially interfere with the use made and proposed to be made of such property by the Company and its subsidiaries or (ii)&nbsp;would not
reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(u)&#8195;<I>Intellectual Property.</I>
Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus or as would not, individually or in the aggregate, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
have a Material Adverse Effect: (i)&nbsp;the Company and its subsidiaries own, have, or can acquire on reasonable terms valid and enforceable rights to use all patents, trademarks, service marks,
trade names, domain names and other source indicators, copyrights and copyrightable works, <FONT STYLE="white-space:nowrap">know-how</FONT> (including trade secrets and other unpatented or unpatentable proprietary or confidential information,
systems or procedures) and all other similar intellectual property (including all registrations and applications for registration of, and all goodwill associated with, the foregoing) (collectively, &#147;Intellectual Property&#148;) used in or
necessary for the conduct of their respective businesses and as proposed to be conducted; (ii)&nbsp;the Company is unaware of any facts which would form a reasonable basis for an action, suit, proceeding or claim asserting that the Company and its
subsidiaries&#146; conduct of their respective businesses has infringed, misappropriated or otherwise violated any Intellectual Property of any third party; (iii)&nbsp;the Company is unaware of any facts which would form a reasonable basis for an
action, suit, proceeding or claim asserting that the Company or its subsidiaries would, upon the commercialization of any product candidate, infringe, misappropriate or otherwise violate any Intellectual Property of any third party; (iv)&nbsp;the
Company and its subsidiaries have not received any written notice and are not otherwise aware of any pending or threatened claim alleging infringement, misappropriation or other violation of any Intellectual Property of any person, or challenging
the validity, enforceability, scope or ownership of any Intellectual Property owned by or exclusively licensed to the Company or its subsidiaries; (v)&nbsp;to the knowledge of the Company, no Intellectual Property owned by or exclusively licensed to
the Company and its subsidiaries has been infringed, misappropriated or otherwise violated by any person; (vi)&nbsp;to the knowledge of the Company, all Intellectual Property owned by or exclusively licensed to the Company and its subsidiaries is
valid and enforceable; (vii)&nbsp;the Company and its subsidiaries have taken reasonable steps in accordance with normal industry practice to maintain the confidentiality of all Intellectual Property, the value of which to the Company or its
subsidiaries is contingent upon maintaining the confidentiality thereof; and (viii)&nbsp;to the actual knowledge of the Company, the Company, its subsidiaries, and counsel for the Company, its subsidiaries or any of their respective licensors, have
complied with the duties of candor, good faith and disclosure, as required by the United States Patent and Trademark Office and all foreign offices having similar requirements, with respect to the prosecution of the patents and patent applications
owned by or exclusively licensed to the Company or its subsidiaries and for which such duty is owed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v)&#8195;<I>No Undisclosed
Relationships</I>. No relationship, direct or indirect, exists between or among the Company or its subsidiaries, on the one hand, and the directors, officers, stockholders, customers, suppliers or other affiliates of the Company or its subsidiaries,
on the other, that is required by the Securities Act to be described in each of the Registration Statement and the Prospectus and that is not so described in such documents and in the Pricing Disclosure Package. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(w)&#8195;<I>Investment Company Act</I>. The Company is not and, after giving effect to the offering and sale of the Securities and the
application of the proceeds thereof as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, will not be required to register as an &#147;investment company&#148; or an entity &#147;controlled&#148; by an
&#147;investment company&#148; within the meaning of the Investment Company Act of 1940, as amended, and the rules and regulations of the Commission thereunder (collectively, the &#147;Investment Company Act&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x)&#8195;<I>Taxes.</I> The Company and its subsidiaries have paid all federal, state, local
and foreign taxes and filed all tax returns required to be paid or filed through the date hereof, except for those taxes and tax returns whose failure to pay or file would not reasonably be expected to have a Material Adverse Effect; and except as
otherwise disclosed in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus, there is no tax deficiency that has been, or would reasonably be expected to be, asserted against the Company or its subsidiaries or any of
their respective properties or assets that has had or would reasonably be expected to have a Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(y)&#8195;<I>Licenses and Permits.</I> The Company and its subsidiaries possess all licenses,
<FONT STYLE="white-space:nowrap">sub-licenses,</FONT> certificates, permits and other authorizations issued by, and have made all declarations and filings with, the appropriate federal, state, local or foreign governmental or regulatory authorities
that are necessary for the ownership or lease of their respective properties or the conduct of their respective businesses as described in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus, except where the
failure to possess or make the same would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; and except as described in each of the Registration Statement, the Pricing Disclosure Package and the
Prospectus, neither the Company nor its subsidiaries have received written notice of any revocation or modification of any such license, <FONT STYLE="white-space:nowrap">sub-license,</FONT> certificate, permit or authorization or has any reason to
believe that any such license, <FONT STYLE="white-space:nowrap">sub-license,</FONT> certificate, permit or authorization will not be renewed in the ordinary course, except where such revocation, modification, or
<FONT STYLE="white-space:nowrap">non-renewal</FONT> would not, individually or in the aggregate, have a Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(z)&#8195;<I>No Labor Disputes.</I> No labor disturbance by or dispute with employees of the Company or its subsidiaries exists or, to the
knowledge of the Company, is contemplated or threatened, and the Company is not aware of any existing or imminent labor disturbance by, or dispute with, the employees of its or its subsidiaries&#146; principal suppliers, contractors or customers,
except as would not reasonably be expected to have a Material Adverse Effect. Neither the Company nor its subsidiaries have received any notice of cancellation or termination with respect to any collective bargaining agreement to which it is a
party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(aa)&#8195;<I>Certain Environmental Matters</I>. (i)&nbsp;The Company and its subsidiaries (x)&nbsp;are in compliance with all,
and have not violated any, applicable federal, state, local and foreign laws (including common law), rules, regulations, requirements, decisions, judgments, decrees, orders and other legally enforceable requirements relating to pollution or the
protection of human health or safety, the environment, natural resources, hazardous or toxic substances or wastes, pollutants or contaminants (collectively, &#147;Environmental Laws&#148;); (y) have received and are in compliance with all, and have
not violated any, permits, licenses, certificates or other authorizations or approvals required of them under any Environmental Laws to conduct their respective businesses; and (z)&nbsp;have not received written notice of any actual or potential
liability or obligation under or relating to, or any actual or potential violation of, any Environmental Laws, including for the investigation or remediation of any disposal or release of hazardous or toxic substances or wastes, pollutants or
contaminants, and have no knowledge of any event or condition that would reasonably be expected to result in any such notice; (ii)&nbsp;there are no costs or liabilities associated with Environmental Laws of or relating to the Company or its
subsidiaries, except in the case of each of (i)&nbsp;and (ii) above, for any such matter as would not, individually or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in the aggregate, reasonably be expected to have a Material Adverse Effect; and (iii)&nbsp;except as described in each of the Pricing Disclosure Package and the Prospectus, (x)&nbsp;there is no
proceeding that is pending, or that is known by the Company to be contemplated, against the Company or its subsidiaries under any Environmental Laws in which a governmental entity is also a party, other than such proceeding regarding which the
Company reasonably believes no monetary sanctions of $300,000 or more will be imposed, (y)&nbsp;the Company and its subsidiaries are not aware of any facts or issues regarding compliance with Environmental Laws, or liabilities or other obligations
under Environmental Laws or concerning hazardous or toxic substances or wastes, pollutants or contaminants, that would reasonably be expected to have a material effect on the capital expenditures, earnings or competitive position of the Company and
its subsidiaries, and (z)&nbsp;neither the Company nor its subsidiaries anticipate material capital expenditures relating to any Environmental Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(bb)&#8195;<I>Compliance with ERISA</I>. (i)&nbsp;Each employee benefit plan, within the meaning of Section&nbsp;3(3) of the Employee
Retirement Income Security Act of 1974, as amended (&#147;ERISA&#148;), for which the Company or any member of its &#147;Controlled Group&#148; (defined as any entity, whether or not incorporated, that is under common control with the Company within
the meaning of Section&nbsp;4001(a)(14) of ERISA or any entity that would be regarded as a single employer with the Company under Section&nbsp;414(b), (c), (m) or (o)&nbsp;of the Code) would have any liability (each, a &#147;Plan&#148;) has been
maintained in compliance with its terms and the requirements of any applicable statutes, orders, rules and regulations, including but not limited to ERISA and the Code; (ii)&nbsp;no prohibited transaction, within the meaning of Section&nbsp;406 of
ERISA or Section&nbsp;4975 of the Code, has occurred with respect to any Plan, excluding transactions effected pursuant to a statutory or administrative exemption; (iii)&nbsp;for each Plan that is subject to the funding rules of Section&nbsp;412 of
the Code or Section&nbsp;302 of ERISA, no Plan has failed (whether or not waived), or is reasonably expected to fail, to satisfy the minimum funding standards (within the meaning of Section&nbsp;302 of ERISA or Section&nbsp;412 of the Code)
applicable to such Plan; (iv)&nbsp;no Plan is, or is reasonably expected to be, in &#147;at risk status&#148; (within the meaning of Section&nbsp;303(i) of ERISA) and no Plan that is a &#147;multiemployer plan&#148; within the meaning of
Section&nbsp;4001(a)(3) of ERISA is in &#147;endangered status&#148; or &#147;critical status&#148; (within the meaning of Sections 304 and 305 of ERISA); (v) the fair market value of the assets of each Plan exceeds the present value of all benefits
accrued under such Plan (determined based on those assumptions used to fund such Plan); (vi) no &#147;reportable event&#148; (within the meaning of Section&nbsp;4043(c) of ERISA and the regulations promulgated thereunder) has occurred or is
reasonably expected to occur; (vii)&nbsp;each Plan that is intended to be qualified under Section&nbsp;401(a) of the Code is so qualified, and, to the knowledge of the Company, nothing has occurred, whether by action or by failure to act, which
would reasonably be expected to cause the loss of such qualification; (viii)&nbsp;neither the Company nor any member of the Controlled Group has incurred, nor reasonably expects to incur, any liability under Title IV of ERISA (other than
contributions to the Plan or premiums to the Pension Benefit Guarantee Corporation, in the ordinary course and without default) in respect of a Plan (including a &#147;multiemployer plan&#148; within the meaning of Section&nbsp;4001(a)(3) of ERISA);
and (ix)&nbsp;none of the following events has occurred or is reasonably likely to occur: (A)&nbsp;a material increase in the aggregate amount of contributions required to be made to all Plans by the Company or its Controlled Group affiliates in the
current fiscal year of the Company and its Controlled Group affiliates compared to the amount of such contributions made in the Company&#146;s and its Controlled Group affiliates&#146; most recently completed fiscal year; or (B)&nbsp;a
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
material increase in the Company and its subsidiaries&#146; &#147;accumulated post-retirement benefit obligations&#148; (within the meaning of Accounting Standards Codification Topic <FONT
STYLE="white-space:nowrap">715-60)</FONT> compared to the amount of such obligations in the Company and its subsidiaries&#146; most recently completed fiscal year, except in each case with respect to the events or conditions set forth in
(i)&nbsp;through (ix) hereof, as would not, individually or in the aggregate, have a Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(cc)&#8195;<I>Disclosure
Controls</I>. The Company and its subsidiaries maintain an effective system of &#147;disclosure controls and procedures&#148; (as defined in Rule <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> of the Exchange Act) that complies with the
requirements of the Exchange Act and that has been designed to ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time
periods specified in the Commission&#146;s rules and forms, including controls and procedures designed to ensure that such information is accumulated and communicated to the Company&#146;s management as appropriate to allow timely decisions
regarding required disclosure. The Company and its subsidiaries have carried out evaluations of the effectiveness of their disclosure controls and procedures as required by Rule <FONT STYLE="white-space:nowrap">13a-15</FONT> of the Exchange Act.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(dd)&#8195;<I>Accounting Controls. </I>The Company and its subsidiaries maintain systems of &#147;internal control over financial
reporting&#148; (as defined in Rule <FONT STYLE="white-space:nowrap">13a-15(f)</FONT> of the Exchange Act) that are designed to comply with the requirements of the Exchange Act and have been designed by, or under the supervision of, their respective
principal executive and principal financial officers, or persons performing similar functions, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in
accordance with GAAP. The Company and its subsidiaries maintain internal accounting controls sufficient to provide reasonable assurance that (i)&nbsp;transactions are executed in accordance with management&#146;s general or specific authorizations;
(ii)&nbsp;transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability; (iii)&nbsp;access to assets is permitted only in accordance with management&#146;s general
or specific authorization; (iv)&nbsp;the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences; and (v)&nbsp;interactive data in eXtensible
Business Reporting Language included or incorporated by reference in the Registration Statement, the Prospectus and the Pricing Disclosure Package fairly presents the information called for in all material respects and is prepared in accordance with
the Commission&#146;s rules and guidelines applicable thereto. Except as disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, there are no material weaknesses in the Company&#146;s internal controls. The
Company&#146;s auditors and the Audit Committee of the Board of Directors of the Company have been advised of: (i)&nbsp;all significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting
which have adversely affected or are reasonably likely to adversely affect the Company&#146;s ability to record, process, summarize and report financial information; and (ii)&nbsp;any fraud, whether or not material, that involves management or other
employees who have a significant role in the Company&#146;s internal controls over financial reporting<I>.</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ee)&#8195;<I>eXtensible
Business Reporting Language</I>. The interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement fairly presents the information called for in all material respects and has been
prepared in accordance with the Commission&#146;s rules and guidelines applicable thereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ff)&#8195;<I>Insurance. </I>The Company and its subsidiaries have insurance covering their
respective properties, operations, personnel and businesses, including business interruption insurance, which insurance is in amounts and insures against such losses and risks as are generally maintained by similarly situated companies and which the
Company believes are reasonably adequate to protect the Company and its subsidiaries and their respective businesses; and neither the Company nor its subsidiaries have (i)&nbsp;received notice from any insurer or agent of such insurer that capital
improvements or other expenditures are required or necessary to be made in order to continue such insurance or (ii)&nbsp;any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to
obtain similar coverage at reasonable cost from similar insurers as may be necessary to continue its business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(gg)&#8195;<I>Cybersecurity; Data Protection. </I>The Company and its subsidiaries&#146; information technology assets and equipment,
computers, systems, networks, hardware, software, websites, applications, and databases (including the data of their respective customers, employees, suppliers, vendors and any third party data maintained by or on behalf of the Company and its
subsidiaries) (collectively, &#147;IT Systems&#148;), are adequate for, and operate and perform in all material respects as required in connection with the operation of the business of the Company and its subsidiaries, free and clear of all material
bugs, errors, defects, Trojan horses, time bombs, malware and other corruptants (collectively, &#147;Bugs&#148;), except where such Bugs would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. The
Company and its subsidiaries have implemented and maintained commercially reasonable controls, policies, procedures, and safeguards as are generally maintained by similarly situated companies and which the Company and its subsidiaries believe are
reasonably adequate to protect their material confidential information and the integrity, continuous operation, redundancy and security of all IT Systems and data (including all personal, personally identifiable, sensitive, confidential or regulated
data (&#147;Data&#148;)) used in connection with their businesses. Without limiting the foregoing, the Company and its subsidiaries have used commercially reasonable efforts to establish and maintain, and have established, maintained, implemented
and complied with, reasonable information technology, information security, cyber security and data protection controls, policies and procedures, including oversight, access controls, encryption, technological and physical safeguards and business
continuity/disaster recovery and security plans as are generally maintained by similarly situated companies that are designed to protect against and prevent breach, destruction, loss, unauthorized distribution, use, access, disablement,
misappropriation or modification, or other compromise or misuse of or relating to any information technology system or Data used in connection with the operation of the Company&#146;s and its subsidiaries&#146; businesses that would, individually or
in the aggregate, reasonably be expected to have a Material Adverse Effect (&#147;Breach&#148;). To the knowledge of the Company, there has been no such Breach. The Company and its subsidiaries have not been notified of and have no knowledge of any
event or condition that would reasonably be expected to result in, any such Breach. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(hh)&#8195;<I>Privacy</I>. The Company and its
subsidiaries have complied, and are presently in compliance, in all material respects, with all internal and external privacy policies, contractual obligations, industry standards, applicable laws, statutes, judgments, orders, rules and regulations
of any court or arbitrator or other governmental or regulatory authority and any legal obligations regarding the collection, use, transfer, import, export, storage, protection, disposal and disclosure
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
by the Company and its subsidiaries of Data (&#147;Data Security Obligations&#148;), except where the violation of such Data Security Obligations would not, individually or in the aggregate,
reasonably be expected to have a Material Adverse Effect. Neither the Company nor its subsidiaries have received any notification of or complaint regarding, and are aware of any other facts that, individually or in the aggregate, would reasonably
indicate <FONT STYLE="white-space:nowrap">non-compliance</FONT> with any Data Security Obligation. There is no pending, or to the knowledge of the Company, threatened action, suit or proceeding by or before any court or governmental agency,
authority or body alleging <FONT STYLE="white-space:nowrap">non-compliance</FONT> with any Data Security Obligation. The Company and its subsidiaries have at all times taken steps as are generally taken by similarly situated companies (including,
without limitation, implementing and monitoring compliance with adequate measures with respect to technical and physical security) to protect such information against loss and against unauthorized access, use, modification, disclosure or other
misuse, except in each case to the extent that the failure to do so would not reasonably be expected to have a Material Adverse Effect. To the knowledge of the Company, except as disclosed in the Registration Statement, the Pricing Disclosure
Package or the Prospectus or as would not individually or in the aggregate have a Material Adverse Effect, there has been no unauthorized access to such information. The Company and its subsidiaries have taken all reasonably necessary actions to
comply with the European Union General Data Protection Regulation (and are taking all reasonably necessary actions to be in compliance as of the effective date of any applicable laws and regulations with respect to Data that have been announced as
of the date hereof and which is statutorily required to become effective within 12 months after the date hereof, and for which any <FONT STYLE="white-space:nowrap">non-compliance</FONT> with same would be reasonably expected to have a Material
Adverse Effect) as are generally taken by similarly situated companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&#8195;<I>No Unlawful Payments.</I> Neither the Company nor
its subsidiaries nor any director, officer or employee of the Company or its subsidiaries nor, to the knowledge of the Company, any agent, affiliate or other person associated with or acting on behalf of the Company or its subsidiaries have
(i)&nbsp;used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expense relating to political activity; (ii)&nbsp;made or taken an act in furtherance of an offer, promise or authorization of any direct or
indirect unlawful payment or benefit to any foreign or domestic government official or employee, including of any government-owned or controlled entity or of a public international organization, or any person acting in an official capacity for or on
behalf of any of the foregoing, or any political party or party official or candidate for political office; (iii)&nbsp;violated or is in violation of any provision of the Foreign Corrupt Practices Act of 1977, as amended, or any applicable law or
regulation implementing the OECD Convention on Combating Bribery of Foreign Public Officials in International Business Transactions, or committed an offence under the Bribery Act 2010 of the United Kingdom or any other applicable anti-bribery or
anti-corruption law; or (iv)&nbsp;made, offered, agreed, requested or taken an act in furtherance of any unlawful bribe or other unlawful benefit, including, without limitation, any rebate, payoff, influence payment, kickback or other unlawful or
improper payment or benefit. The Company and its subsidiaries have instituted, maintain and enforce, and will continue to maintain and enforce policies and procedures designed to promote and ensure compliance with all applicable anti-bribery and
anti-corruption laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(jj)&#8195;<I>Compliance with Anti-Money Laundering Laws</I>. The operations of the Company
and its subsidiaries are and have been conducted at all times in compliance with applicable financial recordkeeping and reporting requirements, including those of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the
applicable money laundering statutes of all jurisdictions where the Company or its subsidiaries conduct business, the rules and regulations thereunder and any related or similar rules, regulations or guidelines issued, administered or enforced by
any governmental agency (collectively, the &#147;Anti-Money Laundering Laws&#148;) and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or its subsidiaries with
respect to the Anti-Money Laundering Laws is pending or, to the knowledge of the Company, threatened. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(kk)&#8195;<I>No Conflicts with
Sanctions Laws. </I>Neither the Company nor its subsidiaries, directors, officers, or employees, nor, to the knowledge of the Company, any agent, affiliate or other person associated with or acting on behalf of the Company or its subsidiaries is
currently the subject or the target of any sanctions administered or enforced by the U.S. government, (including, without limitation, the Office of Foreign Assets Control of the U.S. Department of the Treasury or the U.S. Department of State and
including, without limitation, the designation as a &#147;specially designated national&#148; or &#147;blocked person&#148;), the United Nations Security Council, the European Union, His Majesty&#146;s Treasury or other relevant sanctions authority
(collectively, &#147;Sanctions&#148;), nor are the Company or its subsidiaries located, organized or resident in a country or territory that is the subject or target of Sanctions, including, without limitation, Cuba, Iran, North Korea, Syria, the
Crimea region and the <FONT STYLE="white-space:nowrap">so-called</FONT> Donetsk People&#146;s Republic, or <FONT STYLE="white-space:nowrap">so-called</FONT> Luhansk People&#146;s Republic or any other Covered Region of Ukraine identified pursuant to
Executive Order 14065 (each, a &#147;Sanctioned Country&#148;); and the Company will not directly or indirectly use the proceeds of the offering of the Securities hereunder, or lend, contribute or otherwise make available such proceeds to any
subsidiary, joint venture partner or other person or entity (i)&nbsp;to fund or facilitate any activities of or business with any person that, at the time of such funding or facilitation, is the subject or target of Sanctions, (ii)&nbsp;to fund or
facilitate any activities of or business in any Sanctioned Country or (iii)&nbsp;in any other manner that will result in a violation by any person (including any person participating in the transaction, whether as underwriter, advisor, investor or
otherwise) of Sanctions. Since the Company&#146;s inception, the Company and its subsidiaries have not knowingly engaged in and are not now knowingly engaged in any dealings or transactions with any person that at the time of the dealing or
transaction is or was the subject or the target of Sanctions or with any Sanctioned Country. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ll)&#8195;<I>No Restrictions on
Subsidiaries</I>. The subsidiaries of the Company are not currently prohibited, directly or indirectly, under any agreement or other instrument to which they are a party or are subject, from paying any dividends to the Company, from making any other
distribution on such subsidiaries&#146; capital stock or similar ownership interest, from repaying to the Company any loans or advances to such subsidiaries from the Company or from transferring any of such subsidiaries&#146; properties or assets to
the Company or any other subsidiaries of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(mm)&#8195;<I>No Broker&#146;s Fees.</I> Neither the Company nor its subsidiaries
are a party to any contract, agreement or understanding with any person (other than this Agreement) that would give rise to a valid claim against any of them or any Underwriter for a brokerage commission, finder&#146;s fee or like payment in
connection with the offering and sale of the Securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(nn)&#8195;<I>No Registration Rights</I>. No person has the right to require the Company or
its subsidiaries to register any securities for sale under the Securities Act by reason of the filing of the Registration Statement with the Commission or the issuance and sale of the Securities, except for such rights as have duly been waived. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(oo)&#8195;<I>No Stabilization.</I> Neither the Company nor its subsidiaries or, to the Company&#146;s knowledge, affiliates have taken,
directly or indirectly, any action designed to or that would reasonably be expected to cause or result in any stabilization or manipulation of the price of the Securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(pp)&#8195;<I>Margin Rules</I>. Neither the issuance, sale and delivery of the Securities nor the application of the proceeds thereof by the
Company as described in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus will violate Regulation T, U or X of the Board of Governors of the Federal Reserve System or any other regulation of such Board of
Governors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(qq)&#8195;<I>Forward-Looking Statements.</I> No forward-looking statement (within the meaning of Section&nbsp;27A of the
Securities Act and Section&nbsp;21E of the Exchange Act) included or incorporated by reference in any of the Registration Statement, the Pricing Disclosure Package or the Prospectus has been made or reaffirmed without a reasonable basis or has been
disclosed other than in good faith. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(rr)&#8195;<I>Statistical and Market Data.</I> Nothing has come to the attention of the Company that
has caused the Company to believe that the statistical and market-related data included or incorporated by reference in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus is not based on or derived from sources
that are reliable and accurate in all material respects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ss)&#8195;<I>Sarbanes-Oxley Act</I>. There is and has been no failure on the
part of the Company or, to the knowledge of the Company, any of the Company&#146;s directors or officers, in their capacities as such, to comply with any applicable provision of the Sarbanes-Oxley Act of 2002, as amended and the rules and
regulations promulgated in connection therewith, including Section&nbsp;402 related to loans and Sections 302 and 906 related to certifications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(tt)&#8195;<I>Status under the Securities Act</I>. At the time of filing the Registration Statement and any post-effective amendment thereto,
at the earliest time thereafter that the Company or any offering participant made a <I>bona fide</I> offer (within the meaning of Rule 164(h)(2) under the Securities Act) of the Securities and at the date hereof, the Company was not and is not an
&#147;ineligible issuer,&#148; and is a well-known seasoned issuer, in each case as defined in Rule 405 under the Securities Act. The Company has paid the registration fee for this offering pursuant to Rule 456(b)(1) under the Securities Act or will
pay such fee within the time period required by such rule (without giving effect to the proviso therein) and in any event prior to the Closing Date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(uu)&#8195;<I>No Ratings</I>. There are (and prior to the Closing Date, will be) no debt
securities, convertible securities or preferred stock issued or guaranteed by the Company or its subsidiaries that are rated by a &#147;nationally recognized statistical rating organization&#148;, as such term is defined in Section&nbsp;3(a)(62)
under the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vv)&#8195;<I>Preclinical Studies</I>. (i)&nbsp;Except as described in the Registration Statement, the Pricing
Disclosure Package and the Prospectus, the preclinical studies conducted by or, to the knowledge of the Company, on behalf of or sponsored by the Company or its subsidiaries, or in which the Company or its subsidiaries have participated, that are
described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, or the results of which are referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus, as applicable, were, and if still
pending are, being conducted in all material respects in accordance with standard medical and scientific research standards and procedures for products or product candidates comparable to those being developed by the Company and all applicable
statutes and all applicable rules and regulations of the U.S. Food and Drug Administration and comparable regulatory agencies outside of the United States to which they are subject, including the European Medicines Agency (collectively, the
&#147;Regulatory Authorities&#148;), and applicable Good Laboratory Practice requirements; (ii)&nbsp;the descriptions in the Registration Statement, the Pricing Disclosure Package and the Prospectus of the results of such studies are accurate and
complete descriptions in all material respects and fairly present the data derived therefrom; (iii)&nbsp;the Company has no knowledge of any other studies not described in the Registration Statement, the Pricing Disclosure Package and the
Prospectus, the results of which are materially inconsistent with or call into question the results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus; (iv)&nbsp;the Company and its subsidiaries
have operated at all times and are currently in compliance with all applicable statutes, rules and regulations of the Regulatory Authorities, except where such <FONT STYLE="white-space:nowrap">non-compliance</FONT> would not, individually or in the
aggregate, have a Material Adverse Effect; (v)&nbsp;the Company has provided the Underwriters with all material written notices, correspondence and summaries of all other communications from the Regulatory Authorities; and (vi)&nbsp;neither the
Company nor its subsidiaries have received any written notices, correspondence or other communications from the Regulatory Authorities or any other governmental agency requiring or threatening the termination, material modification or suspension of
any preclinical studies that are described in the Registration Statement, the Pricing Disclosure Package and the Prospectus or the results of which are referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus,
other than ordinary course communications with respect to modifications in connection with the design and implementation of such studies or trials, and, to the Company&#146;s knowledge, there are no reasonable grounds for the same. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ww)&#8195;<I>Regulatory Filings</I>. The Company has not failed to file with the Regulatory Authorities any material filing, declaration,
listing, registration, report or submission with respect to the Company&#146;s product candidates that are described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus; all such filings, declarations,
listings, registrations, reports or submissions, as applicable, were in material compliance with applicable laws when filed; and no material deficiencies regarding compliance with applicable law have been asserted by any applicable regulatory
authority with respect to any such filings, declarations, listings, registrations, reports or submissions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.&#8195;<U>Further Agreements of the Company</U>. The Company covenants and agrees with
each Underwriter that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&#8195;<I>Required Filings.</I> The Company will file the final Prospectus with the Commission
within the time periods specified by Rule 424(b) and Rule 430A, 430B or 430C under the Securities Act, will file any Issuer Free Writing Prospectus to the extent required by Rule 433 under the Securities Act; and the Company will file promptly all
reports and any definitive proxy or information statements required to be filed by the Company with the Commission pursuant to Section&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the date of the Prospectus and for so long as the
delivery of a prospectus is required in connection with the offering or sale of the Securities; and the Company will furnish copies of the Prospectus and each Issuer Free Writing Prospectus (to the extent not previously delivered) to the
Underwriters in New York City prior to 10:00 A.M., New York City time, on the business day next succeeding the date of this Agreement in such quantities as the Representatives may reasonably request. The Company will pay the registration fee for
this offering within the time period required by Rule 456(b)(1) under the Securities Act (without giving effect to the proviso therein) and in any event prior to the Closing Date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&#8195;<I>Delivery of Copies.</I> The Company will deliver, without charge, (i)&nbsp;to the Representatives, two signed
copies of the Registration Statement as originally filed and each amendment thereto, in each case including all exhibits and consents filed therewith and documents incorporated by reference therein; and (ii)&nbsp;to each Underwriter (A)&nbsp;a
conformed copy of the Registration Statement as originally filed and each amendment thereto (without exhibits) and (B)&nbsp;during the Prospectus Delivery Period (as defined below), as many copies of the Prospectus (including all amendments and
supplements thereto and documents incorporated by reference therein and each Issuer Free Writing Prospectus) as the Representatives may reasonably request. As used herein, the term &#147;Prospectus Delivery Period&#148; means such period of time
after the first date of the offering of the Securities as in the opinion of counsel for the Underwriters a prospectus relating to the Securities is required by law to be delivered (or required to be delivered but for Rule 172 under the Securities
Act) in connection with sales of the Securities by any Underwriter or dealer. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&#8195;<I>Amendments or Supplements,
Issuer Free Writing Prospectuses.</I> Before making, preparing, using, authorizing, approving, referring to or filing any Issuer Free Writing Prospectus, and before filing any amendment or supplement to the Registration Statement, the Pricing
Disclosure Package or the Prospectus, whether before or after the time that the Registration Statement becomes effective, the Company will furnish to the Representatives and counsel for the Underwriters a copy of the proposed Issuer Free Writing
Prospectus, amendment or supplement for review and will not make, prepare, use, authorize, approve, refer to or file any such Issuer Free Writing Prospectus or file any such proposed amendment or supplement to which the Representatives reasonably
object. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&#8195;<I>Notice to the Representatives.</I> The Company will advise the Representatives promptly, and confirm
such advice in writing (which advice may be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
delivered via electronic mail), (i) when the Registration Statement has become effective; (ii)&nbsp;when any amendment to the Registration Statement has been filed or becomes effective;
(iii)&nbsp;when any supplement to the Pricing Disclosure Package, the Prospectus or any Issuer Free Writing Prospectus or any amendment to the Prospectus has been filed or distributed; (iv)&nbsp;of any request by the Commission for any amendment to
the Registration Statement or any amendment or supplement to the Prospectus or the receipt of any comments from the Commission relating to the Registration Statement or any other request by the Commission for any additional information; (v)&nbsp;of
the issuance by the Commission or any other governmental or regulatory authority of any order suspending the effectiveness of the Registration Statement or preventing or suspending the use of any Preliminary Prospectus, any of the Pricing Disclosure
Package or the Prospectus or the initiation or, to the knowledge of the Company, threatening of any proceeding for that purpose or pursuant to Section&nbsp;8A of the Securities Act; (vi)&nbsp;of the occurrence of any event or development within the
Prospectus Delivery Period as a result of which the Prospectus, any of the Pricing Disclosure Package or any Issuer Free Writing Prospectus as then amended or supplemented would include any untrue statement of a material fact or omit to state a
material fact necessary in order to make the statements therein, in the light of the circumstances existing when the Prospectus, the Pricing Disclosure Package or any such Issuer Free Writing Prospectus is delivered to a purchaser, not misleading;
(vii)&nbsp;of the receipt by the Company of any notice of objection of the Commission to the use of the Registration Statement or any post-effective amendment thereto pursuant to Rule 401(g)(2) under the Securities Act; and (viii)&nbsp;of the
receipt by the Company of any notice with respect to any suspension of the qualification of the Securities for offer and sale in any jurisdiction or the initiation or, to the knowledge of the Company, threatening of any proceeding for such purpose;
and the Company will use its reasonable best efforts to prevent the issuance of any such order suspending the effectiveness of the Registration Statement, preventing or suspending the use of any Preliminary Prospectus, any of the Pricing Disclosure
Package or the Prospectus or suspending any such qualification of the Securities and, if any such order is issued, will use its reasonable best efforts to obtain as soon as possible the withdrawal thereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&#8195;<I>Ongoing Compliance.</I> (1)&nbsp;If during the Prospectus Delivery Period (i)&nbsp;any event or development shall
occur or condition shall exist as a result of which the Prospectus as then amended or supplemented would include any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in the
light of the circumstances existing when the Prospectus is delivered to a purchaser, not misleading or (ii)&nbsp;it is necessary to amend or supplement the Prospectus to comply with law, the Company will promptly notify the Underwriters thereof and
forthwith prepare and, subject to paragraph (c)&nbsp;above, file with the Commission and furnish to the Underwriters and to such dealers as the Representatives may designate such amendments or supplements to the Prospectus (or any document to be
filed with the Commission and incorporated by reference therein) as may be necessary so that the statements in the Prospectus as so amended or supplemented (or any document to be filed with the Commission and incorporated by reference therein) will
not, in the light of the circumstances existing when the Prospectus is delivered to a purchaser, be misleading or so that the Prospectus will comply with law and (2)&nbsp;if at any time prior to the Closing
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Date (i)&nbsp;any event or development shall occur or condition shall exist as a result of which the Pricing Disclosure Package as then amended or supplemented would include any untrue statement
of a material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances existing when the Pricing Disclosure Package is delivered to a purchaser, not misleading or (ii)&nbsp;it is
necessary to amend or supplement the Pricing Disclosure Package to comply with law, the Company will promptly notify the Underwriters thereof and forthwith prepare and, subject to paragraph (c)&nbsp;above, file with the Commission (to the extent
required) and furnish to the Underwriters and to such dealers as the Representatives may designate such amendments or supplements to the Pricing Disclosure Package (or any document to be filed with the Commission and incorporated by reference
therein) as may be necessary so that the statements in the Pricing Disclosure Package as so amended or supplemented will not, in the light of the circumstances existing when the Pricing Disclosure Package is delivered to a purchaser, be misleading
or so that the Pricing Disclosure Package will comply with law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)&#8195;<I>Blue Sky Compliance.</I> The Company will
qualify the Securities for offer and sale under the securities or Blue Sky laws of such jurisdictions as the Representatives shall reasonably request and will continue such qualifications in effect so long as required for distribution of the
Securities; <U>provided</U> that the Company shall not be required to (i)&nbsp;qualify as a foreign corporation or other entity or as a dealer in securities in any such jurisdiction where it would not otherwise be required to so qualify,
(ii)&nbsp;file any general consent to service of process in any such jurisdiction or (iii)&nbsp;subject itself to taxation in any such jurisdiction if it is not otherwise so subject. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g)&#8195;<I>Earning Statement. </I>The Company will make generally available to its security holders and the Representatives
as soon as practicable an earning statement that satisfies the provisions of Section&nbsp;11(a) of the Securities Act and Rule 158 of the Commission promulgated thereunder covering a period of at least twelve months beginning with the first fiscal
quarter of the Company occurring after the &#147;effective date&#148; (as defined in Rule 158) of the Registration Statement, provided that the Company will be deemed to have furnished such statements to its security holders and the Representatives
to the extent they are filed on the Commission&#146;s Electronic Data Gathering, Analysis and Retrieval system. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h)&#8195;<I>Clear Market. </I>For a period of 45 days after the date of the Prospectus (the &#147;Restricted Period&#148;),
the Company will not (i)&nbsp;offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of,
directly or indirectly, or submit to, or file with, the Commission a registration statement under the Securities Act relating to, any shares of Stock or any securities convertible into or exercisable or exchangeable for Stock, or publicly disclose
the intention to undertake any of the foregoing, or (ii)&nbsp;enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Stock or such other securities, whether any such
transaction described in clause (i)&nbsp;or (ii) above is to be settled by delivery of Stock or such other securities, in cash or otherwise, without the prior written consent of J.P. Morgan Securities LLC, Jefferies LLC, Cantor Fitzgerald&nbsp;&amp;
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Co., Citigroup Global Markets Inc. and Wells Fargo Securities, LLC, other than (A)&nbsp;the Securities to be sold hereunder, (B)&nbsp;any shares of Stock of the Company issued upon the exercise
of options granted under Company Stock Plans or issued upon vesting and settlement of restricted stock units granted under the Company Stock Plans, (C)&nbsp;any options and other awards granted under a Company Stock Plan, (D)&nbsp;the filing by the
Company of any registration statement on Form <FONT STYLE="white-space:nowrap">S-8</FONT> or a successor form thereto relating to a Company Stock Plan, (E)&nbsp;shares of Common Stock which may be issuable to The Broad Institute, the President and
Fellows of Harvard College or their affiliates pursuant to the Company&#146;s license agreements, (F)&nbsp;shares of Common Stock which may be issuable to the former stockholders and optionholders of Guide Therapeutics, Inc. pursuant to the
Agreement and Plan of Merger entered into with Guide Therapeutics, Inc. on February&nbsp;22, 2021, (G) shares of Stock or other securities issued in connection with a transaction with an unaffiliated third party that includes a bona fide commercial
relationship (including joint ventures, marketing or distribution arrangements, collaboration agreements or licensing agreements) or any acquisition of assets of not less than a majority or controlling portion of the equity of another entity,
provided that (x)&nbsp;the aggregate number of the shares issued pursuant to clause (G)&nbsp;shall not exceed more than ten percent (10%) of the total number of outstanding shares of Stock immediately following the issuance and sale of the Shares
pursuant to this Agreement, and (y)&nbsp;the recipient of any such shares of Stock or securities issued pursuant to clause (G)&nbsp;during the Restricted Period shall enter into (if it has not previously entered into) an agreement substantially in
the form of Exhibit A hereto, (H)&nbsp;shares of Stock issued pursuant to the Sales Agreement, by and between the Company and Jefferies LLC, dated April&nbsp;1, 2021, as amended, provided that no sales shall be made thereunder until 30 days from the
date of the Prospectus and (I)&nbsp;the delivery of Warrant Shares upon exercise of the Warrants. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&#8195;<I>Use of
Proceeds.</I> The Company will apply the net proceeds from the sale of the Securities as described in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus under the heading &#147;Use of Proceeds.&#148; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j)&#8195;<I>No Stabilization.</I> Neither the Company nor its subsidiaries will take, directly or indirectly, without giving
effect to activities by the Underwriters, any action designed to or that could reasonably be expected to cause or result in any stabilization or manipulation of the price of the Stock or violation of the applicable provisions of Regulation M under
the Exchange Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k)&#8195;<I>Exchange Listing. </I>The Company will use its reasonable best efforts to list the Shares
and the Warrant Shares on the Nasdaq Market. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l)&#8195;<I>Reports.</I> During a period of three years from the date of
this Agreement, the Company will furnish to the Representatives, as soon as commercially reasonable after the date they are available, copies of all reports or other communications (financial or other) furnished to holders of the Securities or the
Warrant Shares, and copies of any reports and financial statements furnished to or filed with the Commission or any national securities exchange or automatic quotation system; <U>provided</U> the Company will be deemed to have furnished such reports
and financial statements to the Representatives to the extent they are filed on the Commission&#146;s Electronic Data Gathering, Analysis, and Retrieval system, or any successor to such system. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m)&#8195;<I>Record Retention</I>. The Company will, pursuant to reasonable
procedures developed in good faith, retain copies of each Issuer Free Writing Prospectus that is not filed with the Commission in accordance with Rule 433 under the Securities Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n)&#8195;<I>Warrant Shares Reserved</I>. The Company shall, at all times while any Warrants are outstanding, reserve and keep
available out of its authorized but unissued and otherwise unreserved shares of common stock, solely for the purpose of enabling it to issue Warrant Shares upon exercise of such Warrants, the number of Warrant Shares that are initially issuable and
deliverable upon the exercise of the then-outstanding Warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.&#8195;<U>Certain Agreements of the Underwriters</U>. Each Underwriter
hereby represents and agrees that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&#8195;It has not used, authorized use of, referred to or participated in the
planning for use of, and will not use, authorize use of, refer to or participate in the planning for use of, any &#147;free writing prospectus&#148;, as defined in Rule 405 under the Securities Act (which term includes use of any written information
furnished to the Commission by the Company and not incorporated by reference into the Registration Statement and any press release issued by the Company) other than (i)&nbsp;a free writing prospectus that contains no &#147;issuer information&#148;
(as defined in Rule 433(h)(2) under the Securities Act) that was not included (including through incorporation by reference) in any Preliminary Prospectus or a previously filed Issuer Free Writing Prospectus, (ii)&nbsp;any Issuer Free Writing
Prospectus listed on <U>Annex A</U> or prepared pursuant to Section&nbsp;3(c) or Section&nbsp;4(c) above (including any electronic road show), or (iii)&nbsp;any free writing prospectus prepared by such Underwriter and approved by the Company in
advance in writing (each such free writing prospectus referred to in clauses (i)&nbsp;or (iii), an &#147;Underwriter Free Writing Prospectus&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&#8195;It has not used and will not use, without the prior written consent of the Company, any free writing prospectus that
contains the final terms of the Securities unless such terms have previously been included in a free writing prospectus filed with the Commission; <I>provided </I>that any Underwriter using such a term sheet shall notify the Company, and provide a
copy of such term sheet to the Company, prior to, or substantially concurrently with, the first use of such term sheet. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&#8195;It is not subject to any pending proceeding under Section&nbsp;8A of the Securities Act with respect to the offering
(and will promptly notify the Company if any such proceeding against it is initiated during the Prospectus Delivery Period). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.&#8195;<U>Conditions of Underwriters&#146; Obligations.</U> The obligation of each Underwriter to purchase the Securities on the Closing
Date, as provided herein is subject to the performance by the Company of its covenants and other obligations hereunder and to the following additional conditions: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&#8195;<I>Registration Compliance; No Stop Order.</I> No order suspending
the effectiveness of the Registration Statement shall be in effect, and no proceeding for such purpose, pursuant to Rule 401(g)(2) or pursuant to Section&nbsp;8A under the Securities Act, shall be pending before or threatened by the Commission; the
Prospectus and each Issuer Free Writing Prospectus shall have been timely filed with the Commission under the Securities Act (in the case of an Issuer Free Writing Prospectus, to the extent required by Rule 433 under the Securities Act) and in
accordance with Section&nbsp;4(a) hereof; and all requests by the Commission for additional information shall have been complied with to the reasonable satisfaction of the Representatives. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&#8195;<I>Representations and Warranties.</I> The representations and warranties of the Company contained herein shall be
true and correct on the date hereof and on and as of the Closing Date; and the statements of the Company and its officers made in any certificates delivered pursuant to this Agreement shall be true and correct on and as of the Closing Date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&#8195;<I>No Material Adverse Change.</I> No event or condition of a type described in Section&nbsp;3(g) hereof shall have
occurred or shall exist, which event or condition is not described in the Pricing Disclosure Package (excluding any amendment or supplement thereto) and the Prospectus (excluding any amendment or supplement thereto) and the effect of which in the
judgment of the Representatives makes it impracticable or inadvisable to proceed with the offering, sale or delivery of the Securities on the Closing Date, on the terms and in the manner contemplated by this Agreement, the Pricing Disclosure Package
and the Prospectus. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&#8195;<I>Officers&#146; Certificate.</I> The Representatives shall have received on and as of the
Closing Date, a certificate of the chief financial officer or chief accounting officer of the Company and one additional senior executive officer of the Company who is satisfactory to the Representatives, on behalf of the Company and not in their
individual capacity, (i)&nbsp;confirming that such officers have carefully reviewed the Registration Statement, the Pricing Disclosure Package and the Prospectus and, to the knowledge of such officers, the representations set forth in Sections 3(b)
and 3(f) hereof are true and correct, (ii)&nbsp;confirming that the other representations and warranties of the Company in this Agreement are true and correct and that the Company has complied in all material respects with all agreements and
satisfied all conditions on its part to be performed or satisfied hereunder at or prior to the Closing Date, and (iii)&nbsp;to the effect set forth in paragraphs (a), (b) and (c)&nbsp;above. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&#8195;<I>Comfort Letters.</I> On the date of this Agreement and on the Closing Date, Deloitte&nbsp;&amp; Touche LLP shall
have furnished to the Representatives, at the request of the Company, letters, dated the respective dates of delivery thereof and addressed to the Underwriters, in form and substance reasonably satisfactory to the Representatives, containing
statements and information of the type customarily included in accountants&#146; &#147;comfort letters&#148; to underwriters with respect to the financial statements and certain financial information contained or incorporated by reference in each of
the Registration Statement, the Pricing Disclosure Package and the Prospectus; provided, that the letter delivered on the Closing Date shall use a <FONT STYLE="white-space:nowrap">&#147;cut-off&#148;</FONT> date not earlier than the date hereof.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)&#8195;<I>Opinion and <FONT STYLE="white-space:nowrap">10b-5</FONT>
Statement of Counsel for the Company.</I> Wilmer Cutler Pickering Hale and Dorr LLP, counsel for the Company, shall have furnished to the Representatives, at the request of the Company, their written opinion and
<FONT STYLE="white-space:nowrap">10b-5</FONT> statement, dated the Closing Date, and addressed to the Underwriters, in form and substance reasonably satisfactory to the Representatives. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g)&#8195;<I>Opinion of Intellectual Property Counsel for the Company</I>. The Representatives shall have received, on and as
of the Closing Date, an opinion of Greenberg Traurig LLP, intellectual property counsel for the Company, addressed to the Underwriters and in form and substance satisfactory to the Representatives. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h)&#8195;<I>Opinion and <FONT STYLE="white-space:nowrap">10b-5</FONT> Statement of Counsel for the Underwriters.</I> The
Representatives shall have received on and as of the Closing Date, an opinion and <FONT STYLE="white-space:nowrap">10b-5</FONT> statement, addressed to the Underwriters, of Davis Polk&nbsp;&amp; Wardwell LLP, counsel for the Underwriters, with
respect to such matters as the Representatives may reasonably request, and such counsel shall have received such documents and information as they may reasonably request to enable them to pass upon such matters. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&#8195;<I>No Legal Impediment to Issuance and Sale.</I> No action shall have been taken and no statute, rule, regulation or
order shall have been enacted, adopted or issued by any federal, state or foreign governmental or regulatory authority that would, as of the Closing Date, prevent the issuance or sale of the Securities; and no injunction or order of any federal,
state or foreign court shall have been issued that would, as of the Closing Date, prevent the issuance or sale of the Securities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j)&#8195;<I>Good Standing</I>. The Representatives shall have received on and as of the Closing Date, satisfactory evidence of
the good standing of the Company and its subsidiaries in their respective jurisdictions of organization and their good standing in such other jurisdictions as the Representatives may reasonably request, in each case in writing or any standard form
of telecommunication from the appropriate governmental authorities of such jurisdictions. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k)&#8195;<I>Exchange
Listing.</I> The Shares to be delivered on the Closing Date and any Warrant Shares to be delivered upon exercise of the Warrants, as the case may be, shall have been approved for listing on the Nasdaq Market. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l)&#8195;<I><FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreements</I>. The
<FONT STYLE="white-space:nowrap">&#147;lock-up&#148;</FONT> agreements, each substantially in the form of <U>Exhibit A</U> hereto, between you and certain shareholders, officers and directors of the Company relating to sales and certain other
dispositions of shares of Stock or certain other securities, delivered to you on or before the date hereof, shall be in full force and effect on the Closing Date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m)&#8195;<I>Additional Documents.</I> On or prior to the Closing Date, the Company shall have furnished to the Representatives
such further certificates and documents as the Representatives may reasonably request. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n)&#8195;<I>Form of Warrant.</I> On or prior to the Closing Date, the
Representatives shall have received a form of Warrant in form and substance reasonably satisfactory to the Representatives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All opinions,
letters, certificates and evidence mentioned above or elsewhere in this Agreement shall be deemed to be in compliance with the provisions hereof only if they are in form and substance reasonably satisfactory to counsel for the Underwriters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.&#8195;<U>Indemnification and Contribution</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&#8195;<I>Indemnification of the Underwriters.</I> The Company agrees to indemnify and hold harmless each Underwriter, its affiliates,
directors, officers, employees and each person, if any, who controls such Underwriter within the meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act, from and against any and all losses, claims, damages and
liabilities (including, without limitation, legal fees and other expenses incurred in connection with any suit, action or proceeding or any claim asserted, as such fees and expenses are incurred), joint or several, that arise out of, or are based
upon, (i)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement or caused by any omission or alleged omission to state therein a material fact required to be stated therein or necessary in
order to make the statements therein, not misleading, or (ii)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in the Prospectus (or any amendment or supplement thereto), any Preliminary Prospectus, any Issuer Free
Writing Prospectus, any &#147;issuer information&#148; filed or required to be filed pursuant to Rule 433(d) under the Securities Act, any road show as defined in Rule 433(h) under the Securities Act (a &#147;road show&#148;) or any Pricing
Disclosure Package (including any Pricing Disclosure Package that has subsequently been amended), or caused by any omission or alleged omission to state therein a material fact necessary in order to make the statements therein, in light of the
circumstances under which they were made, not misleading, in each case except insofar as such losses, claims, damages or liabilities arise out of, or are based upon, any untrue statement or omission or alleged untrue statement or omission made in
reliance upon and in conformity with any information relating to any Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for use therein, it being understood and agreed that the only such
information furnished by any Underwriter consists of the information described as such in paragraph (b)&nbsp;below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&#8195;<I>Indemnification of the Company.</I> Each Underwriter agrees, severally and not jointly, to indemnify and hold harmless the
Company, its directors, its officers who signed the Registration Statement and each person, if any, who controls the Company within the meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act to the same extent as the
indemnity set forth in paragraph (a)&nbsp;above, but only with respect to any losses, claims, damages or liabilities that arise out of, or are based upon, any untrue statement or omission or alleged untrue statement or omission made in reliance upon
and in conformity with any information relating to such Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for use in the Registration Statement, the Prospectus (or any amendment or supplement
thereto), any Preliminary Prospectus, any Issuer Free Writing Prospectus, any road show or any Pricing Disclosure Package (including any Pricing Disclosure Package that has subsequently been amended), it being understood and agreed upon that the
only </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such information furnished by any Underwriter consists of the following information in the Prospectus furnished on behalf of each Underwriter: the concession and reallowance figures appearing in
the third paragraph under the caption &#147;Underwriting&#148;, the information contained in the thirteenth, fourteenth and fifteenth paragraphs under the caption &#147;Underwriting.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&#8195;<I>Notice and Procedures.</I> If any suit, action, proceeding (including any governmental or regulatory investigation), claim or
demand shall be brought or asserted against any person in respect of which indemnification may be sought pursuant to the preceding paragraphs of this Section&nbsp;7, such person (the &#147;Indemnified Person&#148;) shall promptly notify the person
against whom such indemnification may be sought (the &#147;Indemnifying Person&#148;) in writing; <U>provided</U> that the failure to notify the Indemnifying Person shall not relieve it from any liability that it may have under the preceding
paragraphs of this Section&nbsp;7 except to the extent that it has been materially prejudiced (through the forfeiture of substantive rights or defenses) by such failure; and <U>provided</U>, <U>further</U>, that the failure to notify the
Indemnifying Person shall not relieve it from any liability that it may have to an Indemnified Person otherwise than under the preceding paragraphs of this Section&nbsp;7. If any such proceeding shall be brought or asserted against an Indemnified
Person and it shall have notified the Indemnifying Person thereof, the Indemnifying Person shall retain counsel reasonably satisfactory to the Indemnified Person (who shall not, without the consent of the Indemnified Person, be counsel to the
Indemnifying Person) to represent the Indemnified Person and any others entitled to indemnification pursuant to this Section that the Indemnifying Person may designate in such proceeding and shall pay the reasonable and documented fees and expenses
in such proceeding and shall pay the reasonable and documented fees and expenses of such counsel related to such proceeding, as incurred. In any such proceeding, any Indemnified Person shall have the right to retain its own counsel, but the fees and
expenses of such counsel shall be at the expense of such Indemnified Person unless (i)&nbsp;the Indemnifying Person and the Indemnified Person shall have mutually agreed to the contrary; (ii)&nbsp;the Indemnifying Person has failed within a
reasonable time to retain counsel reasonably satisfactory to the Indemnified Person; (iii)&nbsp;the Indemnified Person shall have reasonably concluded that there may be legal defenses available to it that are different from or in addition to those
available to the Indemnifying Person; or (iv)&nbsp;the named parties in any such proceeding (including any impleaded parties) include both the Indemnifying Person and the Indemnified Person and representation of both parties by the same counsel
would be inappropriate due to actual or potential differing interests between them. It is understood and agreed that the Indemnifying Person shall not, in connection with any proceeding or related proceeding in the same jurisdiction, be liable for
the fees and expenses of more than one separate firm (in addition to any local counsel) for all Indemnified Persons, and that all such fees and expenses shall be paid or reimbursed as they are incurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&#8195;Any such separate firm for any Underwriter, its affiliates, directors and officers and any control persons of such Underwriter shall
be designated in writing by J.P. Morgan Securities LLC, Jefferies LLC, Cantor Fitzgerald&nbsp;&amp; Co., Citigroup Global Markets Inc. and Wells Fargo Securities, LLC and any such separate firm for the Company, its directors, its officers who signed
the Registration Statement and any control persons of the Company shall be designated in writing by the Company. The Indemnifying Person shall not be liable for any settlement of any proceeding effected without its written consent, but if settled
with such consent, the Indemnifying Person agrees to indemnify each Indemnified Person from and against </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any loss or liability by reason of such settlement. Notwithstanding the foregoing sentence, if at any time an Indemnified Person shall have requested that an Indemnifying Person reimburse the
Indemnified Person for reasonable and documented fees and expenses of counsel as contemplated by this paragraph, the Indemnifying Person shall be liable for any settlement of any proceeding effected without its written consent if (i)&nbsp;such
settlement is entered into more than 30 days after receipt by the Indemnifying Person of such request and (ii)&nbsp;the Indemnifying Person shall not have reimbursed the Indemnified Person in accordance with such request prior to the date of such
settlement. No Indemnifying Person shall, without the written consent of the Indemnified Person, effect any settlement of any pending or threatened proceeding in respect of which any Indemnified Person is or could have been a party and
indemnification could have been sought hereunder by such Indemnified Person, unless such settlement (x)&nbsp;includes an unconditional release of such Indemnified Person, in form and substance reasonably satisfactory to such Indemnified Person, from
all liability on claims that are the subject matter of such proceeding and (y)&nbsp;does not include any statement as to or any admission of fault, culpability or a failure to act by or on behalf of any Indemnified Person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&#8195;<I>Contribution.</I> If the indemnification provided for in paragraphs (a)&nbsp;or (b) above is unavailable to an Indemnified Person
or insufficient in respect of any losses, claims, damages or liabilities referred to therein, then each Indemnifying Person under such paragraph, in lieu of indemnifying such Indemnified Person thereunder, shall contribute to the amount paid or
payable by such Indemnified Person as a result of such losses, claims, damages or liabilities (i)&nbsp;in such proportion as is appropriate to reflect the relative benefits received by the Company, on the one hand, and the Underwriters on the other,
from the offering of the Securities or (ii)&nbsp;if the allocation provided by clause (i)&nbsp;is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause (i)&nbsp;but also
the relative fault of the Company, on the one hand, and the Underwriters on the other, in connection with the statements or omissions that resulted in such losses, claims, damages or liabilities, as well as any other relevant equitable
considerations. The relative benefits received by the Company, on the one hand, and the Underwriters on the other, shall be deemed to be in the same respective proportions as the net proceeds (before deducting expenses) received by the Company from
the sale of the Securities and the total underwriting discounts and commissions received by the Underwriters in connection therewith, in each case as set forth in the table on the cover of the Prospectus, bear to the aggregate offering price of the
Securities. The relative fault of the Company, on the one hand, and the Underwriters on the other, shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged
omission to state a material fact relates to information supplied by the Company or by the Underwriters and the parties&#146; relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)&#8195;<I>Limitation on Liability.</I> The Company and the Underwriters agree that it would not be just and equitable if contribution
pursuant to paragraph (d)&nbsp;above were determined by <U>pro</U> <U>rata</U> allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method of allocation that does not take account of the equitable
considerations referred to in paragraph (d)&nbsp;above. The amount paid or payable by an Indemnified Person as a result of the losses, claims, damages and liabilities referred to in paragraph (d)&nbsp;above shall be deemed to include, subject to the
limitations set forth above, any legal or other expenses reasonably </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
incurred by such Indemnified Person in connection with any such action or claim. Notwithstanding the provisions of paragraphs (d)&nbsp;and (e), in no event shall an Underwriter be required to
contribute any amount in excess of the amount by which the total underwriting discounts and commissions received by such Underwriter with respect to the offering of the Securities exceeds the amount of any damages that such Underwriter has otherwise
been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f) of the Securities Act) shall be entitled to
contribution from any person who was not guilty of such fraudulent misrepresentation. The Underwriters&#146; obligations to contribute pursuant to paragraphs (d)&nbsp;and (e) are several in proportion to their respective purchase obligations
hereunder and not joint. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g)&#8195;<I><FONT STYLE="white-space:nowrap">Non-Exclusive</FONT> Remedies.</I> The remedies provided for in
this Section&nbsp;7 paragraphs (a)&nbsp;through (e) are not exclusive and shall not limit any rights or remedies which may otherwise be available to any Indemnified Person at law or in equity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.&#8195;<U>Effectiveness of Agreement</U>. This Agreement shall become effective as of the date first written above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.&#8195;<U>Termination</U>. This Agreement may be terminated in the absolute discretion of the Representatives, by notice to the Company, if
after the execution and delivery of this Agreement and on or prior to the Closing Date (i)&nbsp;trading generally shall have been suspended or materially limited on or by any of the New York Stock Exchange or The Nasdaq Stock Market;
(ii)&nbsp;trading of any securities issued or guaranteed by the Company shall have been suspended on any exchange or in any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market; (iii)&nbsp;a general
moratorium on commercial banking activities shall have been declared by federal or New York State authorities; or (iv)&nbsp;there shall have occurred any outbreak or escalation of hostilities or any change in financial markets or any calamity or
crisis, either within or outside the United States, that, in the judgment of the Representatives, is material and adverse and makes it impracticable or inadvisable to proceed with the offering, sale or delivery of the Securities on the Closing Date
on the terms and in the manner contemplated by this Agreement, the Pricing Disclosure Package and the Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.&#8195;<U>Defaulting
Underwriter</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&#8195;If, on the Closing Date, any Underwriter defaults on its obligation to purchase the Securities that it has
agreed to purchase hereunder on such date, the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters may in their discretion arrange for the purchase of such Securities by other persons satisfactory to the Company on the terms
contained in this Agreement. If, within 36 hours after any such default by any Underwriter, the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters do not arrange for the purchase of such Securities, then the Company shall be
entitled to a further period of 36 hours within which to procure other persons satisfactory to the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters to purchase such Securities on such terms. If other persons become obligated or
agree to purchase the Securities of a defaulting Underwriter, either the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters or the Company may postpone the Closing Date for up to five full business days in order to effect any
changes that in the opinion of counsel for the Company or counsel for the Underwriters may be necessary in the Registration Statement and the Prospectus or in any other document or arrangement, and the Company agrees to promptly prepare any
amendment or supplement to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Registration Statement and the Prospectus that effects any such changes. As used in this Agreement, the term &#147;Underwriter&#148; includes, for all purposes of this Agreement unless the
context otherwise requires, any person not listed in <U>Schedule 1</U> hereto that, pursuant to this Section&nbsp;10, purchases Securities that a defaulting Underwriter agreed but failed to purchase. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&#8195;If, after giving effect to any arrangements for the purchase of the Securities of a defaulting Underwriter or Underwriters by the <FONT
STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters and the Company as provided in paragraph (a)&nbsp;above, the aggregate number of Securities that remain unpurchased on the Closing Date does not exceed
<FONT STYLE="white-space:nowrap">one-eleventh</FONT> of the aggregate number of Securities to be purchased on such date, then the Company shall have the right to require each <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriter to
purchase the number of Securities that such Underwriter agreed to purchase hereunder on such date plus such Underwriter&#146;s pro rata share (based on the number of Securities that such Underwriter agreed to purchase on such date) of the Securities
of such defaulting Underwriter or Underwriters for which such arrangements have not been made. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&#8195;If, after giving effect to any
arrangements for the purchase of the Securities of a defaulting Underwriter or Underwriters by the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters and the Company as provided in paragraph (a)&nbsp;above, the aggregate number of
Securities that remain unpurchased on the Closing Date exceeds <FONT STYLE="white-space:nowrap">one-eleventh</FONT> of the aggregate amount of Securities to be purchased on such date, or if the Company shall not exercise the right described in
paragraph (b)&nbsp;above, then this Agreement shall terminate without liability on the part of the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters. Any termination of this Agreement pursuant to this Section&nbsp;10 shall be
without liability on the part of the Company, except that the Company will continue to be liable for the payment of expenses as set forth in Section&nbsp;11 hereof (other than with respect to the defaulting underwriter(s)) and except that the
provisions of Section&nbsp;7 hereof shall not terminate and shall remain in effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&#8195;Nothing contained herein shall relieve a
defaulting Underwriter of any liability it may have to the Company or any <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriter for damages caused by its default. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.&#8195;<U>Payment of Expenses</U><I>.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&#8195;Whether or not the transactions contemplated by this Agreement are consummated or this Agreement is terminated, the Company will pay
or cause to be paid all costs and expenses incident to the performance of its obligations hereunder, including without limitation, (i)&nbsp;the costs incident to the authorization, issuance, sale, preparation and delivery of the Securities and any
taxes payable in that connection; (ii)&nbsp;the costs incident to the preparation, printing and filing under the Securities Act of the Registration Statement, any Preliminary Prospectus, any Issuer Free Writing Prospectus, any Pricing Disclosure
Package and the Prospectus (including all exhibits, amendments and supplements thereto) and the distribution thereof; (iii)&nbsp;the fees and expenses of the Company&#146;s counsel and independent accountants; (iv)&nbsp;the reasonable and documented
fees and expenses incurred in connection with the registration or qualification and determination of eligibility for investment of the Securities under the laws of such jurisdictions as the Representatives may designate and the preparation, printing
and distribution of a Blue Sky Memorandum (including the related reasonable and documented fees and expenses of counsel for the Underwriters, not to exceed $10,000);&nbsp;(v) the cost of preparing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
stock certificates; (vi)&nbsp;the costs and charges of any transfer agent and any registrar; (vii)&nbsp;all expenses and application fees incurred in connection with any filing with, and
clearance of the offering by, FINRA (including the related reasonable and documented fees and expenses of counsel for the Underwriters not to exceed $40,000); (viii) all expenses incurred by the Company in connection with any &#147;road show&#148;
presentation to potential investors (provided, however, that the Underwriters and the Company shall each pay 50% of the cost of chartering any aircraft to be used in connection with the road show by both the Company and the Underwriters, and that
all lodging, commercial airfare and individual expenses of the Underwriters shall be the responsibility of the Underwriters); and (ix)&nbsp;all expenses and application fees related to the listing of the Shares and the Warrant Shares on the Nasdaq
Market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&#8195;If (i)&nbsp;this Agreement is terminated pursuant to Section&nbsp;9, (ii) the Company for any reason fails to tender
the Securities for delivery to the Underwriters or (iii)&nbsp;the Underwriters decline to purchase the Securities for any reason permitted under this Agreement, the Company agrees to reimburse the Underwriters for all
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs and expenses (including the fees and expenses of their counsel) reasonably incurred by the Underwriters in connection with this Agreement and the
offering contemplated hereby; provided, however, that no additional amounts beyond what has been reimbursed pursuant to the foregoing will be owed to the Underwriters other than under Section&nbsp;7 hereof. For the avoidance of doubt, it is
understood that the Company shall not pay or reimburse any costs, fees or expenses incurred by any Underwriter that defaults on its obligations to purchase the Securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.&#8195;<U>Persons Entitled to Benefit of Agreement</U>. This Agreement shall inure to the benefit of and be binding upon the parties hereto
and their respective successors and the officers and directors and any controlling persons referred to herein, and the affiliates of each Underwriter referred to in Section&nbsp;7 hereof. Nothing in this Agreement is intended or shall be construed
to give any other person any legal or equitable right, remedy or claim under or in respect of this Agreement or any provision contained herein. No purchaser of Securities from any Underwriter shall be deemed to be a successor merely by reason of
such purchase. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.&#8195;<U>Survival</U>. The respective indemnities, rights of contribution, representations, warranties and agreements
of the Company and the Underwriters contained in this Agreement or made by or on behalf of the Company or the Underwriters pursuant to this Agreement or any certificate delivered pursuant hereto shall survive the delivery of and payment for the
Securities and shall remain in full force and effect, regardless of any termination of this Agreement or any investigation made by or on behalf of the Company or the Underwriters or the directors, officers, controlling persons or affiliates referred
to in Section&nbsp;7 hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.&#8195;<U>Certain Defined Terms</U>. For purposes of this Agreement, (a)&nbsp;except where otherwise
expressly provided, the term &#147;affiliate&#148; has the meaning set forth in Rule 405 under the Securities Act; (b)&nbsp;the term &#147;business day&#148; means any day other than a day on which banks are permitted or required to be closed in New
York City; and (c)&nbsp;the term &#147;subsidiary&#148; has the meaning set forth in Rule 405 under the Securities Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.&#8195;<U>Compliance with USA Patriot Act</U>. In accordance with the requirements of the
USA Patriot Act (Title III of Pub. L. <FONT STYLE="white-space:nowrap">107-56</FONT> (signed into law October&nbsp;26, 2001)), the Underwriters are required to obtain, verify and record information that identifies their respective clients, including
the Company, which information may include the name and address of their respective clients, as well as other information that will allow the Underwriters to properly identify their respective clients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16.&#8195;<U>Miscellaneous</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&#8195;<I>Notices.</I> All notices and other communications hereunder shall be in writing and shall be deemed to have been duly given if
mailed or transmitted and confirmed by any standard form of telecommunication. Notices to the Underwriters shall be given to the Representatives c/o J.P. Morgan Securities LLC, 383 Madison Avenue, New York, New York 10179, fax: (212) <FONT
STYLE="white-space:nowrap">622-8358,</FONT> Attention: Equity Syndicate Desk; Jefferies LLC, 520 Madison Avenue, New York, New York 10022, Attention: General Counsel; c/o Cantor Fitzgerald&nbsp;&amp; Co. at 110 East 59th Street, New York, New York
10022, Attention: Head of Equity Capital Markets by <FONT STYLE="white-space:nowrap">e-mail</FONT> at <FONT STYLE="white-space:nowrap">notices-IBD@cantor.com,</FONT> with a copy to counsel by <FONT STYLE="white-space:nowrap">e-mail</FONT> at <FONT
STYLE="white-space:nowrap">#Legal-IBD@cantor.com;</FONT> c/o Citigroup Global Markets Inc., 388 Greenwich Street, New York, New York 10013, Attention: General Counsel, fax: (646) <FONT STYLE="white-space:nowrap">291-1469;</FONT> c/o Wells Fargo
Securities, LLC, 500 West 33rd Street, New York, New York 10001, Attention: Equity Syndicate Department, fax: (212) <FONT STYLE="white-space:nowrap">214-5918.</FONT> Notices to the Company shall be given to it at Beam Therapeutics Inc., 238 Main
Street, Cambridge, MA 02142, Attention: Chief Legal Officer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&#8195;<I>Governing Law.</I> This Agreement and any claim, controversy or
dispute arising under or related to this Agreement shall be governed by and construed in accordance with the laws of the State of New York. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&#8195;<I>Recognition of the U.S. Special Resolution Regimes</I>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) In the event that any Underwriter that is a Covered Entity becomes subject to a proceeding under a U.S. Special Resolution
Regime, the transfer from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this
Agreement, and any such interest and obligation, were governed by the laws of the United States or a state of the United States. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) In the event that any Underwriter that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a
proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S.
Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">As used in
this Section&nbsp;16(c): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;BHC Act Affiliate&#148; has the meaning assigned to the term &#147;affiliate&#148; in, and shall be
interpreted in accordance with, 12 U.S.C. &#167; 1841(k). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;Covered Entity&#148; means any of the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(i) a &#147;covered entity&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 252.82(b); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(ii) a &#147;covered bank&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 47.3(b); or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(iii) a &#147;covered FSI&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 382.2(b). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;Default Right&#148; has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. &#167;&#167; 252.81,
47.2 or 382.1, as applicable. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;U.S. Special Resolution Regime&#148; means each of (i)&nbsp;the Federal Deposit Insurance Act and the
regulations promulgated thereunder and (ii)&nbsp;Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&#8195;<I>Waiver of Jury Trial.</I> Each of the parties hereto hereby waives any right to trial by jury in any suit or proceeding arising
out of or relating to this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&#8195;<I>Counterparts.</I> This Agreement may be signed in counterparts (which may include
counterparts delivered by any standard form of telecommunication), each of which shall be an original and all of which together shall constitute one and the same instrument. The words &#147;execution,&#148; &#147;signed,&#148; &#147;signature,&#148;
and words of like import in this Agreement or in any other certificate, agreement or document related to this Agreement, if any, shall include images of manually executed signatures transmitted by facsimile or other electronic format (including,
without limitation, &#147;pdf,&#148; &#147;tif&#148; or &#147;jpg&#148;) and other electronic signatures (including, without limitation, DocuSign and AdobeSign). The use of electronic signatures and electronic records (including, without limitation,
any contract or other record created, generated, sent, communicated, received, or stored by electronic means) shall be of the same legal effect, validity and enforceability as a manually executed signature or use of a paper-based record-keeping
system to the fullest extent permitted by applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act and any other applicable law, including, without
limitation, any state law based on the Uniform Electronic Transactions Act or the Uniform Commercial Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)&#8195;<I>Amendments or
Waivers.</I> No amendment or waiver of any provision of this Agreement, nor any consent or approval to any departure therefrom, shall in any event be effective unless the same shall be in writing and signed by the parties hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g)&#8195;<I>Headings.</I> The headings herein are included for convenience of reference only and are not intended to be part of, or to affect
the meaning or interpretation of, this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page Follows] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the foregoing is in accordance with your understanding, please indicate your acceptance
of this Agreement by signing in the space provided below. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="88%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">BEAM THERAPEUTICS INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:&#8195;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ John Evans</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: John Evans</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to the Underwriting Agreement</I>] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accepted: As of the date first written above </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">J.P. MORGAN SECURITIES LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">JEFFERIES LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CANTOR FITZGERALD&nbsp;&amp; CO. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CITIGROUP GLOBAL MARKETS INC.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">WELLS FARGO SECURITIES, LLC </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For themselves and on behalf
of the </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">several Underwriters listed </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">in <U>Schedule 1</U>
hereto. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">J.P. MORGAN SECURITIES LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:&#8195;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ David Ke</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: David Ke</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Managing Director</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">JEFFERIES LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:&#8195;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Charlie Glazer</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Charlie Glazer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Managing Director</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">CANTOR FITZGERALD&nbsp;&amp; CO.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:&#8195;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Asif Ahmed</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Asif Ahmed</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Global <FONT STYLE="white-space:nowrap">Co-Head</FONT> of ECM</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">CITIGROUP GLOBAL MARKETS INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:&#8195;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ John Whittaker</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: John Whittaker</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Managing Director</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">WELLS FARGO SECURITIES, LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:&#8195;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Donald Ho</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Donald Ho</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Executive Director</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to the Underwriting Agreement</I>] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Schedule 1 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Underwriter</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Warrants</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">J.P. Morgan Securities LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,814,607</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">505,796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jefferies LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,230,337</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">280,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cantor Fitzgerald&nbsp;&amp; Co.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,068,820</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">266,948</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Citigroup Global Markets Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,422,753</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">210,748</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wells Fargo Securities, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,615,169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">140,498</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,151,686</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,404,988</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Schedule 1-1 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Annex A </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Pricing Disclosure Package</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Pricing Information Provided Orally by Underwriters</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Shares: 16,151,686 </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Offering Price Per Share: $28.48 </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Warrants: 1,404,988 </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Offering Price Per Warrant: $28.47 </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The number of shares and warrants to be issued may be reallocated among shares or warrants such that the
aggregate number of shares and warrants issued does not exceed 17,556,674. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Exercise Price for the Warrants: $0.01 </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on the Company&#146;s planned use of the net proceeds from this offering and its existing cash, cash
equivalents and marketable securities of approximately $850.7&nbsp;million as of December&nbsp;31, 2024, the Company estimates that such funds will be sufficient to enable it to fund operating expenses and capital expenditure requirements into 2028.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Annex A-1 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit A </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">FORM OF <FONT STYLE="white-space:nowrap">LOCK-UP</FONT> AGREEMENT </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">[&#9679;], 2025 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">J.P. Morgan Securities LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jefferies LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cantor Fitzgerald&nbsp;&amp; Co. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Citigroup Global Markets Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Wells Fargo Securities, LLC </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As Representatives of the </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">several Underwriters listed </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">in <U>Schedule 1</U> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">to the Underwriting Agreement </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">referred to below </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o J.P. Morgan Securities LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">383 Madison Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, NY 10179 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Jefferies LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">520 Madison Avenue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, NY 10022 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Cantor Fitzgerald&nbsp;&amp; Co. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">110 East 59th Street, 6th Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10022 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Citigroup Global Markets Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">388 Greenwich Street </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10013 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Wells Fargo Securities, LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">500 West 33rd Street, 14th Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10001 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Re:&#8195;Beam Therapeutics Inc. &#150; Public Offering </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned
understands that you, each as one of several representatives (the &#147;Representatives&#148;) of the several Underwriters, propose to enter into an underwriting agreement </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(the &#147;Underwriting Agreement&#148;) with Beam Therapeutics Inc., a Delaware corporation (the &#147;Company&#148;), providing for the public offering (the &#147;Public Offering&#148;) by the
several Underwriters named in Schedule 1 to the Underwriting Agreement (the &#147;Underwriters&#148;), of common stock, par value $0.01 per share (&#147;Common Stock&#148;), of the Company, and if applicable,
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to purchase shares of Common Stock (the &#147;Securities&#148;). Capitalized terms used herein and not otherwise defined shall have the meanings set forth in the Underwriting Agreement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In consideration of the Underwriters&#146; agreement to purchase and make the Public Offering of the Securities, and for other good and
valuable consideration receipt of which is hereby acknowledged, the undersigned hereby agrees that, without the prior written consent of J.P. Morgan Securities LLC, Jefferies LLC, Cantor Fitzgerald&nbsp;&amp; Co., Citigroup Global Markets Inc. and
Wells Fargo Securities, LLC on behalf of the Underwriters, the undersigned will not, and will not cause any direct or indirect affiliate to, during the period beginning on the date of this letter agreement (this &#147;Letter Agreement&#148;) and
ending at the close of business 45 days after the date of the final prospectus relating to the Public Offering (the &#147;Prospectus&#148;) (such period, the &#147;Restricted Period&#148;), (1) offer, pledge, sell, contract to sell, sell any option
or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or
exercisable or exchangeable for Common Stock (including without limitation, Common Stock or such other securities which may be deemed to be beneficially owned by the undersigned in accordance with the rules and regulations of the Securities and
Exchange Commission and securities which may be issued upon exercise of a stock option or warrant), (2) enter into any hedging, swap or other agreement or transaction that transfers, in whole or in part, any of the economic consequences of ownership
of the Common Stock or such other securities, whether any such transaction described in clause (1)&nbsp;or (2) above is to be settled by delivery of the Common Stock or such other securities, in cash or otherwise, (3)&nbsp;make any demand for or
exercise any right with respect to the registration of any shares of Common Stock or any security convertible into or exercisable or exchangeable for Common Stock, or (4)&nbsp;publicly disclose the intention to do any of the foregoing. The
undersigned acknowledges and agrees that the foregoing precludes the undersigned from engaging in any hedging or other transactions or arrangements (including, without limitation, any short sale or the purchase or sale of, or entry into, any put or
call option, or combination thereof, forward, swap or any other derivative transaction or instrument, however described or defined) designed or intended, or which could reasonably be expected to lead to or result in, a sale or disposition or
transfer (whether by the undersigned or any other person) of any economic consequences of ownership, in whole or in part, directly or indirectly, of any shares of Common Stock, or securities convertible into or exercisable or exchangeable for Common
Stock, whether any such transaction or arrangement (or instrument provided for thereunder) would be settled by delivery of the Common Stock or such other securities, in cash or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing paragraph shall not apply to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A)&#8195;transfers of shares of Common Stock or any security convertible into or exercisable or exchangeable for Common Stock as a bona fide
gift or gifts or for bona fide estate planning purposes, including without limitation transfers to charitable organizations, </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B)&#8195;transfers or distributions of shares of Common Stock or any security convertible
into or exercisable or exchangeable for Common Stock to (a)&nbsp;limited partners, members, stockholders or holders of similar equity interests in the undersigned or (b)&nbsp;to another corporation, partnership, limited liability company, trust or
other business entity that is an affiliate (as defined in Rule 405 promulgated under the Securities Act of 1933, as amended) of the undersigned, including without limitation any general partner, limited partner, managing member, manager, member,
employee, officer or director of such entity or any trust for the benefit of any of the foregoing or any affiliate of the foregoing, or to any investment fund or other entity controlled or managed by the undersigned or affiliates of the undersigned,
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(C)&#8195;transactions relating to Common Stock or other securities acquired in the Public Offering or open market transactions after the
completion of the Public Offering; <I>provided</I> that no public filing, report or announcement shall be voluntarily made, and if any filing under Section&nbsp;16(a) of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;),
or other public filing, report or announcement reporting a reduction in beneficial ownership of shares of Common Stock in connection with such transfer or distribution shall be legally required during the Restricted Period, such filing, report or
announcement shall clearly indicate the nature and conditions of such transfer, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(D)&#8195;transfers or dispositions (i)&nbsp;of Common
Stock or any security convertible into or exercisable or exchangeable for Common Stock by will or intestacy, <I>provided</I> that any required filing under Section&nbsp;16 of the Exchange Act, shall clearly indicate in the footnotes thereto that the
filing relates to the circumstances described in this clause and no other public filing, report or announcement shall be required or made voluntarily in connection with such transfer or disposition or (ii)&nbsp;to any Family Member or to a trust
whose beneficiaries consist exclusively of one or more of the undersigned and/or a Family Member, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(E)&#8195;transfers or dispositions of
Common Stock or any security convertible into or exercisable or exchangeable for Common Stock pursuant to a domestic order or negotiated divorce settlement, <I>provided</I> that any required filing under Section&nbsp;16 of the Exchange Act shall
clearly indicate in the footnotes thereto that the filing relates to the circumstances described in this clause and no other public filing, report or announcement shall be required or made voluntarily in connection with such transfer or disposition,
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(F)&#8195;the exercise of a warrant or the exercise of a stock option granted under a stock incentive plan described in the Prospectus
for shares of Common Stock, <I>provided </I>that the underlying Common Stock received by the undersigned shall continue to be subject to the terms of this Letter Agreement, and <I>provided further</I> that no filing under Section&nbsp;16 of the
Exchange Act or other public filing, report or announcement shall be voluntarily made, and if the undersigned is required to make any public filing, report or announcement under Section&nbsp;16 of the Exchange Act, such public filing, report or
announcement shall clearly indicate in the footnotes thereto that the filing relates to the circumstances described in this clause, that no Common Stock was sold by the reporting person and that Common Stock so received is subject to the terms of
this Letter Agreement, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(G)&#8195;transfers or dispositions of restricted stock to the Company pursuant to any contractual arrangement in
effect on the date of the Public Offering and described in the </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Prospectus that provides for the repurchase of the undersigned&#146;s Common Stock in connection with the termination of services to the Company, <I>provided </I>that no filing under
Section&nbsp;16 of the Exchange Act or other public filing, report or announcement shall be voluntarily made, and if the undersigned is required to make any public filing, report or announcement under Section&nbsp;16 of the Exchange Act, such public
filing, report or announcement shall clearly indicate in the footnotes thereto that the filing relates to the circumstances described in this clause, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(H)&#8195;the disposition of Common Stock to the Company, or the withholding of Common Stock by the Company, in connection with the vesting,
settlement, or exercise of restricted stock units, options, warrants or other rights to purchase shares of Common Stock (including, in each case, by way of &#147;net&#148; or &#147;cashless&#148; exercise), including for the payment of exercise
price and tax and remittance payments due as a result of the vesting, settlement, or exercise of such restricted stock units, options, warrants or rights, provided that any such shares of Common Stock received upon such exercise, vesting or
settlement shall be subject to the terms of this Letter Agreement, and provided further that any such restricted stock units, options, warrants or rights are held by the undersigned pursuant to an agreement or equity awards granted under a stock
incentive plan or other equity award plan, each such agreement or plan which is described in the Prospectus; <I>provided however, </I>that no filing by any party under the Exchange Act, or other public announcement shall be made voluntarily in
connection with such transfer or distribution (other than a filing on a Form 5, Schedule 13G or Schedule 13G/A, Schedule 13D or Schedule 13D/A, or Schedule 13F, each of which shall clearly indicate therein the nature and conditions of such
transfer), </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(I)&#8195;the establishment of a trading plan pursuant to Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the
Exchange Act for the transfer of Common Stock (a &#147;Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> Plan&#148;), <I>provided</I> that (a)&nbsp;such plan does not provide for the transfer of Common Stock during the Restricted Period and
(b)&nbsp;the entry into such plan is not voluntarily publicly disclosed, included in any filings under the Exchange Act or otherwise, during the Restricted Period and that any required filings under the Exchange Act upon any sales shall clearly
indicate that such sales were pursuant to a Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> Plan, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(J)&#8195;transactions pursuant to
any trading plan pursuant to Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> Plan, entered into prior to the date hereof; provided that any required filings under the Exchange Act upon any sales shall clearly indicate that such sales were
pursuant to a Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> Plan, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(K)&#8195;pursuant to a bona fide third party tender offer for
all outstanding Common Stock of the Company, merger, consolidation or other similar transaction approved by the Company&#146;s Board of Directors and made to all holders of the Company&#146;s securities involving a Change of Control of the Company
(including, without limitation, the entering into of any <FONT STYLE="white-space:nowrap">lock-up,</FONT> voting or similar agreement pursuant to which the undersigned may agree to transfer, sell, tender or otherwise dispose of Common Stock or other
such securities in connection with such transaction, or vote any Common Stock or other such securities in favor of any such transaction), provided that in the event that such tender offer, merger, consolidation or other such transaction is not
completed, such securities held by the undersigned shall remain subject to the provisions of this Letter Agreement, or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(L)&#8195;pursuant
to &#147;sell to cover&#148; transactions in the open market for Common Stock otherwise deliverable in connection with the exercise or settlement of restricted stock units </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
granted under a stock incentive plan or other equity award plan, which plan is described in the Prospectus, in an amount no greater than a number sufficient to cover the tax withholdings or
remittance payments due as a result of the vesting or settlement of such restricted stock units; <I>provided </I>that the shares of Common Stock received upon such vesting or settlement other than those sold pursuant to this clause (L)&nbsp;shall
remain subject to the restrictions on transfer set forth in this Letter Agreement; <I>provided further</I>, that if a filing on Form 4 is required in connection such sale, then such filing is permitted provided that at least one business day&#146;s
notice shall be provided to the Representatives prior to such proposed filing; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>provided</U> that in the case of any transfer or distribution pursuant
to clause (A), (B), (D) or (E), each donee or distributee shall execute and deliver to the Representative a <FONT STYLE="white-space:nowrap">lock-up</FONT> letter in the form of this Letter Agreement; and <U>provided</U>, <U>further</U>, that in the
case of any transfer or distribution pursuant to clause (A), (B) or (D)(ii), no filing by any party (donor, donee, transferor or transferee) under the Exchange Act (other than, in the case of clause (A)&nbsp;only, a filing on a Form 4 which shall
clearly indicate in the footnote thereto the nature and conditions of such transfer) or other public announcement shall be made voluntarily in connection with such transfer or distribution; and <U>provided</U>, <U>further</U>, in the case of clauses
(B)&nbsp;and (D)(ii), any such transfer shall not involve a disposition for value. If the undersigned is an officer or director of the Company, the undersigned further agrees that the foregoing provisions shall be equally applicable to any
Company-directed Securities the undersigned may purchase in the Public Offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of clause (D), &#147;Family Member&#148;
shall mean a spouse or domestic partner, child, grandchild or other lineal descendant (including by adoption), father, mother, brother or sister of the undersigned. For purposes of clause (K), &#147;Change of Control&#148; shall mean the transfer
(whether by tender offer, merger, consolidation or other similar transaction), in one transaction or a series of related transactions, to a person or group of affiliated persons (other than an Underwriter pursuant to the Public Offering), of the
Company&#146;s voting securities if, after such transfer such person or group of affiliated persons, other than the Company or its subsidiaries, becomes the beneficial owner (as defined in Rules <FONT STYLE="white-space:nowrap">13d-3</FONT> and <FONT
STYLE="white-space:nowrap">13d-5</FONT> of the Exchange Act) of greater than 50% of the outstanding voting securities of the Company (or the surviving entity). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the avoidance of doubt, the undersigned hereby waives any and all notice requirements and rights with respect to the registration of any
securities pursuant to any agreement, instrument, understanding or otherwise, including any stockholders agreement, investors rights agreement or registration rights agreement or similar agreement, to which the undersigned is a party or under which
the undersigned is entitled to any right or benefit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In furtherance of the foregoing, the Company, and any duly appointed transfer agent
for the registration or transfer of the securities described herein, are hereby authorized to decline to make any transfer of securities if such transfer would constitute a violation or breach of this Letter Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned hereby represents and warrants that the undersigned has full power and authority to enter into this Letter Agreement. All
authority herein conferred or agreed to be conferred and any obligations of the undersigned shall be binding upon the successors, assigns, </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
heirs or personal representatives of the undersigned. This Letter Agreement may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S.
federal ESIGN Act of 2000, e.g., www.docusign.com or www.echosign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned acknowledges and agrees that the Underwriters have not provided any recommendation or investment advice nor have the
Underwriters solicited any action from the undersigned with respect to the Public Offering of the Securities and the undersigned has consulted their own legal, accounting, financial, regulatory and tax advisors to the extent deemed appropriate. The
undersigned further acknowledges and agrees that, although the Representative may be required or choose to provide certain Regulation Best Interest and Form CRS disclosures to you in connection with the Public Offering, the Representative and the
other Underwriters are not making a recommendation to you to participate in the Public Offering, enter into this Letter Agreement, or sell any Shares at the price determined in the Public Offering, and nothing set forth in such disclosures is
intended to suggest that the Representative or any Underwriter is making such a recommendation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned understands that, if
(i)&nbsp;either the Company or the Representatives notifies the other in writing prior to the execution of the Underwriting Agreement that it does not intend to proceed with the Public Offering, (ii)&nbsp;the Underwriting Agreement does not become
effective by March&nbsp;31, 2025, (iii) the Underwriting Agreement (other than the provisions thereof which survive termination) shall terminate or be terminated prior to payment for and delivery of the Common Stock to be sold thereunder, or
(iv)&nbsp;the registration statement filed with the Securities and Exchange Commission in connection with the Public Offering is withdrawn, the undersigned shall be released from all obligations under this Letter Agreement. The undersigned
understands that the Underwriters are entering into the Underwriting Agreement and proceeding with the Public Offering in reliance upon this Letter Agreement. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Letter Agreement and any claim, controversy or dispute arising under or related to this
Letter Agreement shall be governed by and construed in accordance with the laws of the State of New York. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="88%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:&#8195;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Title:</P></TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit B </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">FORM OF <FONT STYLE="white-space:nowrap">PRE-FUNDED</FONT> WARRANT </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BEAM THERAPEUTICS INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF <FONT STYLE="white-space:nowrap">PRE-FUNDED</FONT> WARRANT TO PURCHASE COMMON STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Number of Shares: [&#8195;&#8195;&#8195;] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">(subject to adjustment) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Warrant No.
[&#8195;&#8195;&#8195;] Original Issue Date: [&#8195;&#8195;&#8195;&#8195;&#8195;], 2025 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beam Therapeutics Inc., a Delaware corporation (the
&#147;<B>Company</B>&#148;), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [&#8195;&#8195;&#8195;] or its permitted registered assigns (the &#147;<B>Holder</B>&#148;), is
entitled, subject to the terms set forth below, to purchase from the Company up to a total of [&#8195;&#8195;&#8195;] shares of common stock, $0.01 par value per share (the &#147;<B>Common Stock</B>&#148;), of the Company (each such share, a
&#147;<B>Warrant Share</B>&#148; and all such shares, the &#147;<B>Warrant Shares</B>&#148;) at an exercise price per share equal to $0.01 per share (as adjusted from time to time as provided in Section&nbsp;9 herein, the &#147;<B>Exercise
Price</B>&#148;), upon surrender of this <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant to Purchase Common Stock (including any Warrants to Purchase Common Stock issued in exchange, transfer or replacement hereof, the
&#147;<B>Warrant</B>&#148;) at any time and from time to time on or after the date hereof (the &#147;<B>Original Issue Date</B>&#148;) and through and including the date this Warrant is exercised in full (the &#147;<B>Expiration Date</B>&#148;),
subject to the following terms and conditions: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. <I>Definitions</I>. For purposes of this Warrant, the following terms shall have the following meanings:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) &#147;<B>Affiliate</B>&#148; means any Person directly or indirectly controlled by, controlling or under common control with, a Holder, as such terms
are used in and construed under Rule 405 under the Securities Act, but only for so long as such control shall continue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) &#147;<B>Closing Sale
Price</B>&#148; means, for any security as of any date, the last trade price for such security on the Principal Trading Market for such security, as reported by Bloomberg L.P., or, if such Principal Trading Market begins to operate on an extended
hours basis and does not designate the last trade price, then the last trade price of such security immediately prior to 4:00 P.M., New York City time, as reported by Bloomberg L.P., or if the security is not listed for trading on a national
securities exchange or other trading market on the relevant date, the last quoted bid price for the security in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market on the relevant date as
reported by OTC Markets Group Inc. (or a similar organization or agency succeeding to its functions of reporting prices). If the Closing Sale Price cannot be calculated for a security on a particular date on any of the foregoing bases, the Closing
Sale Price of such security on such date shall be the fair market value as mutually determined by the Company and the Holder. If the Company and the Holder are unable to agree upon the fair market value of such security, then the board of directors
of the Company (the &#147;<B>Board of Directors</B>&#148;) shall use its good faith judgment to determine the fair market value of such security on such date. The Board of Directors&#146; determination shall be binding upon all parties absent
demonstrable error. All such determinations shall be appropriately adjusted for any stock dividend, stock split, stock combination or other similar transaction during the applicable calculation period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(c) &#147;<B>Commission</B>&#148; means the United States Securities and Exchange Commission. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) &#147;<B>Marketable Securities</B>&#148; means securities meeting all of the following requirements:
(i)&nbsp;the issuer thereof is then subject to the reporting requirements of Section&nbsp;13 or Section&nbsp;15(d) of the Securities Exchange Act of 1934, as amended (the &#147;<B>Exchange Act</B>&#148;), and is then current in its filing of all
required reports and other information under the Securities Act and the Exchange Act; (ii)&nbsp;the class and series of shares or other security of the issuer that would be received by Holder in connection with the Fundamental Transaction (as
defined below) were Holder to exercise this Warrant on or prior to the closing thereof is then traded or quoted on a nationally recognized securities exchange, inter-dealer quotation system or <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market, and (iii)&nbsp;following the closing of such Fundamental Transaction, the Holder would not be restricted from publicly <FONT STYLE="white-space:nowrap">re-selling</FONT> all of the
issuer&#146;s shares and/or other securities that would be received by the Holder in such Fundamental Transaction were the Holder to exercise or convert this Warrant in full on or prior to the closing of such Fundamental Transaction except to the
extent that any such restriction arises solely under federal or state securities laws, rules or regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(e) &#147;<B>Person</B>&#148; means an
individual, partnership, corporation, limited liability company, business trust, joint stock company, trust, unincorporated association, joint venture or any other entity or organization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(e) &#147;<B>Principal Trading Market</B>&#148; means the national securities exchange or other trading market on which the Common Stock is primarily listed
on and quoted for trading, which, as of the Original Issue Date, shall be the Nasdaq Global Select Market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(f) &#147;<B>Registration Statement</B>&#148;
means the Company&#146;s Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-277427),</FONT> that became effective on February&nbsp;28, 2024. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(g) &#147;<B>Securities Act</B>&#148; means the Securities Act of 1933, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(h) &#147;<B>Standard Settlement Period</B>&#148; means the standard settlement period, expressed in a number of Trading Days, for the Principal Trading
Market with respect to the Common Stock that is in effect on the date of delivery of an applicable Exercise Notice, which as of the Original Issue Date was &#147;T+1.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(i) &#147;<B>Trading Day</B>&#148; means any weekday on which the Principal Trading Market is open for trading. If the Common Stock is not listed or admitted
for trading, &#147;Trading Day&#148; means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or any day on which banking institutions in New York City are authorized or required by law or other
governmental action to close. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(j) &#147;<B>Transfer Agent</B>&#148; means Computershare Trust Company, N.A., the Company&#146;s transfer agent and
registrar for the Common Stock, and any successor appointed in such capacity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. <I>Issuance of Securities; Registration of Warrants</I>. The Warrant, as
initially issued by the Company, is offered and sold pursuant to the Registration Statement. As of the Original Issue Date, the Warrant Shares are issuable under the Registration Statement. Accordingly, the Warrant and, assuming issuance pursuant to
the Registration Statement or an exchange meeting the requirements of Section&nbsp;3(a)(9) of the Securities Act as in effect on the Original Issue Date, the Warrant Shares, are not &#147;restricted securities&#148; under Rule 144 promulgated under
the Securities Act as of the Original Issue Date. The Company shall register ownership of this </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Warrant, upon records to be maintained by the Company for that purpose (the &#147;<B>Warrant
Register</B>&#148;), in the name of the record Holder (which shall include the initial Holder or, as the case may be, any assignee to which this Warrant is permissibly assigned hereunder) from time to time. The Company may deem and treat the
registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary. This Warrant may be, at the option of the
Holder, either (x)&nbsp;represented by an original Warrant certificate or (y)&nbsp;issued by book-entry registration in the Warrant Register. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3.
<I>Registration of Transfers</I>. Subject to compliance with all applicable securities laws and the rules of the Principal Trading Market, the Company shall, or will cause its Transfer Agent to, register the transfer of all or any portion of this
Warrant in the Warrant Register, upon surrender of this Warrant, and payment for all applicable transfer taxes (if any) by the Holder or any subsequent holder. Notwithstanding the foregoing, no surrender of this Warrant shall be required if such
Warrant is represented by book-entry registration in the Warrant Register. Upon any such registration of transfer, a new warrant to purchase Common Stock in substantially the form of this Warrant (any such new warrant, a &#147;<B>New
Warrant</B>&#148;) evidencing the portion of this Warrant so transferred shall be issued to the transferee, and a New Warrant evidencing the remaining portion of this Warrant not so transferred, if any, shall be issued to the transferring Holder.
The acceptance of the New Warrant by the transferee thereof shall be deemed the acceptance by such transferee of all of the rights and obligations in respect of the New Warrant that the Holder has in respect of this Warrant. The Company shall, or
will cause its Transfer Agent to, prepare, issue and deliver at the Company&#146;s own expense any New Warrant under this Section&nbsp;3. Until due presentment for registration of transfer, the Company may treat the registered Holder hereof as the
owner and holder for all purposes, and the Company shall not be affected by any notice to the contrary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4. <I>Exercise and Duration of Warrants</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) All or any part of this Warrant shall be exercisable by the registered Holder in the manner set forth herein (including Section&nbsp;10) at any time and
from time to time on or after the Original Issue Date and through and including the Expiration Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) The Holder may exercise this Warrant by
delivering to the Company an exercise notice, in the form attached as Schedule 1 hereto (the &#147;<B>Exercise Notice</B>&#148;), completed and duly signed. The date on which such Exercise Notice is delivered to the Company (as determined in
accordance with the notice provisions hereof) is an &#147;<B>Exercise Date</B>.&#148; The Holder shall not be required to deliver the original Warrant in order to effect an exercise hereunder. Execution and delivery of the Exercise Notice shall have
the same effect as cancellation of the original Warrant and issuance of a New Warrant evidencing the right to purchase the remaining number of Warrant Shares, if any. The aggregate exercise price of this Warrant, except for the Exercise Price, was <FONT
STYLE="white-space:nowrap">pre-funded</FONT> to the Company on or before the Original Issue Date, and consequently no additional consideration (other than the Exercise Price) shall be required to be paid by the Holder to effect any exercise of this
Warrant. The Holder shall not be entitled to the return or refund of all, or any portion, of such <FONT STYLE="white-space:nowrap">pre-funded</FONT> exercise price under any circumstance or for any reason whatsoever. <B>The Holder and any assignee,
by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the </B><B>Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at
any given time may be less than the amount stated on the face hereof.</B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5. <I>Delivery of Warrant Shares</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) Upon exercise of this Warrant in accordance with the terms of this Warrant (including Section&nbsp;10), the Company shall promptly (but in no event later
than the number of Trading Days comprising the Standard Settlement Period after the Exercise Date), upon the request of the Holder, credit or instruct the Transfer Agent to credit such aggregate number of shares of Common Stock to which the Holder
is entitled pursuant to such exercise to the Holder&#146;s or its designee&#146;s balance account with The Depository Trust Company (&#147;<B>DTC</B>&#148;) through its Deposit Withdrawal At Custodian system, or if the Transfer Agent is not
participating in the Fast Automated Securities Transfer Program or if the certificates or book-entry positions are required to bear a legend regarding restriction on transferability, issue and dispatch by overnight courier to the address as
specified in the Exercise Notice, a certificate or book-entry position, registered in the Company&#146;s share register in the name of the Holder or its designee, for the number of shares of Common Stock to which the Holder is entitled pursuant to
such exercise. The Holder, or any Person so designated by the Holder to receive Warrant Shares, shall be deemed to have become the holder of record of such Warrant Shares as of the Exercise Date, irrespective of the date such Warrant Shares are
credited to the Holder&#146;s DTC account or the date of delivery of the certificates or book-entry positions evidencing such Warrant Shares, as the case may be. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) If, within the number of Trading Days comprising the Standard Settlement Period following the Exercise Date, the Company fails to deliver to the Holder a
certificate or book-entry position representing the required number of Warrant Shares in the manner required pursuant to Section&nbsp;5(a) or fails to cause the Transfer Agent to credit the Holder&#146;s DTC account for such number of Warrant Shares
to which the Holder is entitled, and if after such number of days and prior to the receipt of such Warrant Shares, the Holder purchases (in an open market transaction or otherwise) shares of Common Stock to deliver in satisfaction of a sale by the
Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a &#147;<B><FONT STYLE="white-space:nowrap">Buy-In</FONT></B>&#148;) but did not receive within the Standard Settlement Period, then the Company shall, within
three (3)&nbsp;Trading Days after the Holder&#146;s request promptly honor its obligation to deliver to the Holder a certificate or certificates or book-entry positions representing such Warrant Shares and pay cash to the Holder in an amount equal
to the excess (if any) of (x)&nbsp;Holder&#146;s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased in the <FONT STYLE="white-space:nowrap">Buy-In,</FONT> less (y)&nbsp;the product of
(A)&nbsp;the number of shares of Common Stock purchased in the <FONT STYLE="white-space:nowrap">Buy-In,</FONT> times (B)&nbsp;the Closing Sale Price of a share of Common Stock on the Exercise Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(c) To the extent permitted by law and subject to Section&nbsp;5(b), the Company&#146;s obligations to cause the Transfer Agent to issue and deliver Warrant
Shares in accordance with and subject to the terms hereof (including the limitations set forth in Section&nbsp;11 below) are absolute and unconditional, irrespective of any action or inaction by the Holder to enforce the same, any waiver or consent
with respect to any provision hereof, the recovery of any judgment against any Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by the Holder or any other
Person of any obligation to the Company or any violation or alleged violation of law by the Holder or any other Person, and irrespective of any other circumstance that might otherwise limit such obligation of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Company to the Holder in connection with the issuance of Warrant Shares. Subject to Section&nbsp;5(b),
nothing herein shall limit the Holder&#146;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the
Company&#146;s failure to timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6. <I>Charges,
Taxes and Expenses</I>. Issuance and delivery of shares of Common Stock upon exercise of this Warrant shall be made without charge to the Holder for any issue or transfer tax, transfer agent fee or other incidental tax or expense (excluding any
applicable stamp duties) in respect of the issuance of such shares, all of which taxes and expenses shall be paid by the Company; <I>provided</I>, <I>however</I>, that the Company shall not be required to pay any tax that may be payable in respect
of any transfer involved in the registration of any Warrant Shares or the Warrants in a name other than that of the Holder or an Affiliate thereof. The Holder shall be responsible for all other tax liability that may arise as a result of holding or
transferring this Warrant or receiving Warrant Shares upon exercise hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7. <I>Replacement of Warrant</I>. If this Warrant is mutilated, lost, stolen
or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation hereof, or in lieu of and substitution for this Warrant, a New Warrant, but only upon receipt of evidence reasonably satisfactory to
the Company of such loss, theft or destruction (in such case) and, in each case, a customary and reasonable indemnity and surety bond, if requested by the Company. Applicants for a New Warrant under such circumstances shall also comply with such
other reasonable regulations and procedures and pay such other reasonable third-party costs as the Company may prescribe. If a New Warrant is requested as a result of a mutilation of this Warrant, then the Holder shall deliver such mutilated Warrant
to the Company as a condition precedent to the Company&#146;s obligation to issue the New Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8. <I>Reservation of Warrant Shares</I>. The Company
covenants that it will, at all times while this Warrant is outstanding, reserve and keep available out of the aggregate of its authorized but unissued and otherwise unreserved Common Stock, solely for the purpose of enabling it to issue Warrant
Shares upon exercise of this Warrant as herein provided, the number of Warrant Shares that are initially issuable and deliverable upon the exercise of this entire Warrant, free from preemptive rights or any other contingent purchase rights of
persons other than the Holder (taking into account the adjustments and restrictions of Section&nbsp;9). The Company covenants that all Warrant Shares so issuable and deliverable shall, upon issuance and the payment of the applicable Exercise Price
in accordance with the terms hereof, be duly and validly authorized, issued and fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> The Company will take all such action as may be reasonably necessary to assure that such shares of
Common Stock may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of any securities exchange or automated quotation system upon which the Common Stock may be listed. The Company further
covenants that it will not, without the prior written consent of the Holder, take any actions to increase the par value of the Common Stock at any time while this Warrant is outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">9. <I>Certain Adjustments</I>. The Exercise Price and number of Warrant Shares issuable upon exercise of this Warrant (the &#147;<B>Number of Warrant
Shares</B>&#148;) are subject to adjustment from time to time as set forth in this Section&nbsp;9. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) <U>Stock Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding,
(i)&nbsp;pays a stock dividend on its Common Stock or otherwise makes a distribution on any class of capital stock issued and outstanding on the Original Issue Date and in accordance with the terms of such stock on the Original Issue Date or as
amended, that is payable in shares of Common Stock, (ii)&nbsp;subdivides its outstanding shares of Common Stock into a larger number of shares of Common Stock, (iii)&nbsp;combines its outstanding shares of Common Stock into a smaller number of
shares of Common Stock or (iv)&nbsp;issues by reclassification of shares of capital stock any additional shares of Common Stock, then in each such case the Number of Warrant Shares shall be multiplied by a fraction, the numerator of which shall be
the number of shares of Common Stock outstanding immediately after such event and the denominator of which shall be the number of shares of Common Stock outstanding immediately before such event. Any adjustment made pursuant to clause (i)&nbsp;of
this paragraph shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution, provided, however, that if such record date shall have been fixed and such dividend is
not fully paid on the date fixed therefor, the Number of Warrant Shares shall be recomputed accordingly as of the close of business on such record date and thereafter the Number of Warrant Shares shall be adjusted pursuant to this paragraph as of
the time of actual payment of such dividends. Any adjustment pursuant to clause (ii), (iii) or (iv)&nbsp;of this paragraph shall become effective immediately after the effective date of such subdivision, combination or issuance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) <U>Pro Rata Distributions</U>. If the Company, at any time while this Warrant is outstanding, distributes to all holders of Common Stock for no
consideration (i)&nbsp;evidences of its indebtedness, (ii)&nbsp;any security (other than a distribution of Common Stock covered by the preceding paragraph), (iii) rights or warrants to subscribe for or purchase any security (including Common Stock),
or (iv)&nbsp;cash or any other asset (in each case, a &#147;<B>Distribution</B>&#148;), other than a reclassification as to which Section&nbsp;9(c) applies, then in each such case, the Holder shall be entitled to participate in such Distribution to
the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without
limitation, the ownership limitation set forth in Section&nbsp;11(a) hereof) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of Common Stock are to
be determined for the participation in such Distribution;<I> provided</I>, <I>however</I>, to the extent that the Holder&#146;s right to participate in any such Distribution would result in the Holder exceeding the ownership limitation set forth in
Section&nbsp;11(a) hereof, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any Common Stock as a result of such Distribution to such extent) and the portion of such
Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as the delivery to such Holder of such portion would not result in the Holder exceeding the ownership limitation set forth in Section&nbsp;11(a) hereof.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(c) <U>Fundamental Transactions</U>. If, at any time while this Warrant is outstanding (i)&nbsp;the Company effects any merger or consolidation of the
Company with or into another Person, in which the Company is not the surviving entity, (ii)&nbsp;the Company effects any sale to another Person of all or substantially all of its assets in one transaction or a series of related transactions,
(iii)&nbsp;pursuant to any tender offer or exchange offer (whether by the Company or another Person), holders of capital stock tender shares representing more than 50% of the voting power of the capital stock </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">of the Company and the Company or such other Person, as applicable, accepts such tender for payment,
(iv)&nbsp;the Company consummates a stock purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, <FONT STYLE="white-space:nowrap">spin-off</FONT> or scheme of arrangement) with another
Person whereby such other Person acquires more than the 50% of the voting power of the capital stock of the Company (except for any such transaction in which the stockholders of the Company immediately prior to such transaction maintain, in
substantially the same proportions, the voting power of such Person immediately after the transaction) or (v)&nbsp;the Company effects any reclassification of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is
effectively converted into or exchanged for other securities, cash or property (other than as a result of a subdivision or combination of shares of Common Stock covered by Section&nbsp;9(a) above) (in any such case, a &#147;<B>Fundamental
Transaction</B>&#148;), then following such Fundamental Transaction the Holder shall have the right to receive, upon exercise of this Warrant, the same amount and kind of securities, cash or property as it would have been entitled to receive upon
the occurrence of such Fundamental Transaction if it had been, immediately prior to such Fundamental Transaction, the holder of the Number of Warrant Shares (in the case of clause (iii)&nbsp;above, assuming it had tendered, and the offeror had
accepted, such Warrant Shares) (the &#147;<B>Alternate Consideration</B>&#148;). The Company shall not effect any Fundamental Transaction in which the Company is not the surviving entity or the Alternate Consideration includes securities of another
Person unless (i)&nbsp;the Alternate Consideration is solely cash and the Company provides for the simultaneous &#147;cashless exercise&#148; of this Warrant pursuant to Section&nbsp;10 below or (ii)&nbsp;prior to or simultaneously with the
consummation thereof, any successor to the Company, surviving entity or other Person (including any purchaser of assets of the Company) shall assume the obligation to deliver to the Holder such Alternate Consideration as, in accordance with the
foregoing provisions, the Holder may be entitled to receive, and the other obligations under this Warrant. The provisions of this paragraph (c)&nbsp;shall similarly apply to subsequent transactions analogous of a Fundamental Transaction type.
Notwithstanding the foregoing, in the event of a Fundamental Transaction where the consideration payable to holders of Common Stock consists solely of cash, solely of Marketable Securities or a combination of cash and Marketable Securities, then
this Warrant shall automatically be deemed to be exercised in full in a &#147;cashless exercise&#148; pursuant to Section&nbsp;10 below effective immediately prior to and contingent upon the consummation of such Fundamental Transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) <U>Exercise Price</U>. Simultaneously with any adjustment to the Number of Warrant Shares pursuant to Section&nbsp;9, the Exercise Price shall be
increased or decreased proportionately, so that after such adjustment the aggregate Exercise Price payable hereunder for the increased or decreased Number of Warrant Shares shall be the same as the aggregate Exercise Price in effect immediately
prior to such adjustment. Notwithstanding the foregoing, in no event may the Exercise Price be adjusted below the par value of the Common Stock then in effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(e) <U>Calculations</U>. All calculations under this Section&nbsp;9 shall be made to the nearest <FONT STYLE="white-space:nowrap">one-hundredth</FONT> of one
cent or the nearest whole share, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(f) <U>Notice of Adjustments</U>. Upon the occurrence of each adjustment pursuant to this Section&nbsp;9,
the Company at its expense will, at the written request of the Holder, promptly compute such adjustment, in good faith, in accordance with the terms of this Warrant and prepare a certificate setting forth such adjustment, including a statement of
the adjusted Exercise Price and adjusted </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">number or type of Warrant Shares or other securities issuable upon exercise of this Warrant (as applicable),
describing the transactions giving rise to such adjustments and showing in detail the facts upon which such adjustment is based. Upon written request, the Company will promptly deliver a copy of each such certificate to the Holder and to the
Transfer Agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(g) <U>Notice of Corporate Events</U>. If, while this Warrant is outstanding, the Company (i)&nbsp;declares a dividend or any other
distribution of cash, securities or other property in respect of its Common Stock, including, without limitation, any granting of rights or warrants to subscribe for or purchase any capital stock of the Company or any subsidiary,
(ii)&nbsp;authorizes or approves, enters into any agreement contemplating or solicits stockholder approval for any Fundamental Transaction or (iii)&nbsp;authorizes the voluntary dissolution, liquidation or winding up of the affairs of the Company,
then, except if such notice and the contents thereof shall be deemed to constitute material <FONT STYLE="white-space:nowrap">non-public</FONT> information, the Company shall deliver to the Holder a notice of such transaction at least ten
(10)&nbsp;days prior to the applicable record or effective date on which a Person would need to hold Common Stock in order to participate in or vote with respect to such transaction; provided, however, that the failure to deliver such notice or any
defect therein shall not affect the validity of the corporate action required to be described in such notice. In the event such notice and the contents thereof shall be deemed to constitute material <FONT STYLE="white-space:nowrap">non-public</FONT>
information, the Company shall (on the same time frame set forth in the immediately prior sentence) offer the Holder the ability to sign a confidentiality agreement related thereto sufficient to allow the Holder to receive such notice, and the
Company shall deliver such notice immediately upon execution of such confidentiality agreement. In addition, if while this Warrant is outstanding, the Company authorizes or approves, enters into any agreement contemplating or solicits stockholder
approval for any Fundamental Transaction contemplated by Section&nbsp;9(c), other than a Fundamental Transaction under clause (iii)&nbsp;of Section&nbsp;9(c), then, except if such notice and the contents thereof shall be deemed to constitute
material <FONT STYLE="white-space:nowrap">non-public</FONT> information, the Company shall deliver to the Holder a notice of such Fundamental Transaction at least ten (10)&nbsp;days prior to the date such Fundamental Transaction is consummated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10. <I>Cashless Exercise</I>. Notwithstanding anything contained herein to the contrary, this Warrant may only be exercised through a &#147;cashless
exercise.&#148; Upon exercise, the Company shall issue to the Holder the number of Warrant Shares in an exchange of securities effected pursuant to Section&nbsp;3(a)(9) of the Securities Act as determined as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">X = Y <FONT STYLE="white-space:nowrap">[(A-B)/A]</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">where:
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;X&#148; equals the number of Warrant Shares to be issued to the Holder; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Y&#148; equals the total number of Warrant Shares with respect to which this Warrant is then being exercised; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;A&#148; equals the Closing Sale Price per share of Common Stock as of the Trading Day on the date immediately preceding the Exercise Date; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;B&#148; equals the Exercise Price per Warrant Share then in effect on the Exercise Date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of Rule 144 promulgated under the Securities Act, it is intended, understood and acknowledged
that the Warrant Shares issued in such a &#147;cashless exercise&#148; transaction shall be deemed to have been acquired by the Holder, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised, and the holding
period for the Warrant Shares shall be deemed to have commenced, on the date this Warrant was originally issued (provided that the Commission continues to take the position that such treatment is proper at the time of such exercise). In no event
will the exercise of this Warrant be settled in cash. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11. <I>Limitations on Exercise</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) Notwithstanding anything to the contrary contained herein, the Company shall not effect any exercise of this Warrant, and the Holder shall not be entitled
to exercise this Warrant, for a number of Warrant Shares in excess of that number of Warrant Shares which, upon giving effect or immediately prior to such exercise, would cause (i)&nbsp;the aggregate number of shares of Common Stock beneficially
owned by the Holder, its Affiliates and any other Persons whose beneficial ownership of Common Stock would be aggregated with the Holder&#146;s for purposes of Section&nbsp;13(d) of the Exchange Act to exceed [4.99][9.99][19.99]% (the
&#147;<B>Maximum Percentage</B>&#148;) of the total number of issued and outstanding shares of Common Stock of the Company following such exercise, or (ii)&nbsp;the combined voting power of the securities of the Company beneficially owned by the
Holder and its Affiliates and any other Persons whose beneficial ownership of Common Stock would be aggregated with the Holder&#146;s for purposes of Section&nbsp;13(d) of the Exchange Act to exceed the Maximum Percentage of the combined voting
power of all of the securities of the Company then outstanding following such exercise. For purposes of this Warrant, in determining the number of outstanding shares of Common Stock, the Holder may rely on the number of outstanding shares of Common
Stock as reflected in (x)&nbsp;the Company&#146;s most recent Form <FONT STYLE="white-space:nowrap">10-Q</FONT> or Form <FONT STYLE="white-space:nowrap">10-K,</FONT> as the case may be, filed with the Commission prior to the date hereof, (y)&nbsp;a
more recent public announcement by the Company or (z)&nbsp;any other notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the written request of the Holder, the Company shall within three
(3)&nbsp;Trading Days confirm in writing or by electronic mail to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the
conversion or exercise of securities of the Company, including this Warrant, by the Holder since the date as of which such number of outstanding shares of Common Stock was reported. By written notice to the Company, the Holder may from time to time
increase or decrease the Maximum Percentage to any other percentage not in excess of 19.99% specified in such notice; <I>provided</I> that any such increase will not be effective until the sixty-first (61st) day after such notice is delivered to the
Company. For purposes of this Section&nbsp;11(a), the aggregate number of shares of Common Stock or voting securities beneficially owned by the Holder and its Affiliates and any other Persons whose beneficial ownership of Common Stock would be
aggregated with the Holder&#146;s for purposes of Section&nbsp;13(d) of the Exchange Act shall include the shares of Common Stock issuable upon the exercise of this Warrant with respect to which such determination is being made, but shall exclude
the number of shares of Common Stock which would be issuable upon (x)&nbsp;exercise of the remaining unexercised and <FONT STYLE="white-space:nowrap">non-cancelled</FONT> portion of this Warrant by the Holder and (y)&nbsp;exercise or conversion of
the unexercised, <FONT STYLE="white-space:nowrap">non-converted</FONT> or <FONT STYLE="white-space:nowrap">non-cancelled</FONT> portion of any other securities of the Company that do not have voting power (including without limitation any securities
of the Company which would entitle the holder thereof to acquire at any time Common </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stock, including without limitation any debt, preferred stock, right, option, warrant or other instrument
that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock), that are subject to a limitation on conversion or exercise analogous to the limitation contained herein and
are beneficially owned by the Holder or any of its Affiliates and other Persons whose beneficial ownership of Common Stock would be aggregated with the Holder&#146;s for purposes of Section&nbsp;13(d) of the Exchange Act, and such Holder is solely
responsible for any schedules required to be filed in accordance therewith. Any provision of this Warrant to the contrary notwithstanding, the Holder hereby releases the Company and agrees to hold the Company harmless from all liability resulting
from the Holder&#146;s ownership exceeding the Maximum Percentage as a result of the exercise of this Warrant pursuant to its terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) This
Section&nbsp;11 shall not restrict the number of shares of Common Stock which a Holder may receive or beneficially own in order to determine the amount of securities or other consideration that such Holder may receive in the event of a Fundamental
Transaction as contemplated in Section&nbsp;9(c) of this Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">12. <I>No Fractional Shares</I>. No fractional Warrant Shares will be issued in
connection with any exercise of this Warrant. In lieu of any fractional shares that would otherwise be issuable, the number of Warrant Shares to be issued shall be rounded down to the next whole number and the Company shall pay the Holder in cash
the fair market value (based on the Closing Sale Price) for any such fractional shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">13. <I>Notices</I>. Any and all notices or other communications
or deliveries hereunder (including, without limitation, any Exercise Notice) shall be in writing and shall be deemed given and effective on the earliest of (i)&nbsp;the date of transmission, if such notice or communication is delivered via confirmed
<FONT STYLE="white-space:nowrap">e-mail</FONT> prior to 5:30 P.M., New York City time, on a Trading Day, (ii)&nbsp;the next Trading Day after the date of transmission, if such notice or communication is delivered via confirmed <FONT
STYLE="white-space:nowrap">e-mail</FONT> on a day that is not a Trading Day or later than 5:30 P.M., New York City time, on any Trading Day, (iii)&nbsp;the Trading Day following the date of mailing, if sent by nationally recognized overnight courier
service specifying next business day delivery, or (iv)&nbsp;upon actual receipt by the Person to whom such notice is required to be given, if by hand delivery. The addresses and <FONT STYLE="white-space:nowrap">e-mail</FONT> addresses for such
communications shall be: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If to the Company: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beam
Therapeutics Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">238 Main Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cambridge, MA 02142 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: Chief Legal Officer </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Telephone: <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">857-327-8775</FONT></FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email: [***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If to the Holder, to its address or <FONT STYLE="white-space:nowrap">e-mail</FONT> address set forth herein or on the books and records of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Or, in each of the above instances, to such other address or <FONT STYLE="white-space:nowrap">e-mail</FONT>
address as the recipient party has specified by written notice given to each other party at least five (5)&nbsp;days prior to the effectiveness of such change. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">14. <I>Warrant Agent</I>. The Company shall initially serve as warrant agent under this Warrant. Upon ten (10)&nbsp;days&#146; notice to the Holder, the
Company may appoint a new warrant agent. Any corporation into which the Company or any new warrant agent may be merged or any corporation resulting from any consolidation to which the Company or any new warrant agent shall be a party or any
corporation to which the Company or any new warrant agent transfers substantially all of its corporate trust or shareholders services business shall be a successor warrant agent under this Warrant without any further act. Any such successor warrant
agent shall promptly cause notice of its succession as warrant agent to be mailed (by first class mail, postage prepaid) to the Holder at the Holder&#146;s last address as shown on the Warrant Register. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">15. <I>Miscellaneous</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) <U>No Rights as a
Stockholder</U>. Except as otherwise set forth in this Warrant, the Holder, solely in such Person&#146;s capacity as a holder of this Warrant, shall not be entitled to vote or receive dividends or be deemed the holder of share capital of the Company
for any purpose, nor shall anything contained in this Warrant be construed to confer upon the Holder, solely in such Person&#146;s capacity as the Holder of this Warrant, any of the rights of a stockholder of the Company or any right to vote, give
or withhold consent to any corporate action (whether any reorganization, issue of stock, reclassification of stock, consolidation, merger, amalgamation, conveyance or otherwise), receive notice of meetings, receive dividends or subscription rights,
or otherwise, prior to the issuance to the Holder of the Warrant Shares which such Person is then entitled to receive upon the due exercise of this Warrant. In addition, nothing contained in this Warrant shall be construed as imposing any
liabilities on the Holder to purchase any securities (upon exercise of this Warrant or otherwise) or as a stockholder of the Company, whether such liabilities are asserted by the Company or by creditors of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) <U>Authorized Shares</U>. Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without
limitation, amending its certificate or articles of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance
or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set
forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i)&nbsp;not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such
increase in par value, (ii)&nbsp;take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> Warrant Shares upon the exercise
of this Warrant, and (iii)&nbsp;use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof as may be necessary to enable the Company to perform its
obligations under this Warrant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(c) <U>Successors and Assigns</U>. Subject to compliance with applicable securities laws, this Warrant may
be assigned by the Holder. This Warrant may not be assigned by the Company without the written consent of the Holder, except to a successor in the event of a Fundamental Transaction. This Warrant shall be binding on and inure to the benefit of the
Company and the Holder and their respective successors and assigns. Subject to the preceding sentence, nothing in this Warrant shall be construed to give to any Person other than the Company and the Holder any legal or equitable right, remedy or
cause of action under this Warrant. This Warrant may be amended only in writing signed by the Company and the Holder, or their successors and assigns. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) <U>Amendment and Waiver</U>. Except as otherwise provided herein, this Warrant may be modified or amended or the provisions hereof waived with the written
consent of the Company and the Holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(e) <U>Acceptance</U>. Receipt of this Warrant by the Holder shall constitute acceptance of and agreement to all
of the terms and conditions contained herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(f) <U>Governing Law; Jurisdiction</U>. ALL QUESTIONS CONCERNING THE CONSTRUCTION, VALIDITY, ENFORCEMENT
AND INTERPRETATION OF THIS WARRANT SHALL BE GOVERNED BY AND CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO THE PRINCIPLES OF CONFLICTS OF LAW THEREOF. EACH OF THE COMPANY AND THE HOLDER HEREBY
IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL COURTS SITTING IN THE CITY OF NEW YORK, BOROUGH OF MANHATTAN, FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION HEREWITH OR WITH ANY TRANSACTION CONTEMPLATED
HEREBY OR DISCUSSED HEREIN (INCLUDING WITH RESPECT TO THE ENFORCEMENT OF ANY OF THE TRANSACTION DOCUMENTS), AND HEREBY IRREVOCABLY WAIVES, AND AGREES NOT TO ASSERT IN ANY SUIT, ACTION OR PROCEEDING, ANY CLAIM THAT IT IS NOT PERSONALLY SUBJECT TO THE
JURISDICTION OF ANY SUCH COURT. EACH OF THE COMPANY AND THE HOLDER HEREBY IRREVOCABLY WAIVES PERSONAL SERVICE OF PROCESS AND CONSENTS TO PROCESS BEING SERVED IN ANY SUCH SUIT, ACTION OR PROCEEDING BY MAILING A COPY THEREOF VIA REGISTERED OR
CERTIFIED MAIL OR OVERNIGHT DELIVERY (WITH EVIDENCE OF DELIVERY) TO SUCH PERSON AT THE ADDRESS IN EFFECT FOR NOTICES TO IT AND AGREES THAT SUCH SERVICE SHALL CONSTITUTE GOOD AND SUFFICIENT SERVICE OF PROCESS AND NOTICE THEREOF. NOTHING CONTAINED
HEREIN SHALL BE DEEMED TO LIMIT IN ANY WAY ANY RIGHT TO SERVE PROCESS IN ANY MANNER PERMITTED BY LAW. EACH OF THE COMPANY AND THE HOLDER HEREBY WAIVES ALL RIGHTS TO A TRIAL BY JURY. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(g) <U>Headings</U>. The headings herein are for convenience only, do not constitute a part of this Warrant and shall not be deemed to limit or affect any of
the provisions hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(h) <U>Severability</U>. In case any one or more of the provisions of this Warrant shall be invalid or unenforceable in any
respect, the validity and enforceability of the remaining terms and provisions of this Warrant shall not in any way be affected or impaired thereby, and the Company and the Holder will attempt in good faith to agree upon a valid and enforceable
provision which shall be a commercially reasonable substitute therefor, and upon so agreeing, shall incorporate such substitute provision in this Warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Company has caused this Warrant to be duly executed by its authorized officer as of
the date first indicated above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">BEAM&nbsp;THERAPEUTICS&nbsp;INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="91%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">Agreed and accepted:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">[HOLDER]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="32"></TD>
<TD HEIGHT="32" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF EXERCISE NOTICE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[To be executed by the Holder to purchase shares of Common Stock under the Warrant] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(1) The undersigned is the Holder of <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant to Purchase Common Stock No. &#8195;&#8195; (the &#147;Warrant&#148;) issued by Beam Therapeutics Inc., a Delaware corporation (the &#147;Company&#148;). Capitalized terms used herein and not
otherwise defined herein have the respective meanings set forth in the Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(2) The undersigned hereby exercises its right to purchase
&#8195;&#8195;&#8195;&#8195;&#8195; Warrant Shares pursuant to the Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(3) The Holder intends that payment of the Exercise Price shall be made as a
&#147;Cashless Exercise&#148; under Section&nbsp;10 of the Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(4) Pursuant to this Exercise Notice, the Company shall deliver to the Holder the
applicable number of Warrant Shares determined in accordance with the terms of the Warrant. The Warrant Shares shall be delivered to the following DWAC Account Number: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:39%">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(5) By its delivery of this Exercise
Notice, the undersigned represents and warrants to the Company that in giving effect to the exercise evidenced hereby the Holder will not beneficially own in excess of the number of shares of Common Stock (as determined in accordance with
Section&nbsp;13(d) of the Securities Exchange Act of 1934, as amended) permitted to be owned under Section&nbsp;11(a) of the Warrant to which this notice relates. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="66%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dated:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#8195;&#8195;&#8195;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name&nbsp;of&nbsp;Holder:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#8195;&#8195;&#8195;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#8195;&#8195;&#8195;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#8195;&#8195;&#8195;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#8195;&#8195;&#8195;</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Signature must conform in all respects to name of Holder as specified on the face of the Warrant) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>3
<FILENAME>d930164dex41.htm
<DESCRIPTION>EX-4.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.1 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BEAM THERAPEUTICS INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF <FONT STYLE="white-space:nowrap">PRE-FUNDED</FONT> WARRANT TO PURCHASE COMMON STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Number of Shares: [_________] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">(subject to adjustment) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Warrant No. [___]
Original Issue Date: [___], 2025 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beam Therapeutics Inc., a Delaware corporation (the &#147;<B>Company</B>&#148;), hereby certifies that, for good and
valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [___________] or its permitted registered assigns (the &#147;<B>Holder</B>&#148;), is entitled, subject to the terms set forth below, to purchase from the Company
up to a total of [______] shares of common stock, $0.01 par value per share (the &#147;<B>Common Stock</B>&#148;), of the Company (each such share, a &#147;<B>Warrant Share</B>&#148; and all such shares, the &#147;<B>Warrant Shares</B>&#148;) at an
exercise price per share equal to $0.01 per share (as adjusted from time to time as provided in Section&nbsp;9 herein, the &#147;<B>Exercise Price</B>&#148;), upon surrender of this <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant to
Purchase Common Stock (including any Warrants to Purchase Common Stock issued in exchange, transfer or replacement hereof, the &#147;<B>Warrant</B>&#148;) at any time and from time to time on or after the date hereof (the &#147;<B>Original Issue
Date</B>&#148;) and through and including the date this Warrant is exercised in full (the &#147;<B>Expiration Date</B>&#148;), subject to the following terms and conditions: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. <I>Definitions</I>. For purposes of this Warrant, the following terms shall have the following meanings: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) &#147;<B>Affiliate</B>&#148; means any Person directly or indirectly controlled by, controlling or under common control with, a Holder, as such terms are
used in and construed under Rule 405 under the Securities Act, but only for so long as such control shall continue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) &#147;<B>Closing Sale
Price</B>&#148; means, for any security as of any date, the last trade price for such security on the Principal Trading Market for such security, as reported by Bloomberg L.P., or, if such Principal Trading Market begins to operate on an extended
hours basis and does not designate the last trade price, then the last trade price of such security immediately prior to 4:00 P.M., New York City time, as reported by Bloomberg L.P., or if the security is not listed for trading on a national
securities exchange or other trading market on the relevant date, the last quoted bid price for the security in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market on the relevant date as
reported by OTC Markets Group Inc. (or a similar organization or agency succeeding to its functions of reporting prices). If the Closing Sale Price cannot be calculated for a security on a particular date on any of the foregoing bases, the Closing
Sale Price of such security on such date shall be the fair market value as mutually determined by the Company and the Holder. If the Company and the Holder are unable to agree upon the fair market value of such security, then the board of directors
of the Company (the &#147;<B>Board of Directors</B>&#148;) shall use its good faith judgment to determine the fair market value of such security on such date. The Board of Directors&#146; determination shall be binding upon all parties absent
demonstrable error. All such determinations shall be appropriately adjusted for any stock dividend, stock split, stock combination or other similar transaction during the applicable calculation period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(c) &#147;<B>Commission</B>&#148; means the United States Securities and Exchange Commission. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) &#147;<B>Marketable Securities</B>&#148; means securities meeting all of the following requirements:
(i)&nbsp;the issuer thereof is then subject to the reporting requirements of Section&nbsp;13 or Section&nbsp;15(d) of the Securities Exchange Act of 1934, as amended (the &#147;<B>Exchange Act</B>&#148;), and is then current in its filing of all
required reports and other information under the Securities Act and the Exchange Act; (ii)&nbsp;the class and series of shares or other security of the issuer that would be received by Holder in connection with the Fundamental Transaction (as
defined below) were Holder to exercise this Warrant on or prior to the closing thereof is then traded or quoted on a nationally recognized securities exchange, inter-dealer quotation system or <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market, and (iii)&nbsp;following the closing of such Fundamental Transaction, the Holder would not be restricted from publicly <FONT STYLE="white-space:nowrap">re-selling</FONT> all of the
issuer&#146;s shares and/or other securities that would be received by the Holder in such Fundamental Transaction were the Holder to exercise or convert this Warrant in full on or prior to the closing of such Fundamental Transaction except to the
extent that any such restriction arises solely under federal or state securities laws, rules or regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(e) &#147;<B>Person</B>&#148; means an
individual, partnership, corporation, limited liability company, business trust, joint stock company, trust, unincorporated association, joint venture or any other entity or organization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(e) &#147;<B>Principal Trading Market</B>&#148; means the national securities exchange or other trading market on which the Common Stock is primarily listed
on and quoted for trading, which, as of the Original Issue Date, shall be the Nasdaq Global Select Market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(f) &#147;<B>Registration Statement</B>&#148;
means the Company&#146;s Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-277427),</FONT> that became effective on February&nbsp;28, 2024. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(g) &#147;<B>Securities Act</B>&#148; means the Securities Act of 1933, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(h) &#147;<B>Standard Settlement Period</B>&#148; means the standard settlement period, expressed in a number of Trading Days, for the Principal Trading
Market with respect to the Common Stock that is in effect on the date of delivery of an applicable Exercise Notice, which as of the Original Issue Date was &#147;T+1.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(i) &#147;<B>Trading Day</B>&#148; means any weekday on which the Principal Trading Market is open for trading. If the Common Stock is not listed or admitted
for trading, &#147;Trading Day&#148; means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or any day on which banking institutions in New York City are authorized or required by law or other
governmental action to close. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(j) &#147;<B>Transfer Agent</B>&#148; means Computershare Trust Company, N.A., the Company&#146;s transfer agent and
registrar for the Common Stock, and any successor appointed in such capacity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. <I>Issuance of Securities; Registration of Warrants</I>. The Warrant, as
initially issued by the Company, is offered and sold pursuant to the Registration Statement. As of the Original Issue Date, the Warrant Shares are issuable under the Registration Statement. Accordingly, the Warrant and, assuming issuance pursuant to
the Registration Statement or an exchange meeting the requirements of Section&nbsp;3(a)(9) of the Securities Act as in effect on the Original Issue Date, the Warrant Shares, are not &#147;restricted securities&#148; under Rule 144 promulgated under
the Securities Act as of the Original Issue Date. The Company shall register ownership of this </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Warrant, upon records to be maintained by the Company for that purpose (the &#147;<B>Warrant Register</B>&#148;), in the name of the record Holder (which shall include the initial Holder or, as
the case may be, any assignee to which this Warrant is permissibly assigned hereunder) from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any
distribution to the Holder, and for all other purposes, absent actual notice to the contrary. This Warrant may be, at the option of the Holder, either (x)&nbsp;represented by an original Warrant certificate or (y)&nbsp;issued by book-entry
registration in the Warrant Register. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. <I>Registration of Transfers</I>. Subject to compliance with all applicable securities laws and the rules of the
Principal Trading Market, the Company shall, or will cause its Transfer Agent to, register the transfer of all or any portion of this Warrant in the Warrant Register, upon surrender of this Warrant, and payment for all applicable transfer taxes (if
any) by the Holder or any subsequent holder. Notwithstanding the foregoing, no surrender of this Warrant shall be required if such Warrant is represented by book-entry registration in the Warrant Register. Upon any such registration of transfer, a
new warrant to purchase Common Stock in substantially the form of this Warrant (any such new warrant, a &#147;<B>New Warrant</B>&#148;) evidencing the portion of this Warrant so transferred shall be issued to the transferee, and a New Warrant
evidencing the remaining portion of this Warrant not so transferred, if any, shall be issued to the transferring Holder. The acceptance of the New Warrant by the transferee thereof shall be deemed the acceptance by such transferee of all of the
rights and obligations in respect of the New Warrant that the Holder has in respect of this Warrant. The Company shall, or will cause its Transfer Agent to, prepare, issue and deliver at the Company&#146;s own expense any New Warrant under this
Section&nbsp;3. Until due presentment for registration of transfer, the Company may treat the registered Holder hereof as the owner and holder for all purposes, and the Company shall not be affected by any notice to the contrary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4. <I>Exercise and Duration of Warrants</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) All or any
part of this Warrant shall be exercisable by the registered Holder in the manner set forth herein (including Section&nbsp;10) at any time and from time to time on or after the Original Issue Date and through and including the Expiration Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) The Holder may exercise this Warrant by delivering to the Company an exercise notice, in the form attached as Schedule 1 hereto (the &#147;<B>Exercise
Notice</B>&#148;), completed and duly signed. The date on which such Exercise Notice is delivered to the Company (as determined in accordance with the notice provisions hereof) is an &#147;<B>Exercise Date</B>.&#148; The Holder shall not be required
to deliver the original Warrant in order to effect an exercise hereunder. Execution and delivery of the Exercise Notice shall have the same effect as cancellation of the original Warrant and issuance of a New Warrant evidencing the right to purchase
the remaining number of Warrant Shares, if any. The aggregate exercise price of this Warrant, except for the Exercise Price, was <FONT STYLE="white-space:nowrap">pre-funded</FONT> to the Company on or before the Original Issue Date, and consequently
no additional consideration (other than the Exercise Price) shall be required to be paid by the Holder to effect any exercise of this Warrant. The Holder shall not be entitled to the return or refund of all, or any portion, of such <FONT
STYLE="white-space:nowrap">pre-funded</FONT> exercise price under any circumstance or for any reason whatsoever. <B>The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this
paragraph, following the purchase of a portion of the </B><B>Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.</B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5. <I>Delivery of Warrant Shares</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) Upon exercise of this Warrant in accordance with the terms of this Warrant (including Section&nbsp;10), the Company shall promptly (but in no event later
than the number of Trading Days comprising the Standard Settlement Period after the Exercise Date), upon the request of the Holder, credit or instruct the Transfer Agent to credit such aggregate number of shares of Common Stock to which the Holder
is entitled pursuant to such exercise to the Holder&#146;s or its designee&#146;s balance account with The Depository Trust Company (&#147;<B>DTC</B>&#148;) through its Deposit Withdrawal At Custodian system, or if the Transfer Agent is not
participating in the Fast Automated Securities Transfer Program or if the certificates or book-entry positions are required to bear a legend regarding restriction on transferability, issue and dispatch by overnight courier to the address as
specified in the Exercise Notice, a certificate or book-entry position, registered in the Company&#146;s share register in the name of the Holder or its designee, for the number of shares of Common Stock to which the Holder is entitled pursuant to
such exercise. The Holder, or any Person so designated by the Holder to receive Warrant Shares, shall be deemed to have become the holder of record of such Warrant Shares as of the Exercise Date, irrespective of the date such Warrant Shares are
credited to the Holder&#146;s DTC account or the date of delivery of the certificates or book-entry positions evidencing such Warrant Shares, as the case may be. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) If, within the number of Trading Days comprising the Standard Settlement Period following the Exercise Date, the Company fails to deliver to the Holder a
certificate or book-entry position representing the required number of Warrant Shares in the manner required pursuant to Section&nbsp;5(a) or fails to cause the Transfer Agent to credit the Holder&#146;s DTC account for such number of Warrant Shares
to which the Holder is entitled, and if after such number of days and prior to the receipt of such Warrant Shares, the Holder purchases (in an open market transaction or otherwise) shares of Common Stock to deliver in satisfaction of a sale by the
Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a &#147;<B><FONT STYLE="white-space:nowrap">Buy-In</FONT></B>&#148;) but did not receive within the Standard Settlement Period, then the Company shall, within
three (3)&nbsp;Trading Days after the Holder&#146;s request promptly honor its obligation to deliver to the Holder a certificate or certificates or book-entry positions representing such Warrant Shares and pay cash to the Holder in an amount equal
to the excess (if any) of (x)&nbsp;Holder&#146;s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased in the <FONT STYLE="white-space:nowrap">Buy-In,</FONT> less (y)&nbsp;the product of
(A)&nbsp;the number of shares of Common Stock purchased in the <FONT STYLE="white-space:nowrap">Buy-In,</FONT> times (B)&nbsp;the Closing Sale Price of a share of Common Stock on the Exercise Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(c) To the extent permitted by law and subject to Section&nbsp;5(b), the Company&#146;s obligations to cause the Transfer Agent to issue and deliver Warrant
Shares in accordance with and subject to the terms hereof (including the limitations set forth in Section&nbsp;11 below) are absolute and unconditional, irrespective of any action or inaction by the Holder to enforce the same, any waiver or consent
with respect to any provision hereof, the recovery of any judgment against any Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by the Holder or any other
Person of any obligation to the Company or any violation or alleged violation of law by the Holder or any other Person, and irrespective of any other circumstance that might otherwise limit such obligation of the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company to the Holder in connection with the issuance of Warrant Shares. Subject to Section&nbsp;5(b), nothing herein shall limit the Holder&#146;s right to pursue any other remedies available to
it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company&#146;s failure to timely deliver shares of Common Stock upon exercise of the Warrant as required
pursuant to the terms hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6. <I>Charges, Taxes and Expenses</I>. Issuance and delivery of shares of Common Stock upon exercise of this Warrant shall
be made without charge to the Holder for any issue or transfer tax, transfer agent fee or other incidental tax or expense (excluding any applicable stamp duties) in respect of the issuance of such shares, all of which taxes and expenses shall be
paid by the Company; <I>provided</I>, <I>however</I>, that the Company shall not be required to pay any tax that may be payable in respect of any transfer involved in the registration of any Warrant Shares or the Warrants in a name other than that
of the Holder or an Affiliate thereof. The Holder shall be responsible for all other tax liability that may arise as a result of holding or transferring this Warrant or receiving Warrant Shares upon exercise hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7. <I>Replacement of Warrant</I>. If this Warrant is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange and
substitution for and upon cancellation hereof, or in lieu of and substitution for this Warrant, a New Warrant, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction (in such case) and, in each
case, a customary and reasonable indemnity and surety bond, if requested by the Company. Applicants for a New Warrant under such circumstances shall also comply with such other reasonable regulations and procedures and pay such other reasonable
third-party costs as the Company may prescribe. If a New Warrant is requested as a result of a mutilation of this Warrant, then the Holder shall deliver such mutilated Warrant to the Company as a condition precedent to the Company&#146;s obligation
to issue the New Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8. <I>Reservation of Warrant Shares</I>. The Company covenants that it will, at all times while this Warrant is outstanding,
reserve and keep available out of the aggregate of its authorized but unissued and otherwise unreserved Common Stock, solely for the purpose of enabling it to issue Warrant Shares upon exercise of this Warrant as herein provided, the number of
Warrant Shares that are initially issuable and deliverable upon the exercise of this entire Warrant, free from preemptive rights or any other contingent purchase rights of persons other than the Holder (taking into account the adjustments and
restrictions of Section&nbsp;9). The Company covenants that all Warrant Shares so issuable and deliverable shall, upon issuance and the payment of the applicable Exercise Price in accordance with the terms hereof, be duly and validly authorized,
issued and fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> The Company will take all such action as may be reasonably necessary to assure that such shares of Common Stock may be issued as provided herein without violation of
any applicable law or regulation, or of any requirements of any securities exchange or automated quotation system upon which the Common Stock may be listed. The Company further covenants that it will not, without the prior written consent of the
Holder, take any actions to increase the par value of the Common Stock at any time while this Warrant is outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">9. <I>Certain Adjustments</I>. The
Exercise Price and number of Warrant Shares issuable upon exercise of this Warrant (the &#147;<B>Number of Warrant Shares</B>&#148;) are subject to adjustment from time to time as set forth in this Section&nbsp;9. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) <U>Stock Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding,
(i)&nbsp;pays a stock dividend on its Common Stock or otherwise makes a distribution on any class of capital stock issued and outstanding on the Original Issue Date and in accordance with the terms of such stock on the Original Issue Date or as
amended, that is payable in shares of Common Stock, (ii)&nbsp;subdivides its outstanding shares of Common Stock into a larger number of shares of Common Stock, (iii)&nbsp;combines its outstanding shares of Common Stock into a smaller number of
shares of Common Stock or (iv)&nbsp;issues by reclassification of shares of capital stock any additional shares of Common Stock, then in each such case the Number of Warrant Shares shall be multiplied by a fraction, the numerator of which shall be
the number of shares of Common Stock outstanding immediately after such event and the denominator of which shall be the number of shares of Common Stock outstanding immediately before such event. Any adjustment made pursuant to clause (i)&nbsp;of
this paragraph shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution, provided, however, that if such record date shall have been fixed and such dividend is
not fully paid on the date fixed therefor, the Number of Warrant Shares shall be recomputed accordingly as of the close of business on such record date and thereafter the Number of Warrant Shares shall be adjusted pursuant to this paragraph as of
the time of actual payment of such dividends. Any adjustment pursuant to clause (ii), (iii) or (iv)&nbsp;of this paragraph shall become effective immediately after the effective date of such subdivision, combination or issuance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) <U>Pro Rata Distributions</U>. If the Company, at any time while this Warrant is outstanding, distributes to all holders of Common Stock for no
consideration (i)&nbsp;evidences of its indebtedness, (ii)&nbsp;any security (other than a distribution of Common Stock covered by the preceding paragraph), (iii) rights or warrants to subscribe for or purchase any security (including Common Stock),
or (iv)&nbsp;cash or any other asset (in each case, a &#147;<B>Distribution</B>&#148;), other than a reclassification as to which Section&nbsp;9(c) applies, then in each such case, the Holder shall be entitled to participate in such Distribution to
the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without
limitation, the ownership limitation set forth in Section&nbsp;11(a) hereof) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of Common Stock are to
be determined for the participation in such Distribution;<I> provided</I>, <I>however</I>, to the extent that the Holder&#146;s right to participate in any such Distribution would result in the Holder exceeding the ownership limitation set forth in
Section&nbsp;11(a) hereof, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any Common Stock as a result of such Distribution to such extent) and the portion of such
Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as the delivery to such Holder of such portion would not result in the Holder exceeding the ownership limitation set forth in Section&nbsp;11(a) hereof.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(c) <U>Fundamental Transactions</U>. If, at any time while this Warrant is outstanding (i)&nbsp;the Company effects any merger or consolidation of the
Company with or into another Person, in which the Company is not the surviving entity, (ii)&nbsp;the Company effects any sale to another Person of all or substantially all of its assets in one transaction or a series of related transactions,
(iii)&nbsp;pursuant to any tender offer or exchange offer (whether by the Company or another Person), holders of capital stock tender shares representing more than 50% of the voting power of the capital stock
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of the Company and the Company or such other Person, as applicable, accepts such tender for payment, (iv)&nbsp;the Company consummates a stock purchase agreement or other business combination
(including, without limitation, a reorganization, recapitalization, <FONT STYLE="white-space:nowrap">spin-off</FONT> or scheme of arrangement) with another Person whereby such other Person acquires more than the 50% of the voting power of the
capital stock of the Company (except for any such transaction in which the stockholders of the Company immediately prior to such transaction maintain, in substantially the same proportions, the voting power of such Person immediately after the
transaction) or (v)&nbsp;the Company effects any reclassification of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property (other than
as a result of a subdivision or combination of shares of Common Stock covered by Section&nbsp;9(a) above) (in any such case, a &#147;<B>Fundamental Transaction</B>&#148;), then following such Fundamental Transaction the Holder shall have the right
to receive, upon exercise of this Warrant, the same amount and kind of securities, cash or property as it would have been entitled to receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such Fundamental
Transaction, the holder of the Number of Warrant Shares (in the case of clause (iii)&nbsp;above, assuming it had tendered, and the offeror had accepted, such Warrant Shares) (the &#147;<B>Alternate Consideration</B>&#148;). The Company shall not
effect any Fundamental Transaction in which the Company is not the surviving entity or the Alternate Consideration includes securities of another Person unless (i)&nbsp;the Alternate Consideration is solely cash and the Company provides for the
simultaneous &#147;cashless exercise&#148; of this Warrant pursuant to Section&nbsp;10 below or (ii)&nbsp;prior to or simultaneously with the consummation thereof, any successor to the Company, surviving entity or other Person (including any
purchaser of assets of the Company) shall assume the obligation to deliver to the Holder such Alternate Consideration as, in accordance with the foregoing provisions, the Holder may be entitled to receive, and the other obligations under this
Warrant. The provisions of this paragraph (c)&nbsp;shall similarly apply to subsequent transactions analogous of a Fundamental Transaction type. Notwithstanding the foregoing, in the event of a Fundamental Transaction where the consideration payable
to holders of Common Stock consists solely of cash, solely of Marketable Securities or a combination of cash and Marketable Securities, then this Warrant shall automatically be deemed to be exercised in full in a &#147;cashless exercise&#148;
pursuant to Section&nbsp;10 below effective immediately prior to and contingent upon the consummation of such Fundamental Transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) <U>Exercise
Price</U>. Simultaneously with any adjustment to the Number of Warrant Shares pursuant to Section&nbsp;9, the Exercise Price shall be increased or decreased proportionately, so that after such adjustment the aggregate Exercise Price payable
hereunder for the increased or decreased Number of Warrant Shares shall be the same as the aggregate Exercise Price in effect immediately prior to such adjustment. Notwithstanding the foregoing, in no event may the Exercise Price be adjusted below
the par value of the Common Stock then in effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(e) <U>Calculations</U>. All calculations under this Section&nbsp;9 shall be made to the nearest <FONT
STYLE="white-space:nowrap">one-hundredth</FONT> of one cent or the nearest whole share, as applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(f) <U>Notice of Adjustments</U>. Upon the occurrence of each adjustment pursuant to this Section&nbsp;9,
the Company at its expense will, at the written request of the Holder, promptly compute such adjustment, in good faith, in accordance with the terms of this Warrant and prepare a certificate setting forth such adjustment, including a statement of
the adjusted Exercise Price and adjusted number or type of Warrant Shares or other securities issuable upon exercise of this Warrant (as applicable), describing the transactions giving rise to such adjustments and showing in detail the facts upon
which such adjustment is based. Upon written request, the Company will promptly deliver a copy of each such certificate to the Holder and to the Transfer Agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(g) <U>Notice of Corporate Events</U>. If, while this Warrant is outstanding, the Company (i)&nbsp;declares a dividend or any other distribution of cash,
securities or other property in respect of its Common Stock, including, without limitation, any granting of rights or warrants to subscribe for or purchase any capital stock of the Company or any subsidiary, (ii)&nbsp;authorizes or approves, enters
into any agreement contemplating or solicits stockholder approval for any Fundamental Transaction or (iii)&nbsp;authorizes the voluntary dissolution, liquidation or winding up of the affairs of the Company, then, except if such notice and the
contents thereof shall be deemed to constitute material <FONT STYLE="white-space:nowrap">non-public</FONT> information, the Company shall deliver to the Holder a notice of such transaction at least ten (10)&nbsp;days prior to the applicable record
or effective date on which a Person would need to hold Common Stock in order to participate in or vote with respect to such transaction; provided, however, that the failure to deliver such notice or any defect therein shall not affect the validity
of the corporate action required to be described in such notice. In the event such notice and the contents thereof shall be deemed to constitute material <FONT STYLE="white-space:nowrap">non-public</FONT> information, the Company shall (on the same
time frame set forth in the immediately prior sentence) offer the Holder the ability to sign a confidentiality agreement related thereto sufficient to allow the Holder to receive such notice, and the Company shall deliver such notice immediately
upon execution of such confidentiality agreement. In addition, if while this Warrant is outstanding, the Company authorizes or approves, enters into any agreement contemplating or solicits stockholder approval for any Fundamental Transaction
contemplated by Section&nbsp;9(c), other than a Fundamental Transaction under clause (iii)&nbsp;of Section&nbsp;9(c), then, except if such notice and the contents thereof shall be deemed to constitute material
<FONT STYLE="white-space:nowrap">non-public</FONT> information, the Company shall deliver to the Holder a notice of such Fundamental Transaction at least ten (10)&nbsp;days prior to the date such Fundamental Transaction is consummated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10. <I>Cashless Exercise</I>. Notwithstanding anything contained herein to the contrary, this Warrant may only be exercised through a &#147;cashless
exercise.&#148; Upon exercise, the Company shall issue to the Holder the number of Warrant Shares in an exchange of securities effected pursuant to Section&nbsp;3(a)(9) of the Securities Act as determined as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">X = Y <FONT STYLE="white-space:nowrap">[(A-B)/A]</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">where:
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;X&#148; equals the number of Warrant Shares to be issued to the Holder; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Y&#148; equals the total number of Warrant Shares with respect to which this Warrant is then being exercised; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;A&#148; equals the Closing Sale Price per share of Common Stock as of the Trading Day on the date immediately preceding the Exercise Date; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;B&#148; equals the Exercise Price per Warrant Share then in effect on the Exercise Date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of Rule 144 promulgated under the Securities Act, it is intended, understood and acknowledged
that the Warrant Shares issued in such a &#147;cashless exercise&#148; transaction shall be deemed to have been acquired by the Holder, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised, and the holding
period for the Warrant Shares shall be deemed to have commenced, on the date this Warrant was originally issued (provided that the Commission continues to take the position that such treatment is proper at the time of such exercise). In no event
will the exercise of this Warrant be settled in cash. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11. <I>Limitations on Exercise</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) Notwithstanding anything to the contrary contained herein, the Company shall not effect any exercise of this Warrant, and the Holder shall not be entitled
to exercise this Warrant, for a number of Warrant Shares in excess of that number of Warrant Shares which, upon giving effect or immediately prior to such exercise, would cause (i)&nbsp;the aggregate number of shares of Common Stock beneficially
owned by the Holder, its Affiliates and any other Persons whose beneficial ownership of Common Stock would be aggregated with the Holder&#146;s for purposes of Section&nbsp;13(d) of the Exchange Act to exceed [4.99][9.99][19.99]% (the
&#147;<B>Maximum Percentage</B>&#148;) of the total number of issued and outstanding shares of Common Stock of the Company following such exercise, or (ii)&nbsp;the combined voting power of the securities of the Company beneficially owned by the
Holder and its Affiliates and any other Persons whose beneficial ownership of Common Stock would be aggregated with the Holder&#146;s for purposes of Section&nbsp;13(d) of the Exchange Act to exceed the Maximum Percentage of the combined voting
power of all of the securities of the Company then outstanding following such exercise. For purposes of this Warrant, in determining the number of outstanding shares of Common Stock, the Holder may rely on the number of outstanding shares of Common
Stock as reflected in (x)&nbsp;the Company&#146;s most recent Form <FONT STYLE="white-space:nowrap">10-Q</FONT> or Form <FONT STYLE="white-space:nowrap">10-K,</FONT> as the case may be, filed with the Commission prior to the date hereof, (y)&nbsp;a
more recent public announcement by the Company or (z)&nbsp;any other notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the written request of the Holder, the Company shall within three
(3)&nbsp;Trading Days confirm in writing or by electronic mail to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the
conversion or exercise of securities of the Company, including this Warrant, by the Holder since the date as of which such number of outstanding shares of Common Stock was reported. By written notice to the Company, the Holder may from time to time
increase or decrease the Maximum Percentage to any other percentage not in excess of 19.99% specified in such notice; <I>provided</I> that any such increase will not be effective until the sixty-first (61st) day after such notice is delivered to the
Company. For purposes of this Section&nbsp;11(a), the aggregate number of shares of Common Stock or voting securities beneficially owned by the Holder and its Affiliates and any other Persons whose beneficial ownership of Common Stock would be
aggregated with the Holder&#146;s for purposes of Section&nbsp;13(d) of the Exchange Act shall include the shares of Common Stock issuable upon the exercise of this Warrant with respect to which such determination is being made, but shall exclude
the number of shares of Common Stock which would be issuable upon (x)&nbsp;exercise of the remaining unexercised and <FONT STYLE="white-space:nowrap">non-cancelled</FONT> portion of this Warrant by the Holder and (y)&nbsp;exercise or conversion of
the unexercised, <FONT STYLE="white-space:nowrap">non-converted</FONT> or <FONT STYLE="white-space:nowrap">non-cancelled</FONT> portion of any other securities of the Company that do not have voting power (including without limitation any securities
of the Company which would entitle the holder thereof to acquire at any time Common </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Stock, including without limitation any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise
entitles the holder thereof to receive, Common Stock), that are subject to a limitation on conversion or exercise analogous to the limitation contained herein and are beneficially owned by the Holder or any of its Affiliates and other Persons whose
beneficial ownership of Common Stock would be aggregated with the Holder&#146;s for purposes of Section&nbsp;13(d) of the Exchange Act, and such Holder is solely responsible for any schedules required to be filed in accordance therewith. Any
provision of this Warrant to the contrary notwithstanding, the Holder hereby releases the Company and agrees to hold the Company harmless from all liability resulting from the Holder&#146;s ownership exceeding the Maximum Percentage as a result of
the exercise of this Warrant pursuant to its terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) This Section&nbsp;11 shall not restrict the number of shares of Common Stock which a Holder may
receive or beneficially own in order to determine the amount of securities or other consideration that such Holder may receive in the event of a Fundamental Transaction as contemplated in Section&nbsp;9(c) of this Warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">12. <I>No Fractional Shares</I>. No fractional Warrant Shares will be issued in connection with any exercise of this Warrant. In lieu of any fractional shares
that would otherwise be issuable, the number of Warrant Shares to be issued shall be rounded down to the next whole number and the Company shall pay the Holder in cash the fair market value (based on the Closing Sale Price) for any such fractional
shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">13. <I>Notices</I>. Any and all notices or other communications or deliveries hereunder (including, without limitation, any Exercise Notice)
shall be in writing and shall be deemed given and effective on the earliest of (i)&nbsp;the date of transmission, if such notice or communication is delivered via confirmed <FONT STYLE="white-space:nowrap">e-mail</FONT> prior to 5:30 P.M., New York
City time, on a Trading Day, (ii)&nbsp;the next Trading Day after the date of transmission, if such notice or communication is delivered via confirmed <FONT STYLE="white-space:nowrap">e-mail</FONT> on a day that is not a Trading Day or later than
5:30 P.M., New York City time, on any Trading Day, (iii)&nbsp;the Trading Day following the date of mailing, if sent by nationally recognized overnight courier service specifying next business day delivery, or (iv)&nbsp;upon actual receipt by the
Person to whom such notice is required to be given, if by hand delivery. The addresses and <FONT STYLE="white-space:nowrap">e-mail</FONT> addresses for such communications shall be: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If to the Company: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beam Therapeutics Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">238 Main Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cambridge, MA 02142 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: Chief Legal Officer </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Telephone: <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">857-327-8775</FONT></FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email: [***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If to the Holder, to its address or <FONT STYLE="white-space:nowrap">e-mail</FONT> address set forth herein or on the books and records of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Or, in each of the above instances, to such other address or <FONT STYLE="white-space:nowrap">e-mail</FONT>
address as the recipient party has specified by written notice given to each other party at least five (5)&nbsp;days prior to the effectiveness of such change. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">14. <I>Warrant Agent</I>. The Company shall initially serve as warrant agent under this Warrant. Upon ten (10)&nbsp;days&#146; notice to the Holder, the
Company may appoint a new warrant agent. Any corporation into which the Company or any new warrant agent may be merged or any corporation resulting from any consolidation to which the Company or any new warrant agent shall be a party or any
corporation to which the Company or any new warrant agent transfers substantially all of its corporate trust or shareholders services business shall be a successor warrant agent under this Warrant without any further act. Any such successor warrant
agent shall promptly cause notice of its succession as warrant agent to be mailed (by first class mail, postage prepaid) to the Holder at the Holder&#146;s last address as shown on the Warrant Register. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">15. <I>Miscellaneous</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) <U>No Rights as a
Stockholder</U>. Except as otherwise set forth in this Warrant, the Holder, solely in such Person&#146;s capacity as a holder of this Warrant, shall not be entitled to vote or receive dividends or be deemed the holder of share capital of the Company
for any purpose, nor shall anything contained in this Warrant be construed to confer upon the Holder, solely in such Person&#146;s capacity as the Holder of this Warrant, any of the rights of a stockholder of the Company or any right to vote, give
or withhold consent to any corporate action (whether any reorganization, issue of stock, reclassification of stock, consolidation, merger, amalgamation, conveyance or otherwise), receive notice of meetings, receive dividends or subscription rights,
or otherwise, prior to the issuance to the Holder of the Warrant Shares which such Person is then entitled to receive upon the due exercise of this Warrant. In addition, nothing contained in this Warrant shall be construed as imposing any
liabilities on the Holder to purchase any securities (upon exercise of this Warrant or otherwise) or as a stockholder of the Company, whether such liabilities are asserted by the Company or by creditors of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) <U>Authorized Shares</U>. Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without
limitation, amending its certificate or articles of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance
or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set
forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i)&nbsp;not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such
increase in par value, (ii)&nbsp;take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> Warrant Shares upon the exercise
of this Warrant, and (iii)&nbsp;use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof as may be necessary to enable the Company to perform its
obligations under this Warrant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(c) <U>Successors and Assigns</U>. Subject to compliance with applicable securities laws, this Warrant may
be assigned by the Holder. This Warrant may not be assigned by the Company without the written consent of the Holder, except to a successor in the event of a Fundamental Transaction. This Warrant shall be binding on and inure to the benefit of the
Company and the Holder and their respective successors and assigns. Subject to the preceding sentence, nothing in this Warrant shall be construed to give to any Person other than the Company and the Holder any legal or equitable right, remedy or
cause of action under this Warrant. This Warrant may be amended only in writing signed by the Company and the Holder, or their successors and assigns. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) <U>Amendment and Waiver</U>. Except as otherwise provided herein, this Warrant may be modified or amended or the provisions hereof waived with the written
consent of the Company and the Holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(e) <U>Acceptance</U>. Receipt of this Warrant by the Holder shall constitute acceptance of and agreement to all
of the terms and conditions contained herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(f) <U>Governing Law; Jurisdiction</U>. ALL QUESTIONS CONCERNING THE CONSTRUCTION, VALIDITY, ENFORCEMENT
AND INTERPRETATION OF THIS WARRANT SHALL BE GOVERNED BY AND CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO THE PRINCIPLES OF CONFLICTS OF LAW THEREOF. EACH OF THE COMPANY AND THE HOLDER HEREBY
IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL COURTS SITTING IN THE CITY OF NEW YORK, BOROUGH OF MANHATTAN, FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION HEREWITH OR WITH ANY TRANSACTION CONTEMPLATED
HEREBY OR DISCUSSED HEREIN (INCLUDING WITH RESPECT TO THE ENFORCEMENT OF ANY OF THE TRANSACTION DOCUMENTS), AND HEREBY IRREVOCABLY WAIVES, AND AGREES NOT TO ASSERT IN ANY SUIT, ACTION OR PROCEEDING, ANY CLAIM THAT IT IS NOT PERSONALLY SUBJECT TO THE
JURISDICTION OF ANY SUCH COURT. EACH OF THE COMPANY AND THE HOLDER HEREBY IRREVOCABLY WAIVES PERSONAL SERVICE OF PROCESS AND CONSENTS TO PROCESS BEING SERVED IN ANY SUCH SUIT, ACTION OR PROCEEDING BY MAILING A COPY THEREOF VIA REGISTERED OR
CERTIFIED MAIL OR OVERNIGHT DELIVERY (WITH EVIDENCE OF DELIVERY) TO SUCH PERSON AT THE ADDRESS IN EFFECT FOR NOTICES TO IT AND AGREES THAT SUCH SERVICE SHALL CONSTITUTE GOOD AND SUFFICIENT SERVICE OF PROCESS AND NOTICE THEREOF. NOTHING CONTAINED
HEREIN SHALL BE DEEMED TO LIMIT IN ANY WAY ANY RIGHT TO SERVE PROCESS IN ANY MANNER PERMITTED BY LAW. EACH OF THE COMPANY AND THE HOLDER HEREBY WAIVES ALL RIGHTS TO A TRIAL BY JURY. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(g) <U>Headings</U>. The headings herein are for convenience only, do not constitute a part of this Warrant and shall not be deemed to limit or affect any of
the provisions hereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(h) <U>Severability</U>. In case any one or more of the provisions of this Warrant shall be invalid or
unenforceable in any respect, the validity and enforceability of the remaining terms and provisions of this Warrant shall not in any way be affected or impaired thereby, and the Company and the Holder will attempt in good faith to agree upon a valid
and enforceable provision which shall be a commercially reasonable substitute therefor, and upon so agreeing, shall incorporate such substitute provision in this Warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Company has caused this Warrant to be duly executed by its authorized officer as of
the date first indicated above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">BEAM THERAPEUTICS INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Agreed and accepted:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">[HOLDER]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF EXERCISE NOTICE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[To be executed by the Holder to purchase shares of Common Stock under the Warrant] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(1) The undersigned is the Holder of <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant to Purchase Common Stock No. ___ (the &#147;Warrant&#148;) issued by Beam Therapeutics Inc., a Delaware corporation (the &#147;Company&#148;). Capitalized terms used herein and not otherwise
defined herein have the respective meanings set forth in the Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(2) The undersigned hereby exercises its right to purchase ___________ Warrant
Shares pursuant to the Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(3) The Holder intends that payment of the Exercise Price shall be made as a &#147;Cashless Exercise&#148; under
Section&nbsp;10 of the Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(4) Pursuant to this Exercise Notice, the Company shall deliver to the Holder the applicable number of Warrant Shares
determined in accordance with the terms of the Warrant. The Warrant Shares shall be delivered to the following DWAC Account Number: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(5) By its delivery of this Exercise Notice, the undersigned represents and warrants to the Company that in giving effect to the exercise evidenced hereby the
Holder will not beneficially own in excess of the number of shares of Common Stock (as determined in accordance with Section&nbsp;13(d) of the Securities Exchange Act of 1934, as amended) permitted to be owned under Section&nbsp;11(a) of the Warrant
to which this notice relates. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name of Holder:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Signature must conform in all respects to name of Holder as specified on the face of the Warrant) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>4
<FILENAME>d930164dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g930164g0310130735948.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">March&nbsp;10, 2025</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">+1 617 526 6000 (t)</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">+1 617 526 5000 (f)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">wilmerhale.com</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beam Therapeutics Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">238 Main
Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cambridge, MA 02109 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="96%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Re:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><U>Beam Therapeutics Inc.</U></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This opinion is furnished to you in connection with (i)&nbsp;the Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT>
(File <FONT STYLE="white-space:nowrap">No.&nbsp;333-277427)</FONT> (the &#147;Registration Statement&#148;) filed by Beam Therapeutics Inc., a Delaware corporation (the &#147;Company&#148;), on February&nbsp;28, 2024 with the Securities and Exchange
Commission (the &#147;Commission&#148;) under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), for the registration of, among other things, shares of the Company&#146;s common stock, $0.01 par value per share (the
&#147;Common Stock&#148;), and warrants to purchase shares of Common Stock, in each case which may be issued from time to time on a delayed or continuous basis pursuant to Rule 415 under the Securities Act at an indeterminate aggregate initial
offering price, as set forth in the Registration Statement and the prospectus contained therein (the &#147;Base Prospectus&#148;) and any amendments or supplements thereto; (ii)&nbsp;the preliminary prospectus supplement, dated March&nbsp;9, 2025
(the &#147;Preliminary Prospectus Supplement&#148;); and (iii)&nbsp;the prospectus supplement, dated March 10, 2025 (the &#147;Final Prospectus Supplement&#148; and together with the Preliminary Prospectus Supplement, the &#147;Prospectuses&#148;),
relating to the issuance and sale pursuant to the Registration Statement of (a)&nbsp;up to 16,151,686 shares of Common Stock (the &#147;Shares&#148;), and <FONT STYLE="white-space:nowrap">(b)&nbsp;pre-funded</FONT> warrants (the <FONT
STYLE="white-space:nowrap">&#147;Pre-funded</FONT> Warrants&#148;) to purchase up to 1,404,988 shares of Common Stock. The Shares and the Pre-funded Warrants are collectively referred to herein as the &#147;Securities.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Securities are to be issued and sold by the Company pursuant to an underwriting agreement dated March&nbsp;10, 2025 (the
&#147;Underwriting Agreement&#148;), by and among the Company, J.P. Morgan Securities LLC, Jefferies LLC, Cantor Fitzgerald&nbsp;&amp; Co., Citigroup Global Markets Inc. and Wells Fargo Securities, LLC, as representatives of the several underwriters
named on Schedule 1 thereto, which is being filed with the Commission as Exhibit 1.1 to the Company&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> filed on the date hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are acting as counsel for the Company in connection with the issue and sale by the Company of the Securities. We have examined and relied
upon a signed copy of the Registration Statement and copies of the Base Prospectus and the Prospectuses, each as filed with the Commission. We have also examined and relied upon the Underwriting Agreement, the form of Pre-funded Warrant, minutes of
meetings of the stockholders and the Board of Directors of the Company, including committees thereof, as provided to us by the Company, the Certificate of Incorporation and <FONT STYLE="white-space:nowrap">By-Laws</FONT> of the Company, each as
restated and/or amended to date, and such other documents as we have deemed necessary for purposes of rendering the opinions hereinafter set forth. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In our examination of the foregoing documents, we have assumed the genuineness of all signatures, the authenticity of all documents submitted
to us as originals, the conformity to original documents of all documents submitted to us as copies, the authenticity of the originals of such latter documents, and the legal competence of all signatories to such documents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our opinions set forth below are qualified to the extent that they may be subject to or affected by (i) applicable bankruptcy, insolvency,
reorganization, receivership, moratorium, fraudulent transfer, fraudulent conveyance or similar laws relating to or affecting the rights or remedies of creditors generally, (ii) statutory or decisional law concerning recourse by creditors to
security in the absence of notice or hearing, (iii) duties and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="8%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="21" ALIGN="center">Wilmer Cutler Pickering Hale and Dorr <SMALL>LLP</SMALL>, 60 State Street, Boston, Massachusetts 02109</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Berlin</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Boston</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Brussels</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Denver</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Frankfurt</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">London</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Los&nbsp;Angeles</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">New&nbsp;York</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Palo&nbsp;Alto</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">San&nbsp;Francisco</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Washington</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beam Therapeutics Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March 10, 2025 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 2
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
standards imposed on creditors and parties to contracts, including, without limitation, requirements of good faith, reasonableness and fair dealing, and (iv)&nbsp;general equitable principles. We
express no opinion as to the availability of any equitable or specific remedy upon any breach of any of the agreements as to which we are opining herein, or any of the agreements, documents or obligations referred to therein, or to the successful
assertion of any equitable defenses, inasmuch as the availability of such remedies or the success of any equitable defense may be subject to the discretion of a court. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also express no opinion herein as to any provision of any agreement (i)&nbsp;which may be deemed to or construed to waive any right of the
Company, (ii)&nbsp;to the effect that rights and remedies are not exclusive, that every right or remedy is cumulative and may be exercised in addition to or with any other right or remedy and does not preclude recourse to one or more other rights or
remedies, (iii)&nbsp;relating to the effect of invalidity or unenforceability of any provision of the <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants on the validity or enforceability of any other provision thereof, (iv)&nbsp;which is in
violation of public policy, including, without limitation, any provision relating to indemnification and contribution with respect to securities law matters, (v)&nbsp;purporting to indemnify any person against his, her or its own negligence or
intentional misconduct, (vi)&nbsp;which provides that the terms of the <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants may not be waived or modified except in writing or (vii)&nbsp;relating to choice of law or consent to jurisdiction.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We express no opinion herein as to the laws of any state or jurisdiction other than the General Corporation Law of the State of Delaware
and the state laws of New York. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based upon and subject to the foregoing, we are of the opinion that: (i)&nbsp;the Shares have been duly
authorized for issuance and, when the Shares are issued and paid for in accordance with the terms and conditions of the Underwriting Agreement, such Shares will be validly issued, fully paid and nonassessable, (ii)&nbsp;the <FONT
STYLE="white-space:nowrap">Pre-funded</FONT> Warrants have been duly authorized by the Company and, when the <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants are executed by the Company and delivered and paid for in accordance with the
terms and conditions of the Underwriting Agreement, will constitute valid and legally binding obligations of the Company, and (iii)&nbsp;the shares of Common Stock issuable upon exercise of each <FONT STYLE="white-space:nowrap">Pre-funded</FONT>
Warrant have been duly authorized and reserved for issuance and, when issued, delivered and paid for upon exercise in accordance with the provisions of the <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants, will be validly issued, fully
paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Please note that we are opining only as to the matters expressly set
forth herein, and no opinion should be inferred as to any other matters. This opinion is based upon currently existing statutes, rules, regulations and judicial decisions, and we disclaim any obligation to advise you of any change in any of these
sources of law or subsequent legal or factual developments which might affect any matters or opinions set forth herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We hereby consent
to the filing of this opinion with the Commission, in accordance with the requirements of Item 601(b)(5) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), as an
exhibit to the Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> to be filed by the Company on the date hereof in connection with the issuance and sale of the Securities and to the use of our name therein and in the Registration
Statement and the Prospectuses under the caption &#147;Legal Matters.&#148; In giving such consent, we do not hereby admit that we are in the category of persons whose consent is required under Section&nbsp;7 of the Securities Act or the rules and
regulations of the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sincerely, </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Wilmer Cutler Pickering Hale and Dorr LLP</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>WILMER CUTLER PICKERING HALE AND DORR LLP</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>5
<FILENAME>d930164dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g930164g0310095318781.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Beam Therapeutics Announces Pricing of Underwritten Offering </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cambridge, Mass., March</B><B></B><B>&nbsp;10, 2025 </B>&#150; Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic
medicines through base editing, today announced the pricing of an underwritten offering of 16,151,686 shares of its common stock at an offering price of $28.48 per share, and, in lieu of common stock to certain investors, <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants to purchase 1,404,988 shares of common stock at an offering price of $28.47 per <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant, before deducting underwriter discounts and commissions
and estimated offering expenses. Each <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant will have an exercise price of $0.01 per share, will be exercisable immediately and will be exercisable until exercised in full. Gross proceeds from the
offering are expected to be approximately $500.0&nbsp;million. All of the securities in the offering are to be sold by Beam Therapeutics. The offering is expected to close on or about March&nbsp;11, 2025, subject to customary closing conditions.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beam Therapeutics intends to use the net proceeds from the offering for continued advancement of its platform technology, for continued research,
development and <FONT STYLE="white-space:nowrap">pre-commercialization</FONT> activities for its current portfolio of base editing programs and for other potential programs, including biologics license application submission and <FONT
STYLE="white-space:nowrap">pre-commercial</FONT> activities for <FONT STYLE="white-space:nowrap">BEAM-101,</FONT> for clinical trials, including advancement of a potential pivotal trial for <FONT STYLE="white-space:nowrap">BEAM-302</FONT> for
treatment of <FONT STYLE="white-space:nowrap">alpha-1</FONT> antitrypsin deficiency and of a potential Phase 1/2 clinical trial of the ESCAPE conditioning platform in patients with sickle cell disease, and for general corporate purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">J.P. Morgan, Jefferies, Cantor, Citigroup and Wells Fargo Securities are acting as joint book-running managers for the offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An automatically effective shelf registration statement relating to the securities offered in the offering described above was filed with the Securities and
Exchange Commission (SEC) on February&nbsp;28, 2024. The offering is being made only by means of a prospectus supplement and accompanying prospectus that form part of the registration statement. A preliminary prospectus relating to and describing
the terms of the offering has been filed with the SEC and is available at www.sec.gov. A final prospectus supplement relating to the offering will be filed with the SEC. When available, copies of the final prospectus supplement and the accompanying
prospectus relating to this offering may be obtained by contacting J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 or by email at
<FONT STYLE="white-space:nowrap">prospectus-eq_fi@jpmchase.com</FONT> and postsalemanualrequests@broadridge.com; Jefferies LLC, Attn: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, New York 10022, by telephone at (877) <FONT
STYLE="white-space:nowrap">821-7388</FONT> or by email at Prospectus_Department@Jefferies.com; Cantor Fitzgerald&nbsp;&amp; Co., Attention: Capital Markets, 110 East 59th Street, 6th Floor, New York, NY 10022, or by
<FONT STYLE="white-space:nowrap">e-mail</FONT> at prospectus@cantor.com; Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by telephone at <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-800-831-9146;</FONT></FONT></FONT> or Wells Fargo Securities, 90 South 7th Street, 5th Floor, Minneapolis, MN 55402, at
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">800-645-3751</FONT></FONT> (option #5) or email a request to WFScustomerservice@wellsfargo.com. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall
there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About&nbsp;Beam Therapeutics </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beam Therapeutics (Nasdaq:
BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform with integrated gene editing, delivery and internal
manufacturing capabilities. Beam&#146;s suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences,
without making double-stranded breaks in the DNA. This has the potential to enable a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven
organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cautionary Note Regarding Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical
facts, may constitute &#147;forward-looking statements&#148; within the meaning of The Private Securities Litigation Reform Act of 1995. The words &#147;anticipate,&#148; &#147;expect,&#148; &#147;suggest,&#148; &#147;plan,&#148; &#147;vision,&#148;
&#147;strategy,&#148; &#147;possibility,&#148; &#147;promise,&#148; &#147;believe,&#148; &#147;intend,&#148; &#147;project,&#148; &#147;estimates,&#148; &#147;targets,&#148; &#147;projections,&#148; &#147;potential,&#148; &#147;should,&#148;
&#147;could,&#148; &#147;would,&#148; &#147;may,&#148; &#147;might,&#148; &#147;will,&#148; the negative thereof and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these
identifying words. Investors are cautioned not to place undue reliance on these forward-looking statements, including, but not limited to, statements relating to the size, structure and completion of the offering; the anticipated use of proceeds of
the offering; the therapeutic applications and potential of our technology; and our ability to develop life-long, curative, precision genetic medicines for patients through base editing. Each forward-looking statement is subject to important risks
and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement, including, without limitation, risks and uncertainties related to: market conditions and the completion of the offering on the
anticipated terms or at all; our ability to develop, obtain regulatory approval for, and commercialize our product candidates, which may take longer or cost more than planned; our ability to raise additional funding, which may not be available; our
ability to obtain, maintain and enforce patent and other intellectual property protection for our product candidates; the uncertainty that our product candidates will receive regulatory approval necessary to initiate human clinical trials; that
preclinical testing of our product candidates and preliminary or interim data from preclinical studies and clinical trials may not be predictive of the results or success of ongoing or later clinical trials; that initiation and enrollment of, and
anticipated timing to advance, our clinical trials may take longer than expected; that our product candidates or the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
delivery modalities we rely on to administer them may cause serious adverse events; that our product candidates may experience manufacturing or supply interruptions or failures; risks related to
competitive products; and the other risks and uncertainties identified under the headings &#147;Risk Factors Summary&#148; and &#147;Risk Factors&#148; in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended
December&nbsp;31, 2024, and in any subsequent filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release. Factors or events that could cause our actual results to differ may
emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required
by applicable law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">### </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contacts:
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investors: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holly Manning </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beam Therapeutics </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">hmanning@beamtx.com </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dan Budwick </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1AB </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">dan@1abmedia.com </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>beam-20250310.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 3/11/2025 12:59:54 AM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2024"
  xmlns:beam="http://beamtx.com/20250310"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://beamtx.com/20250310"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2024/naics-2024.xsd" namespace="http://xbrl.sec.gov/naics/2024" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="beam-20250310_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="beam-20250310_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://beamtx.com//20250310/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>beam-20250310_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 3/11/2025 12:59:54 AM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>beam-20250310_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 3/11/2025 12:59:54 AM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://beamtx.com//20250310/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="beam-20250310.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://beamtx.com//20250310/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g930164g0310095318781.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g930164g0310095318781.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !6 *4# 2(  A$! Q$!_\0
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MBSH+675;.*,\&=<;\?@N?Y4V+X<S6.NZ3>VETDB6SK)=/,QWRONR2!R.GO0
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M+P@[MG Q[$T3:7#<27+3*K&7;M;;\R8&.#2R63W"VZSRY6+YF\L%=S=CQTH
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AHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g930164g0310130735948.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g930164g0310130735948.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  4 (H# 2(  A$! Q$!_\0
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IL$,LAD=0\1^8]3S'Q5RW\(Z)!;10FR27RT">9+R[8&,L>Y/>BB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm44851419124288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Mar. 10, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001745999<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 10,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Beam Therapeutics Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39208<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">81-5238376<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">238 Main Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02142<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">857<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">327-8775<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BEAM<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>13
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
M" !9B&I:A!YG8T4$  "+$   &    'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;(V8;W/B-A#&OXK&[?15$O\! J3 #"%)F[E+C@NT-]-.7PA[P9K8EBO)(?GV
M7=G$SO7,FC?!LJW'/ZU6STJ9[*5ZUC& 8:]IDNFI$QN37[FN#F-(N;Z0.63X
M9"M5R@TVU<[5N0(>E9W2Q T\[])-N<B<V:2\MU2SB2Q,(C)8*J:+-.7J[1H2
MN9\ZOO-^XTGL8F-ON+-)SG>P O-'OE38<FN52*20:2$SIF [=>;^U770MQW*
M-_X4L-<?KID=RD;*9]NXCZ:.9XD@@=!8"8X_+[" )+%*R/'O0=2IOVD[?KQ^
M5[\K!X^#V7 -"YE\$Y&)I\[(81%L>9&8)[G_'0X#&EB]4":Z_,OVU;M]SV%A
MH8U,#YV1(!59]<M?#X$XI4-PZ!"4W-6'2LH;;OALHN2>*?LVJMF+<JAE;X03
MF9V5E5'X5& _,[N188%!-HQG$;O-C#!O[#ZK9ANC-G$-?L2^ZH8'P>M*,#@B
M^,#5!?.],Q9XP>#[[BZRU8!!#1B4>KTC>@OY HK]/=]HHW *_VDCJA3Z[0HV
MKZ]TSD.8.IBX&M0+.+-??O(OO5\)OE[-UZ/49W.,7E1&\"[ANS8ZNO^6)QH(
MCG[-T2=U#G.W0!+%$YS#"%[9)WAK(Z*5/,_SA_W!>#PFL 8UUH 4J_-K_99#
M&PO=?73^B8"XK"$N3X-8@A+2YGG$<+6T\M!*=79WI?>P1AN>,FU/L!,VP9'Q
MD:>M8+3.-?"4K6-0/(?"B%!C!H07!."H!AR= HAJ4N52E:[ 5@:CQQ:RP&3#
MG)-1*S$M?'-+T(UKNO$I='<B ?98I!M0;2"T!J;[>6\<>"."Q_<:/_5.(5KS
M5W8?8<Z)K0BKH!WGZY <^>>#H#?J#2\IP@^.[Y]".(\B=$-]]G[!/N-[[$O6
M.I4=DDC''G +@(FAL!)1F(WO^Z1M_X"YL"VIV%KNV\L2+;?@Z4:):$=YK=^8
MOD^[]O_AJ@6!=$LE7T06M@>1UGR84VA-'?!/*@0UVE)J@P7A+Y$?7:@=BE[@
M]P.*K2D&/FWGY1S.<?=X'*6C'@R&%$A3$'S:QS_+$&.RC&5&^4:'2"\8GH^&
M0ZH,^$T=\&D#_Z:$,9!A8-*TR Z>H5NI:*&N#87?.+]/._1*)B(41F0[7-P&
M2R=/6GEHE4Z>QNM]VJB7"LKP *ZO:D^!6R_<''[9;H_,'ZW7118TIA_0#OT#
MV;W6!9)U 7;(=@(VGA_0!KV"L%!V\?G!AJV%25H77X>('6%9_&7X?,9RKM@+
M3PI@/WL7GL]R'*B.N2*!/^SZ:;M>*Q[9Q%N]I1O9FG8= M>W\P>*I+'Z@+;E
M.G2WKV',LQT<W:%U"#W.5S?SKQ13X_'!21Y_FX+:V2C]A@HFMBF8\ZQUR]\A
M>#33W ]'2WM,QPTP?E&S!+8HY%T,T:]5=?*M&D;FY6ES(PV>7<O+&#BN OL"
M/M]*:=X;]@!;__]A]A]02P,$%     @ 68AJ6I^@&_"Q @  X@P   T   !X
M;"]S='EL97,N>&ULW5=M:]LP$/XK0C]@;F)JXI$8MD!AL(U"\V%?E5AV!'KQ
M9+ES^NNGLVPG:75EW8>QS:')W3VZNT=W)YFN6W>2_.'(N2.]DKK=T*-SS?LD
M:0]'KEC[SC1<>Z0R5C'G55LG;6,Y*UMP4C)9WMQDB6)"TV*M.W6G7$L.IM-N
M0V]H4JPKH\^6E :#7\H4)X],;NB62;&W8EC+E)"G8%Z"X6"DL<1Y*GQ#%V!I
MGP*\"!JP'.,HH8T%8Q(RA._]N/P9,&FM5X64,\$E#89BW3#GN-5W7AD6#\87
M$!GEW:GQ#&O+3HOE+3T[##\^R=[8DMLYS8).IF(M>05TK*B/\.M,DP#HG%%>
M* 6KC68#A\EC%'S8 Y?R 5KXK;J*W5<D].)3"6T@L-5)](1&,80)"L2_C!9B
M7X2]_:VPI!&/QGWL_&[TH'_OC./WEE>B'_2^FO-CT1=X=-8T\O1!BEHK'O;^
MRPF+-9O\R-%8\>2SP:0<O(%;2AZY=>)P:?EA6;/CO9NFJ:]PSLM_D/.?K7/-
M-;=,7I+VH_\W5_DMC)/Q]%P<T:L#.EL)7(0;^A7N5WGF0/:=D$[H43N*LN3Z
MQ3GUX1W;^PO\*KY?7_**==+M9G!#S_(77HI.Y?.J>ZC+N.HL?X;[:)'-M[#/
M)73)>UYN1]76^T$D7O!9QP<<GB-WPQ-',)^ Q1' L#P8 \PG>&%Y_J?]K-#]
M! SCMHHB*]1GA?H$KQBR'3Y8GKA/[I_X3O,\3;,,J^AV&V6PQ>J69? 7CX9Q
M P\L#V1Z6ZWQ;N,3\OH<8#U];4*PG>*3B.T4KS4@\;J!1Y['NXWE 0^L"]CL
M0/YX'IBIN$^:0E<Q;M@)QI$\QQ"8Q?B,9AE2G0P^\?Y@IR1-\SR. !9GD*88
M J<11S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$%     @ 68AJ6I>*NQS
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M"Q4&L&]R( DNR94;4EWI>::W=Y-[2:AU[D&P]_ :C1W-CQ^W_ %02P,$%
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MO-9.&G_FB^$_7G\!4$L! A0#%     @ 68AJ6@=!36*!    L0   !
M         ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " !9B&I:
MO9>%GN\    K @  $0              @ &O    9&]C4')O<',O8V]R92YX
M;6Q02P$"% ,4    " !9B&I:F5R<(Q &  "<)P  $P              @ '-
M 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( %F(:EJ$'F=C100
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M2P$"% ,4    " !9B&I:)!Z;HJT   #X 0  &@              @ &Z$0
M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " !9B&I:99!Y
MDAD!  #/ P  $P              @ &?$@  6T-O;G1E;G1?5'EP97-=+GAM
7;%!+!08     "0 ) #X"  #I$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d930164d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com//20250310/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>beam-20250310.xsd</File>
    <File>beam-20250310_lab.xml</File>
    <File>beam-20250310_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" original="d930164d8k.htm">d930164d8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>19
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d930164d8k.htm": {
   "nsprefix": "beam",
   "nsuri": "http://beamtx.com/20250310",
   "dts": {
    "schema": {
     "local": [
      "beam-20250310.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/naics/2024/naics-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "beam-20250310_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "beam-20250310_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "d930164d8k.htm"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 22
   },
   "report": {
    "R1": {
     "role": "http://beamtx.com//20250310/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2025-03-10_to_2025-03-10",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d930164d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2025-03-10_to_2025-03-10",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d930164d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://beamtx.com//20250310/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://beamtx.com//20250310/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://beamtx.com//20250310/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://beamtx.com//20250310/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://beamtx.com//20250310/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://beamtx.com//20250310/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://beamtx.com//20250310/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://beamtx.com//20250310/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://beamtx.com//20250310/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://beamtx.com//20250310/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://beamtx.com//20250310/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://beamtx.com//20250310/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://beamtx.com//20250310/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://beamtx.com//20250310/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://beamtx.com//20250310/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://beamtx.com//20250310/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://beamtx.com//20250310/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://beamtx.com//20250310/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://beamtx.com//20250310/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://beamtx.com//20250310/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://beamtx.com//20250310/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://beamtx.com//20250310/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>20
<FILENAME>0001193125-25-051072-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-25-051072-xbrl.zip
M4$L#!!0    ( %F(:EH,(Q@Q/ ,  #L+   1    8F5A;2TR,#(U,#,Q,"YX
M<V2]5M]OVS80?B_0_^&FIPVH1,N.!UB(4Z1+ P1(T\%-A[T5M'1VB%*D1E*)
M_=_W2$FV8B>>FPS+2RC>?7??_:1/WZ]*"?=HK-!J&J7)( )4N2Z$6DZCVL;<
MYD)$[\_>OCG])8[AXO+J!F*X<ZZR&6,/#P])L1#*:ED[LF"37)<,XKC3_^/V
M*_S56,]@AA*Y12BY=6C@0RUDD0T'PY,T'0Z3M \SR+T]*+C##$8L31DICB$=
M9N-)-CZ!\T_P,9A1<"M*[&-UM39B>>?@U_PW"*@+K11*B6NX%(JK7' )7SK*
M[^!*Y0F<2PDS#[/$TZ*YQR)IK:YLD=G\#DO^]@T )4S93)')NIQ&/A-M(E9S
M(Q-MEJQPAKEUA8R48M)"(_*H!_UWW!Z&*N$E=@-<<#L/H$[B\W/20\R1;]WX
M#[<*Q?$)&8S204^U0+'1#&0LYLE2WS,2[)KU<O$T_>%@,&+4"XXRC#V(%.K[
M 807SZDM^D[V( ^C $@GDPD+TAU*A7L<06M]S!IAT.;.&3&O'5YJ4U[@@M>2
M4+7ZI^92+ 0608MZM$3E'ND\UG#<+-'=\!)MQ7,\,LG41$]%1"13]O>GZR^A
MOZ(S#P (+2?*2AL'3>==ZSQ,Q(%$^J^XRW_LK^)T&(_2A(Q%H/;X'B@>L%<3
MZ<KZ(B*;GCB:B'VN=_TA]H?GO#_=\2_.P.X0^_@G/O[T]Z/BWUL"_P$3K6Y>
M2Z:WR5Y>$\5%WBRJYGA\7;;(5_5FMP]\'L8''>\ND-9K\,F5TBXXZC/A5274
M0K=7=.F;..LZ>88+"(LKXR8W6N+A]<8JHRLT3M!BWPY#8^#.X&(:^6T3=WOF
MF^3SA/9,I[+GX/%X>3$C",KK+;T.ZX3SX&LO!B^G%Y++C6G?#M/(4MYE;SS_
MYW K@S\;+D$L[?50MN>C_K.G]=/!>S^WI '^\'5V]=3+L'D:F.,KK72Y;NA=
MZ+SV[T[W_UP5'Q616E]13YDR$(I T!LR(_5O1ZEOZ'4$"Z3?:B(T;CKP?_13
MKK/0/W)50&,.>O9.V:Z17?NUQ>*S.@OGG,N\EIMTM^!6XQ!PMU#'([?,GL>U
MMUVIN@%FNQ/<WO0GO;EJ-@U]_@!02P,$%     @ 68AJ6@=D I]<!@  OT,
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M22&S=61[1]<R660@C'OMBO1&&&;6?3&1*LMS"$A>SO9,P:03V*"ABV:=?#_
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M3Z9G(OQ&J*H3_89]!_A7SP#?,@X/BVP,ZCR:N[JJH]OUZCA=>L9I1%?]%,O
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MN/8Q4&2K^21@HK/[[P(3QYXGA5+FSRF@:><1*KM=.0)US3YQ\ PN$RE$\G)
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M'[M W>?<<JU)#NEM#WRR')?KF>%@:1P5B&83=B6K]U51WQ?+Z[GW7]#TQ/#
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M(I/C:G2)L:X=J=+RRZ9;9$GB0EM:=7#GOIE0DHG"3X&+/6YB;Q,R"5,2/IP
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MZ/:F2EZ\SZ/B7KSMP^OM0W?DB\'"C\S*==R PT8_\J9P#;Y?</3_4$L#!!0
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MN*1H2^5A>$)6.1T3F8*:_23@JU6=%0WLF.PL&<O9E)WRB-2P#;AK#]R9"-)
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M3WP@G0D5O[-IT]QUTR'8,(6HE&O-:KC/G/F) K2!WS5A!IF0T;P93]3U$,0
M#*&B,AN3K+;%KI4-:&^C&9!$VZIJVCNN#AHTN189:U(G5H5X?'!Z>'!O"VN
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MI[^#T(3$0AH$>POCR94<W4L=@] XW^)?/ND@J_V6V$>8X1/<X*94CPMVP?U
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MA>_Q,S1@IT\%N(U'@G ;@'#=@EY:A7KIF; !-NKVYCY.D/H@ =G\6R%M8?2
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MWZ''_YH:4CSG#A2-HL0C?2HX\J&M*BBJ@F# :I/OY51K5 #C0TH5.!S>*CI
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M<0ATL4"=(V6.^.P.'6_";+P! RR[3OB6 [V_3PM*L4N?,E%6K"8JEIZB9 "
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M#:<.JX&^"PHD((H.S@JZL($3-MO8:WBRTD=&(S'ALZ2?"[[K#=86+#G;%MI
M&^^W7)(;FM8%8V6:X;P$,90A$C6<6'.MK).^\C3#H6C9=R<1F_F$T^.%EW5R
M&*:,&?#DCJYCBB".7,FE9N.WN()$$20E?2YSVC7NMBZLM0KW./WLNI6NMB X
M7EA91. "*7=)F+NRK=>Y*;^B$)]/VF6,B:Z6S K;,(G(>!1^PC-8VR:11,I"
M>4X?"FW5310/;4$5MC+_:5&#/XN ,206<"T@G8;OHEUVK]<^]AX!1/6>H4)W
MD*0I:$F,T)#%632+/$.Y0[U^7G1D1I53%\#(\B/-.Q'M2,9?6-.DJD&.P]J3
M]6U76[MJ%B+8]Z/C@].MM0,.?=&9((:^]YAA/*EG@ STW7^OP9Z8=VHXWX9%
MTEP(X4J6)19H>02O3ZFPP<]*Y0DS._8\)=REHC66/>9!X?8PG=BT:U=P(RAG
M&K[B4U5Z>JL*W;S-S6C7SA)THN@M0>&I%_==7&GKBBCOBHG88+>XHSB^$P5Q
M5F<7H)Q:KG7Y#.+$MHWZ;R413B>>A93=K(-C.7>OYLF>L4;;:C=Z4S5GE+RB
M>XVP?J[O%_V%E>P^%]6-W2T!9N23+A>$67S4[7*9*T&8L908B_CK@F;!M%Y=
M0S=\7:>P<)%=1.(S+AM)S7TV_0!,ZWLTC$=X6,[H:1(IX?.G)%"HHK(Z.ZVS
MU5F"$3J6H@E%3D)LC[FE*#\8AHG"$% Y<W1 ''W<FK-R9(G\#1/T#E:KB?@%
M!W(/:@"<(ZTP;7)IAL:^,TA^&.WX3,DI4TZ<:\@]<D2::O" Q,><?/*0N5Y-
M$*.?8E1M%WML QY(O5V6+A-"1YS9LKBGAV1.<-UR(YG%2'KOR^WX=N_X:Q#H
M:H- F.G=]Z9+/OZB&P;X??+%QYT8;_#FNZP&&)S[IUV$H)7VNPD'WW_E-V-R
M+1=C"#%!AXD3@(>W?V4.+NW57D<4_/KX*W3;X=MRI6I2Z&;E/K@)X6QWK\+!
MI\:NQMM/!LV-:_+3 O36V_>;GF_230&-1^SO;?9PX'W (:PB=B\CA+*B[L-^
M 0-G@75Z'X[@4X6N+TG?.26Y$Q"2@;JYK/W<AL2],VNIAIXD/_[Q5&MH$#B:
M]"@@>(C<HSE !+BK3%>0+B7MM:3G2Z(<'"S.78\D^BPK"D*(&6Q"Z5WK(%;"
M-4E%:_KS>>+DSMB:2I8*&UIZ;>[RH=(&3>$_])6\/I<(%\52FBU#J0(68=6Y
MX.[GBSFIK.R#]"D:>@+8CN)C!=-H*M7@GX&O?VH.U(NL+@,*+.XBT,NHTJ7N
MF\QY*FNL3\!J)^6"/ZL6,W=Q]$_&>&3#(ES!*4Q!2%]2AEQ;)+0-UM3/N:#(
MT-@T/=:MX^.#+$8PHK1;C&IY^%TDOFE9;%K?L ,!UDSD:; _,"30K<BR<I$O
MSG/M&3C!5JJE8S-M'2IH#HHV8X54$_2E0Q1$(7UZB0--,#0I[*,H<"0+WU**
M$IC3X>YPG"NHZR@"(5F I^9+TW10K )D->!B(V_,77;+NPU'I9)8\GME9S.T
M5N:%3Z=2+\B?,]P9PLJ<E-EBTP@ST^\Y:,+\' O/B)'N,SAAM@'\,Q"66IC%
M^'"]1#UI!.K!0\3>]KI.1E!X7C:4:1H6T*+5#M.0?=BA4@Y\S)P[\DDI&&BV
MA6_]SOH2?X/_RR'8E6I&^R&U-E+WKRT?YB>>(N^&^50J[*7(:)/5M>0"_(.9
M4+^R+/I*SBPY84ZLS;?07FK=#3XZ=< 9YJ3J6H\AZMCKH$'8L$GD<K0:;M2:
M\6]OE<NZ0[%J&4NHH!D^DG_(ZVG1D!*D'QD9S\V5$(2&STHY@8B=%1 3+L1Z
MDM$ME8NNK7BT+74;\/'SL(>@OS;)J>:!T$ OLI6_TSU=,VL,67LF(;N ,Y]+
MS2]R6 3A^ARF":[CE&_A?U-W.*;R=XS>JJ0=YS<%W.F]EN'%L>G+71ORQP=E
MI=,%<91Z.>>))N0:47L"<A^:O&VENL%6#>P:"+X@:\X"<?3P:+Z7,$JD5;UJ
M?\"C__ONF[O)+T0#8R7H]>MG:?+?.:%$]<=G< C@(2^+]N]3O&AG/)5_9,O5
MDR\XXG3O:\3I:B-.SZJ[*59R%%BPNTI^7E03N/WXBFF25^7T+EV,?X+>;9*7
M\*XJ(%0F63/5RPZ_WE%R<F+@=K>]3AS</*KR0MM&>)?6*[GD1=?E%'"JA/V"
M+@;\%"E:_2H_[\U"Z/SMD["!AF-7I_.LV9O:WXI,_+0NT5()WV ':-X",WMF
M9J:CPY>(0KP@EICP85GD4?"DYV9%!9+;Y?UUZ*7HK0,_@)FPW,W2\/;.=TK-
M0&8%%>\T347<]DN7;[>HHX$QOU"WQ^TI7H]D1>*G.!8ID1/*&8OYC[["3W65
MS4#RI"VGPA^TI1*E?%Z".%;L2/\SJ\^1F^<9,L.X)&Y16UYKBQ P6Z;6(=R$
MU+7875.X@2\_<@IR22Z)#@4^:2U:%@3]#1(C8U,^(C'+5CDXX%-X,YVYSHC'
M(U\LA0_"9<;O_Y+7I^PSYUR7AO!<=!D&'XS"D$]J\!\VPAE\+TWN'=T[ABG_
M?!BS.[HWF)Z?"&@_LTU=E#D4V]GK5J!17\!F25L'ZH'%P63T]1U')*/>ZBEU
M*6=Q@_.#E[TI'@G:&C6IL-U*=#:(:9!)>*H[BQ1"S/Q#?S,ELK5( BD$]_M#
M!^6;_GL-[J*&2:1)!_P+C>(%!@-(!6+P^R_7E5"[/Q-)(S:<]( !C$4H\,W&
M/L (#3VL@P]&!3A&E*1<+R?>!Y2=D\VQ\J/FS,]>HL621R87^/"R(KI_;) !
M]@8X$WC=)@?'1__I7,&V0NR>?R,2/6G'C:[,%$ODR8(18B%2A0=5T_O#'/WT
M")AW(/:V1I QU@<;LQ)@F1>K0I/M&D*)2'!?=K<MCX$C]#PC3;!X8_> HS3*
M&F&J+>VAQ."XL8*Q2K7%4D<A*F+CFY0LC/L%EV0E)XE6JAW\LZ>,WEHRPJY^
M>TO%,V;M)ALI[&@O\KP,KBW\?<=VG-%)/0$S="'1$%41MCMJ**-E)24[O$(8
M-T;N5Q, 6<-\%\G](W90%<X*#M=P@>[!JX!^R]O8?XJ7QW+#5[D:!/HL^<Q6
M2NB;<>$+X\+_00,D*"5Q^0]5':Q6TI.RS%M/_.] P/'RXAMJ .!MGS/)AW$@
M@>>6N*E)F.G60RA_75U'#=J<ELIRA@(%807P>.1+@$TSNDD_=;>SL\;TQCIK
MJ.+T'>WD+S$.<%)'I@W$+RP?K-/VI1B]&4&P/7#=R%YSKFP@6+T'1@\I6X);
M3(],1TN)X_)KULRR?YLHWNVNR2*@T2#>!SX3S]>]<#5B2O-DDV>U446BOZ6H
MWEPZO>#A]K*[U*(<O0&XV-BU[\0U7?S7)1%24WC,>3-'FQ/E0#OP3<?U(X<F
M7HT1;&^N=[1M)71MX3YK-9@;!7EFGE##O]#$P8,W2G QGIH68U1)@ZUQH_$^
M^LP:Y 4^,TW^O:Z$[(MCVK%\WF4C^#(?%O7HA 9**Z\M?)]&X_>I <>+*ZL(
M!!O@_R)#8?>_AL*N53$N \6(C, H7AP>[]/&X;E) T/<:RWRYY0*V+/Y!NUK
ML(B7H-Y><>Q#^*)MI(FQ;E!G1#B-=[(%?0:I+]O,KG.72N.H67\CR/](0Y+4
MBS--ZJM30%K'.+$ID3AC*RI4(^_S? 6ZS26FT9RKYF0'N/)K9CB FX1=,!?;
MH^S2NI3'S8P_.N7X4<-)F*9:L(/,B^^*NV#?46APGQDQ1R_8Z?&03M/9\=WK
MO?7.EQU-(->4D ^J$2P*KXFK1;_H!5Q=2. L+^_8., ^#M?UL#P^--QGSS!G
M!0+?YSZSQC83H+WHT*^,1^BN$M9+KJV #NTSXSU[Y<,.R$J26MGDHAAE@G!F
MA>6(=Y4#JT7&8 .41?UBP$,0$@^$#^\_60%J \_=B+<X1Y6FQ?&>D\0T-KA,
M^Q0MK^<^"!I3-+5!FDXS):WC46!V=91FA&P=UV);TZSM9;BN"4^-L<(Z1^1'
MKB&<\&V'04[%X8&3@353_[!$R2>";NEFPY>'F3*O[G@4@W[ ;;"SY0ZW>!2I
M<[W$#BQ_>UVM3\_,,LE:NG4Z5,<T7JW%J0<31^-K;1=OB<]$#]2.!M6KZ+*Q
MP0D:XZ0L\P_)"9G"7#V,6-G9<)$M4M$1ITO0@ I_R1GB3L-W4\M/J8WFC(B2
M0H 8?G!H=]V(M/>.9;\19GLD ND1[6%D49I7!TP49%DP"^G *SN<L1PC;;HI
M\8*8]37Z8P8UL$T"+/D,3(O)@!*-Z+V],O-FU5G';3NI1.W%1Y63>NC'H>**
M.9GKDE(+KLF+=OOP!X0(#MQ9Q,,U^/9!$_$)]NAR$5VTJMA(Z% M$>^0X+%9
MU8+RS%L/ %64K%F+F4:*$^(T6_D^Z.8!86(N=84RBKLQX7)8.T]V[_$W#)!;
M&VO(/_XS$+BI$3BQUPT.GZX%J3(U5;JLA_<J\(\R1BMQ&.I[E>M8!8'3%R:/
M8H:A#= 9C2J%R" F>Q5N;C_MUV,//K+VH!;'T.&R-B!'%Y+?P-@^E>Y_= >@
M-U&Y7SI/+&# ]>BR7E!(@AA:W,7=IVP; B&I*QHK :1=\IHNZI!20S/\Z'V$
M++UL(_BA-AY;H<46G%?2')QA]G U0\T/7VX(Y,'7$,@-4BP;H]:73#Q)**-2
MK9+?L&C+-3WN%OUS.N R1"XND>@J&%(QPK<1&:3;Z"!V,*<,4S2[L:B2]O1T
MRK,06%_N5FT[M"G[$OGR"SWO/,8QG"T<"_$,^T7BC1'+*?E".VWI3^"85DI;
ML#L[ :>.L9P=2G-.IN+@4#W5M31#U$116J+>2C&5OULEGHK)(' )0!:PDW29
MX&[?7)B$61DW.H612:PEX-VM(Y^[<)_KXNG$!/7WD<HX F/7N20Q:LQJZIUF
M6JKR_<.%<IE_MB$L]E37)BO0&8-V.]*FQ(P9$/?0-^;-;87:,$3$G]+8!(9'
M^AEL]S3,4/=Z'#VCO(Y3KJXHV%?^4M5MNUEU.N1T_-93/77FV AC1BTUA[Z"
M.!606^1MQ4"/KVTUF/D'ZQ0/\J(QYN4PACOXV$=(!MX506O@ZZ_U['1I'+A^
M%>I[A RUV#3'E!=1OI]H(17S)_=1GPD^%:!&':!7MEJ,TJY4?LD>G]"$XR]
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M[)32^09Y 0.8<^:#+K,"YHWD*-TK,)BU0Q6R6#0KQ(VKB]?__.$3*2W^L+=
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ME;[:-\G=1H2ORJK+X-S 8J_+:^G2XT:L5^Y2\W*>FW[H)#IP=%#KJ(("V2E
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MOF.,=VVL;*+2O9H,+@A"3 ..[?1.C_S^U1?KZRD=SBNZ1%V$ULQRQIG##;P
MUP(C<3)7/T_WBROEJ.8MD%_0/_@78$->70_*FSS'VXT:I;(D,8<K[0PJ?UD-
MD1Q>- TELH<SUMLQ-MWT2W[YXD^XEO=#W/B/L.UTA3'23VTP&0%YJ.5@P&+
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M-?-G3./1->:CYP$6WEG3)/ @SFOARD#"1+)1,C$D*7"BV-T+OM(BTQB\PKU
MF)RW?+VAG3=JRLFP&%>I&$>8H%9TF1-82N[>#FUFTI$P2,*0]@B:@1YK1EX/
MAT>&N41%\#7\*TSG#/)*T"INT(LV&.D0A-G-E>"8]'/S<]=4RT[77O99@ M7
MV.4/80WR#1 :,*0H-2%Y0!%Q7;QDRMJ1X-]I 7GI4I\1<WX'/:ME&=T%3? (
MCH'*,%(=*!DG?JQ>7WR!>1C;AM$HOV#&"4(C+_-!HU4;7L8A6$-"\ @P[5?-
MICJF"0);W8=IS9?I3P)CIED$KZ'O.:#=%&,_"$5JBCIMN@H0A(?:-AO!$'P
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M.O?EKU48?A[:<N[(;JD)HZ--<&*NOK@XNM8%/$\%5QP=="ESGCW0-#2N/&
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MYD<U"C6346*TZANY^1\QNA1#X;?(Z,.=LG0>5 Q$DB2,<>3VM\=Y%./,=N<
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M:K#8H\(WL@!K!4$1E$K$4 $6$CL2O!H8(8LCM U32:W75@1\X@'(T(<<&Y(
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M!UT[AB@VB$V^A=13HH,!M7![)7^X?^/+*:6N3.EFH"9!G9]V!6F-I\UL.&C
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MR&*TV]JR8<M);#^$NH+S4N2HJNGL)6BVV-007R/"(,4=&:8]:'[.6?NC_'S
M;C=VA/Q<1ROKWER5%?/8@ZIZ@UT.9[J[JRM+_]=@T6_]I;\[.O*F)N4@F%:
MS U>C_HH,-#1JV?S<X1AEWEPO K$>UA.AD)]6"]X6?A?4\;+QT!B5/7/BN=D
MN<'#K'RX2;.I"0RZ80;JH'[[N6X#HQR.>'.[  K#PL84G/&4^"=,+$>Q&)5#
M6)\KRJ%."?.T]7*(#@Q'=BF'I@&ENPB^-0E]G(<P4>%%J5E5AK@K MU>_JV'
MW*(DPE,;DF^#1]TSI:RVWC3JKW&+>7VB<XB8+XP^;M^XG0X;X[HA1N>_1FWD
MD646V]6F'"4:+IE6_WNT?@*[A2[*GY*@\Y&),==(9MG0<5!]-R;EU2+;RN7
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M<R2OZ^7:EYZ"PV+42V\H);0DG*9^NK!1(U]"Y@V4F0.1LDORB<1Z5F(T(H#
MV)5R.9[=>.:*%MM> GF(S!Y',3PTHM"BXHA*QC,*IS/(D:]?RPZB+NM9:TR%
MTK(L<1K*XH%R/$O>2^$T5V#H\BC:C5J?X-\?N4$/?PCCV,1OQUU0S7RS@Y[K
MO.V2%7: FI\NL?WNF]-D>[]S\/=__+@!F+6G ,Q7(<P.T" [P$OI%[[VPJ Q
MHFS(D>Z'QU]X;R>#&V%+9<^8L&D^I5(*NM TG2<<,&?_,831HP(,BBW7]+&9
MR)J7P%:!M )(*RM+3Y$!6OF_GH)9!3=J=W__Y*BS U?[?_]IY4_T\Q$8'OJS
M[-\&;A_8U7" Z-<R*O[-$NSY?N?HI/M2_S%UH>-=P5UEX3P]?BW_V-47/__I
M3R#%I[O^#S_+5'BR\M?P2R_6]%OP/\?F\3IN(]D%%=6\Y"3,'<?=/"*P4G!)
M#_!4O-[N=MX+>0.(5.>H^P',JA/^#?@!RWZ4X0C-J\R;WG71KH'C]"R<M_F]
M?_N:78-'G/_K[9N7=G#QGU4RVS]QZS.^BK\ZHPR'_]5G(@'N)W]>H?^[*R^A
M/S??9/&^;N4.LJO\Y8\X\%.$$KRT9Q;^@QKJ-=]D]Z,*_]WUWNIWH_<Z:"<J
M:R*W=VR5RYFZ+GCR-Y'N8 2_L=OYCR^;S_I:L^Z&WS_I[B?=_0,.O%UW_Y!>
MU/J3%W6/R_G7[=<G.^^ZNQ_@TD6 P/;KQ_;]L;?TX?%[=/R[_],]WMD[Z6IT
M\UL,Y[=3;?OI/,46L&(+W8"G+Q8']!&*K_:S?B%5G&]A'@-,YCU\!>3"ZB(%
M3IF&F5/.10P?OD4-W=$H7WI#M?4Q,@F6^TB7.UCD@W(Y^<\_;ZV^V'PE_[%]
MJ.7KRBDJA?RPDUBSF=1*-K'/^6X^R#X11MN@$\TC#6DC];#>82@WA0XX"$F!
M!\_/@O'&^3F?M>[GYY;!Q3<[]X"&JSP;4@"ZUL7FT8@=%M;J6RK$)HH*JRAR
MXN#<>AR0X=7N1^-_IG5X?=QYKO,\'1_#F.#:!,.[SFZN3-*_I<LL-PCET@41
MD;CKB#"(LT*(VP"'<.Y'F/'&(IZEL%%GQ*1P^VXR!-8QF*96*@W#*#F[&:=9
MCM,ZU-VP.83<A*9\?_>7SD[2@;<@ZI-;[M;TX%<XJ%:)#PIL]IKC.7BYNKPR
MZTGXJEGF-)L$ZR]^FFU:W9-0;"XB+28>:&4&<-F3KD.!6N&PBF&47\.^N/:0
MMM5? + D2H>8=-MAU44"<RJ9Z'E]$^=:.(-6)^NQ_-^W8 -:R&8(94P\9"FJ
M3$."@,V12#S7-[B%+Z.-%A%5>H4X(F5C8'JN)FV =)EQ?4?8!D6J3;CA6)W?
MY3%C+FSE/E30)3;'IL1@UM=G!6'<D']JC,<\>_8MXS%V_Y)PQY+&DRV_0A\!
M%0YY+^/\\QC&ANW>7B[I+^^D K ?"\9^CK[2R_P^9M-H=4R+.$P/!FTUQX*V
MOH=0T/>QX!@5T=YY_%_6V4\2]2117[;@%.)\DITGV?E";?0D/4_2\V4+KH'R
M/XSXF$S XP58%T[ >\S&6 1TA0PB2%=0<J,,].\E'D9>Y##CME^F"M6QZ$BM
MXGG6RR/7:?''18AM3,]M_/4OVX>[O\(OWYV^WW_]_P-02P,$%     @ 68AJ
M6HW)O(Q,.P  ,PL! !    !D.3,P,38T9&5X-#$N:'1M[7WY<]I8MO#O5/$_
MJ#)OIO!\V(FS=-9V%;9QPHQC^V'<F;RNKBD!PJ@#$BT)NYF__CO;726!TXF9
MR7OIZDH"2'<Y]]RS+V_>#=Z?'KQYU^T<'S0;;P:]P6GWH/N/W:=[^V\>\B?X
M^J'\'KPY/#_^&!R^/3H_/>__^.##N]Z@^R"X''P\[?[X8!8GT>XTBJ^GQ:NS
M-)N'LP<'0;,![Q]%21%E!V^.>S^IAV_C<3%]]6+O69P\",)9?)W  -&D>$#3
M7*C'YF%V'2>[1;IX]6A1O [D\S MBG3.7TW2I-C-XW]%K_;-YTDXCV>K5X-X
M'N7!670;]--Y"#-U3GMOSWY\D.$B'QR\.3SH_CZ-AW$1P(:#-P\/#]X\O, =
M5RW@\=.ON((1@826<-CMO \&[[K]SD7W:M [N@QZ9T=[FU:S__A^5G-RWG\?
MG)\$;T[.SP;ZM*9Q$>WFBW 4O4K2VRQ</#BXZ'=W3Z[.CKO';Q[BLP?!ATZ_
MWX&7!N?!Q57_Z%WGLAL<G;]_?WX&XYP?_7VK6Y(C/EO.AU$6I)/@<AIF4?XJ
M^/F?ZK]?@C6+N0=T:^7+X:_1J B*- C'OR[S8@YPWZ%55./\5X'(P8<PR\*D
M",[2/=K]+\W&.2PI3L)9T,OS910<AT7$D/FE'3Q^]/C9O:_I, KGP6 : 2I%
MRR(>Y4$O&>VU@S XCF;A+1Q5,$JS19J%19PF0:N81L%?_K3_]/EKP-&C=+X(
MDQ6B$W[WXO5..X"AHN$J&$59$4]BF*R8AD4;%I$%UVDZ#L)DW&S<A+-E.)SA
MV$D>CR,>O1W@Z%DTBN)%@0\&^7(RB4=QE(Q6B#J _J-I@&N26<+1)[@&LVA\
M'8W;%D8A3L&$<9$'BRB;QT41C6'@ZSB'ZP7_#/,<*%WN;>==.H.E.+N)\P!0
M(RYF.+Z%-O@>##7/@SPJ<'/%-!A&L_2VC;\NEMEH&N91,,G2.3TKD&HVE@O"
M.OBC@%.'/?VLUIO3O<"O1NE\#K#.BW3TJ1W\UZ.]1_O!(LP"A%J$&^)GRX>!
M;UWB6\X>8$1K"4$K"@&(^1+_P&'PK/4@"D7IDII1Z##"V<QZ+>?3JGXSMQ80
MA'B6S4;T>Y2-8@#*(HM']C:BWY8 "H"*[-3L+\SE?L*1,2@!?0G\^#?\NLC2
M&T"?<1##QN%H (G^D@SSQ>N7A"%QXBVRJ]9P@6MPH+1<(,B7618E8R94Q11.
M?S/YS:+=DR6\,];D5R!1I,W&A<($^W2"5IR,9LMQG%P'>"+R0HX[JWXA1NI
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MT2RZ08+J'?IORY06&(^MDW=7Q0-L9'\;'TAOHFP7AMH=I4M4;H1+*F:Y9KT
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M"PIJ9-%^UOHK# )PV F)(R"-MDD$2N#1:;QHVS;F-JA"<V+;LS@< @DLT%1
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M_\0S)O0A6D1P*<V&5=34PI.8^JAC!"\AEG?8;K(11>_J\]:%E^'D%RN-@VQ
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M#@3WC]X-$$;^702W#C9W)KZF^F*M/3VWW+#;Z*VZ_XASGI3=3,G>G/'DVRD
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MMS3Y946VS,DD2RJGJL$B<F]N!%UKG:;*SZ8#U[J?W>TG',DQ2>US;S!TUQG
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MV>B<'0<]Y#\7_>Z@@X\&YR?P>N\R^-#I]SLH9KW#:0Z[P=OSGV#X[G%P^#'
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M($%60$\6&X+\FP&(NR#I=$]/+R\Z1R!R_?C@T0/Z? $"H?HLY_<4CP_T';A
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MN>O2-I;-B6P@]^CN91R3 5BO%D\\ZH A;< GBYV )[!3Y!!:4VP/YBY_?,&
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M86TM,C R-3 S,3 N>'-D4$L! A0#%     @ 68AJ6@=D I]<!@  OT,  !4
M             ( !:P,  &)E86TM,C R-3 S,3!?;&%B+GAM;%!+ 0(4 Q0
M   ( %F(:EIYKNZ3L00  '$J   5              "  ?H)  !B96%M+3(P
M,C4P,S$P7W!R92YX;6Q02P$"% ,4    " !9B&I: @VY6-0;  !]F@  #@
M            @ '>#@  9#DS,#$V-&0X:RYH=&U02P$"% ,4    " !9B&I:
MX#PTEN75  #9500 $               @ '>*@  9#DS,#$V-&1E>#$Q+FAT
M;5!+ 0(4 Q0    ( %F(:EJ-R;R,3#L  #,+ 0 0              "  ?$
M 0!D.3,P,38T9&5X-#$N:'1M4$L! A0#%     @ 68AJ6CEJTY$J$   _ST
M !               ( !:SP! &0Y,S Q-C1D97@U,2YH=&U02P$"% ,4
M" !9B&I:(MPX*\L/  !_,   $0              @ '#3 $ 9#DS,#$V-&1E
>>#DY,2YH=&U02P4&      @ " #Z 0  O5P!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>d930164d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="beam-20250310.xsd" xlink:type="simple"/>
    <context id="duration_2025-03-10_to_2025-03-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
        </entity>
        <period>
            <startDate>2025-03-10</startDate>
            <endDate>2025-03-10</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2025-03-10_to_2025-03-10" id="ixv-346">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2025-03-10_to_2025-03-10"
      id="Hidden_dei_EntityCentralIndexKey">0001745999</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2025-03-10_to_2025-03-10" id="ixv-357">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2025-03-10_to_2025-03-10" id="ixv-358">2025-03-10</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2025-03-10_to_2025-03-10" id="ixv-359">Beam Therapeutics Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2025-03-10_to_2025-03-10" id="ixv-360">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2025-03-10_to_2025-03-10" id="ixv-361">001-39208</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2025-03-10_to_2025-03-10" id="ixv-362">81-5238376</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2025-03-10_to_2025-03-10" id="ixv-363">238 Main Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="duration_2025-03-10_to_2025-03-10" id="ixv-364">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2025-03-10_to_2025-03-10" id="ixv-365">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2025-03-10_to_2025-03-10" id="ixv-366">02142</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2025-03-10_to_2025-03-10" id="ixv-367">857</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2025-03-10_to_2025-03-10" id="ixv-368">327-8775</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2025-03-10_to_2025-03-10" id="ixv-369">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2025-03-10_to_2025-03-10" id="ixv-370">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2025-03-10_to_2025-03-10" id="ixv-371">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2025-03-10_to_2025-03-10" id="ixv-372">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2025-03-10_to_2025-03-10" id="ixv-373">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2025-03-10_to_2025-03-10" id="ixv-374">BEAM</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2025-03-10_to_2025-03-10" id="ixv-375">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2025-03-10_to_2025-03-10" id="ixv-376">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
